var title_f37_28_38336="Bexarotene: Patient drug information";
var content_f37_28_38336=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Bexarotene: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/14/36069?source=see_link\">",
"       Bexarotene (systemic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/0/12293?source=see_link\">",
"       Bexarotene (topical): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11302 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-C1AFB1FE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_28_38336=[""].join("\n");
var outline_f37_28_38336=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/14/36069?source=related_link\">",
"      Bexarotene (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/0/12293?source=related_link\">",
"      Bexarotene (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_28_38337="High blood pressure in children";
var content_f37_28_38337=[" <h1 id=\"patTopicTitle\">",
"  Patient information: High blood pressure in children (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?37/28/38337/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38337/contributors\" id=\"au6305\">",
"       Tej K Mattoo, MD, DCH, FRCP",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?37/28/38337/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38337/contributors\" id=\"se5276\">",
"       Patrick Niaudet, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38337/contributors\" id=\"se5611\">",
"       David R Fulton, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?37/28/38337/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38337/contributors\" id=\"de7255\">",
"       Melanie S Kim, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/28/38337?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      HIGH BLOOD PRESSURE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Blood pressure refers to the pressure that blood applies to the inner walls of blood vessels. High blood pressure is also called hypertension. Although hypertension is more common in adults, it often develops during childhood and adolescence, and can increase the risk of early heart disease and stroke during adulthood. Fortunately, high blood pressure can be treated.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS BLOOD PRESSURE?",
"     </span>",
"    </p>",
"    <p>",
"     An individual's blood pressure is defined by two measurements:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Systolic blood pressure is the pressure in the arteries produced when the heart contracts (at the time of a heart beat).",
"      </li>",
"      <li>",
"       Diastolic blood pressure is the pressure in the arteries during relaxation of the heart between heart beats.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Blood pressure is reported as the systolic blood pressure over diastolic blood pressure (eg,",
"     <span class=\"nowrap\">",
"      120/70",
"     </span>",
"     or 120 over 70). The diagnosis of high blood pressure can be based upon either measurement as they are of equal importance.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Normal versus high blood pressure",
"     </span>",
"     &nbsp;&mdash;&nbsp;In children, the normal range for blood pressure is determined by the child's gender, age, and height. The normal range is expressed as a percentile, similar to charts used to track children&rsquo;s growth.",
"    </p>",
"    <p>",
"     As an example, if a child's blood pressure is in the 60",
"     <sup>",
"      th",
"     </sup>",
"     percentile, this means that 60 percent of children who are that age, gender, and height have a lower blood pressure.",
"    </p>",
"    <p>",
"     A child's blood pressure percentile can be calculated here for boys (",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/15/9463?source=see_link\">",
"      calculator 1",
"     </a>",
"     ) or here for girls (",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/33/9751?source=see_link\">",
"      calculator 2",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Blood pressure is separated into three categories based upon the child's blood pressure percentile:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h3\">",
"      Normal blood pressure",
"     </span>",
"     &nbsp;&mdash;&nbsp;Both systolic and diastolic blood pressure &lt;90",
"     <sup>",
"      th",
"     </sup>",
"     percentile.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Prehypertension",
"     </span>",
"     &nbsp;&mdash;&nbsp;Systolic",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     diastolic blood pressure &ge;90",
"     <sup>",
"      th",
"     </sup>",
"     percentile but &lt;95",
"     <sup>",
"      th",
"     </sup>",
"     percentile",
"     <strong>",
"      or",
"     </strong>",
"     if blood pressure exceeds",
"     <span class=\"nowrap\">",
"      120/80",
"     </span>",
"     mmHg (even if &lt;90",
"     <sup>",
"      th",
"     </sup>",
"     percentile for age, gender, and height).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Hypertension",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hypertension is defined as either systolic",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     diastolic blood pressure &ge;95",
"     <sup>",
"      th",
"     </sup>",
"     percentile measured on three or more separate occasions. The degree of hypertension is further delineated by the two following stages.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Stage 1 hypertension &ndash; Systolic",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       diastolic blood pressure between the 95",
"       <sup>",
"        th",
"       </sup>",
"       percentile and 5 mmHg above the 99",
"       <sup>",
"        th",
"       </sup>",
"       percentile.",
"      </li>",
"      <li>",
"       Stage 2 hypertension &ndash; Systolic",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       diastolic blood pressure &ge;99",
"       <sup>",
"        th",
"       </sup>",
"       percentile plus 5 mmHg.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      HIGH BLOOD PRESSURE SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     A slow increase in blood pressure does not usually cause any symptoms. However, a sudden increase in blood pressure in children and adolescents can cause headache, vomiting, seizures, or heart failure.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      BLOOD PRESSURE MEASUREMENT",
"     </span>",
"    </p>",
"    <p>",
"     Expert groups recommend that all children over age three years have their blood pressure measured during routine office visits once per year. Blood pressure measurements may be recommended at an earlier age in children who have kidney or heart disease.",
"    </p>",
"    <p>",
"     It is important for the healthcare provider to measure the blood pressure accurately, using the correct equipment and technique. Parents should be aware of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The blood pressure should be measured after the child has been sitting in a quiet environment for a few minutes. The child should be seated with",
"       <span class=\"nowrap\">",
"        his/her",
"       </span>",
"       back and feet in a supported position. In infants, blood pressure is measured while the child lies on",
"       <span class=\"nowrap\">",
"        his/her",
"       </span>",
"       back. It may be necessary to measure the blood pressure a few times (several minutes apart) to get the most accurate reading.",
"      </li>",
"      <li>",
"       The blood pressure should not be measured if the child is crying or unable to cooperate.",
"      </li>",
"      <li>",
"       An appropriate-size cuff should be used. A cuff that is too small can overestimate the blood pressure.",
"      </li>",
"      <li>",
"       Blood pressure should be measured in the right arm.",
"      </li>",
"      <li>",
"       Stimulants such as cigarettes and caffeine should be avoided for several hours before the blood pressure is measured.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      HIGH BLOOD PRESSURE DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     The diagnosis of hypertension is made when the blood pressure is at or greater than the 95",
"     <sup>",
"      th",
"     </sup>",
"     percentile on three separate measurements, which are separated by days or weeks.",
"    </p>",
"    <p>",
"     When hypertension is diagnosed, testing is recommended to help determine the cause of the hypertension. The evaluation generally includes a medical history and physical examination, measurement of blood pressure in the arms and legs, laboratory tests, and an ultrasound of the heart and kidneys.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      TYPES OF HIGH BLOOD PRESSURE",
"     </span>",
"    </p>",
"    <p>",
"     If a child is diagnosed with high blood pressure, the next step is to determine if a cause of the hypertension can be determined. Patients in whom no cause can be identified have primary or essential hypertension, and those with an identifiable cause have secondary hypertension.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Primary hypertension",
"     </span>",
"     &nbsp;&mdash;&nbsp;Primary hypertension, previously called essential hypertension, has no identifiable cause. It is the most common cause of hypertension in older children and adults.",
"    </p>",
"    <p>",
"     Primary hypertension is more likely in children who:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Have completed puberty",
"      </li>",
"      <li>",
"       Have a family history of hypertension",
"      </li>",
"      <li>",
"       Are overweight or obese",
"      </li>",
"      <li>",
"       Have only mild hypertension (blood pressure at or just above the 95",
"       <sup>",
"        th",
"       </sup>",
"       percentile)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Secondary hypertension",
"     </span>",
"     &nbsp;&mdash;&nbsp;Secondary hypertension has a known cause. The most common causes of secondary hypertension include kidney disease, endocrine disorders, heart disease, and some medications.",
"    </p>",
"    <p>",
"     Secondary hypertension is more likely in children who:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Are younger than 10 years of age",
"      </li>",
"      <li>",
"       Have a sudden increase in blood pressure when the blood pressure has previously been normal",
"      </li>",
"      <li>",
"       Have severe hypertension, defined as stage 2 hypertension (blood pressure &gt;5 mmHg above the 99",
"       <sup>",
"        th",
"       </sup>",
"       percentile). (See",
"       <a class=\"local\" href=\"#H6\">",
"        'Hypertension'",
"       </a>",
"       above.)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      \"White coat\" hypertension",
"     </span>",
"     &nbsp;&mdash;&nbsp;\"White coat\" hypertension is the name given to high blood pressure caused by anxiety when blood pressure is measured in clinic or office. Measuring the blood pressure several times during the office visit (to minimize anxiety)",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     measuring the blood pressure outside the physician's office can help to determine if a person has white coat hypertension or is truly hypertensive.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      HIGH BLOOD PRESSURE TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Treatment of high blood pressure in children is discussed in detail in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/58/931?source=see_link\">",
"      \"Patient information: High blood pressure treatment in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your child&rsquo;s healthcare provider is the best source of information for questions and concerns related to your child&rsquo;s medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H194140795\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H194140802\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/37/30290?source=see_link\">",
"      Patient information: High blood pressure in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/58/34722?source=see_link\">",
"      Patient information: High blood pressure in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/56/40835?source=see_link\">",
"      Patient information: Controlling your blood pressure through lifestyle (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/44/35523?source=see_link\">",
"      Patient information: Polycystic kidney disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/30/23010?source=see_link\">",
"      Patient information: My child is overweight (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H194140810\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/58/931?source=see_link\">",
"      Patient information: High blood pressure treatment in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H194140818\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25943?source=see_link\">",
"      Ambulatory blood pressure monitoring in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17113?source=see_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/7/42105?source=see_link\">",
"      Epidemiology, risk factors, and etiology of hypertension in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/42/2729?source=see_link\">",
"      Evaluation of hypertension in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27626?source=see_link\">",
"      Treatment of hypertension in children and adolescents",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Nemours Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://kidshealth.org/parent/medical/heart/hypertension.html\">",
"      file://kidshealth.org/parent/medical/heart/hypertension.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The National Kidney Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.kidney.org/atoz/atozItem.cfm?id=164\">",
"      www.kidney.org/atoz/atozItem.cfm?id=164",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?37/28/38337/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 10, 2010.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/28/38337?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38337/abstract/1\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38337/abstract/2\">",
"      Williams CL, Hayman LL, Daniels SR, et al. Cardiovascular health in childhood: A statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2002; 106:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38337/abstract/3\">",
"      McNiece KL, Poffenbarger TS, Turner JL, et al. Prevalence of hypertension and pre-hypertension among adolescents. J Pediatr 2007; 150:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38337/abstract/4\">",
"      Falkner B, Gidding SS, Portman R, Rosner B. Blood pressure variability and classification of prehypertension and hypertension in adolescence. Pediatrics 2008; 122:238.",
"     </a>",
"    </li>",
"    <li>",
"     Lande, MB, Flynn, JT. Treatment of hypertension in children and adolescents. Pediatr Nephrol 2007 Aug 10. [Epub ahead of print].",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f37_28_38337=[""].join("\n");
var outline_f37_28_38337=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           HIGH BLOOD PRESSURE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS BLOOD PRESSURE?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           HIGH BLOOD PRESSURE SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           BLOOD PRESSURE MEASUREMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           HIGH BLOOD PRESSURE DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           TYPES OF HIGH BLOOD PRESSURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           HIGH BLOOD PRESSURE TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        CALCULATORS",
"       </h1>",
"       <div id=\"relatedCalculators\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/15/9463?source=related_link\" title=\"calculator 1\">",
"           Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/33/9751?source=related_link\" title=\"calculator 2\">",
"           Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f37_28_38338="Left atrial myxoma TTE TEE I";
var content_f37_28_38338=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Left atrial myxoma on transthoracic and transesophageal echocardiography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A four chamber view from a transthoracic echocardiography (panel A) suggests a well encapsulated mass within the left atrium (arrow). The consistence is fairly uniform although there may be a few rarefactions. Transesophageal echocardiography (panel B) shows the details of the tumor attachment to the lower limbus of the foraminal portion of the interatrial septum. The implied irregularity on transthoracic echocardiography are clearly seen cysts that are also typical of these tumors.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_28_38338=[""].join("\n");
var outline_f37_28_38338=null;
var title_f37_28_38339="Lubiprostone: Drug information";
var content_f37_28_38339=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lubiprostone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/28/1476?source=see_link\">",
"    see \"Lubiprostone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2609746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Amitiza&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F2609750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Chloride Channel Activator;",
"     </li>",
"     <li>",
"      Gastrointestinal Agent, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F2610838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chronic idiopathic constipation:",
"     </b>",
"     Oral: 24 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Irritable bowel syndrome with constipation:",
"     </b>",
"     Females &ge;18 years: Oral: 8 mcg twice daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2610839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2610840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F2610841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Moderate hepatic impairment (Child-Pugh class B):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Chronic idiopathic constipation:",
"     </i>",
"     16 mcg twice daily; may increase to 24 mcg twice daily if tolerated and an adequate response has not been obtained with lower dosage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Irritable bowel syndrome with constipation:",
"     </i>",
"     No dosage adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Severe hepatic impairment (Child-Pugh class C):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Chronic idiopathic constipation:",
"     </i>",
"     8 mcg twice daily; may increase to 16-24 mcg twice daily if tolerated and an adequate response has not been obtained with lower dosage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Irritable bowel syndrome with constipation:",
"     </i>",
"     8 mcg once daily; may increase to 8 mcg twice daily if tolerated and an adequate response has not been obtained at lower dosage",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F2610842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chronic idiopathic constipation: May decrease dose to 24 mcg once daily in case of severe nausea",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2610846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amitiza&reg;: 8 mcg, 24 mcg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2609748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2610844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food and water. Swallow whole; do not break or chew.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2609751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of chronic idiopathic constipation; treatment of irritable bowel syndrome with constipation in adult women",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F2609760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (3% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (7% to 29%; severe: 4%; dose related), diarrhea (7% to 12%; severe 2%)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Edema (3%), chest discomfort/pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (3%), fatigue (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal pain (1% to 8%), abdominal distention (3% to 6%), flatulence (3% to 6%), vomiting (3%), loose stools (3%), dyspepsia (2%), xerostomia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal taste, allergic reactions, anorexia, anxiety, appetite decreased, cold sweat, constipation, cough, defecation urgency, depression, eructation, erythema, fecal incontinence, fibromyalgia, frequent bowel movements, gastritis, heart rate increased, hyperhidrosis, influenza, joint swelling, lethargy, liver enzymes increased, malaise, muscle cramp, muscle spasm, myalgia, pain, palpitation, pharyngolaryngeal pain, pollakiuria, rectal hemorrhage, syncope, tremor, urinary tract infection, weakness, weight gain",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2609755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Known or suspected mechanical bowel obstruction",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2609756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dyspnea: Often described as chest tightness, dyspnea has been observed with use, including postmarketing reports; generally occurs following the first dose with an acute onset (within 30-60 minutes following the first dose) and resolves within a few hours; however,  has been frequently reported with subsequent dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Nausea: Nausea may occur; administer with food to reduce symptoms. In long-term clinical studies for chronic idiopathic constipation, patients were allowed to reduce the dose to 24 mcg once daily if nausea was severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diarrhea: Avoid use in patients with severe diarrhea.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Gastrointestinal obstruction: Symptoms of mechanical gastrointestinal obstruction should be evaluated before prescribing this medicine; use is contraindicated in patients with bowel obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Patients with moderate-to-severe hepatic impairment (Child-Pugh class B or C) have higher systemic drug exposure; dosage adjustment is recommended in this patient population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Males: Not approved for use in males with irritable bowel syndrome with constipation.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F2609752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2609753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies suggest that lubiprostone may cause fetal loss; teratogenic effects were not observed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2609754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15788822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if lubiprostone or its active metabolite are excreted into breast milk. The manufacturer recommends monitoring nursing infants for diarrhea.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F2610843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with food and water to decrease nausea.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Amitiza Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mcg (60): $296.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     24 mcg (60): $296.30",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F14721643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Lubowel (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2610828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bicyclic fatty acid that acts locally at the apical portion of the intestine as a chloride channel activator, increasing intestinal fluid secretion and intestinal motility. Does not alter serum sodium or potassium concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2610830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Systemic: Parent drug: Poor (below levels of detection); Active metabolite (M3): Low",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Gastrointestinal tissue; minimal beyond gastrointestinal tissue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~94%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Rapid and extensive within stomach and jejunum by carbonyl reductase to M3 (active metabolite) and others",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Minimal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: M3: 0.9-1.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: M3: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Parent drug and M3: Feces (trace amounts)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Johanson JF and Ueno R, &ldquo;Lubiprostone, a Locally Acting Chloride Channel Activator, In Adult Patients With Chronic Constipation: A Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety,&rdquo;",
"      <i>",
"       Aliment Pharmacol Ther",
"      </i>",
"      , 2007, 25(11):1351-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/28/38339/abstract-text/17509103/pubmed\" id=\"17509103\" target=\"_blank\">",
"        17509103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10195 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-49B032D4AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_28_38339=[""].join("\n");
var outline_f37_28_38339=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2609746\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2609750\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2610838\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2610839\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2610840\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2610841\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2610842\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2610846\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2609748\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2610844\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2609751\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2609760\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2609755\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2609756\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299620\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221379\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2609752\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2609753\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2609754\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15788822\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2610843\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422176\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14721643\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2610828\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2610830\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10195\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10195|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/28/1476?source=related_link\">",
"      Lubiprostone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_28_38340="Nephrolithiasis during pregnancy";
var content_f37_28_38340=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nephrolithiasis during pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/28/38340/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38340/contributors\">",
"     Glenn M Preminger, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38340/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/28/38340/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38340/contributors\">",
"     Stanley Goldfarb, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38340/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38340/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/28/38340/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38340/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/28/38340/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of a symptomatic stone during pregnancy is a rare event, occurring in about one in every 1500 to 3000 pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38340/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This rate is similar to non-pregnant women of child-bearing age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38340/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H436313749\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Affected patients usually present in the second or third trimester (approximately 20 percent in the first trimester) with acute flank pain (90 percent), which often radiates to the groin or lower abdomen. Hematuria is present in 75 to 95 percent, one-third of whom have gross hematuria, and approximately 40 percent will have pyuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38340/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of these women do not have a prior history of stone disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38340/abstract/2\">",
"     2",
"    </a>",
"    ]. However, it is not clear if such women have an underlying tendency to stone formation or if factors related to pregnancy are responsible. Normal pregnancy is associated with a mild increase in urine calcium excretion (243 versus 194",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in one series), lesser increases in urine citrate and magnesium excretion (which protect against stone formation), and a rise in urine pH but not urine volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38340/abstract/4\">",
"     4",
"    </a>",
"    ]. The urine supersaturation for calcium oxalate is similar to that in nonpregnant women with calcium stones. Additional factors that contribute to stone formation during pregnancy include urinary stasis, secondary to increased progesterone levels and diminished fluid intake, as a result of decreasing bladder capacity from the gravid uterus. Most stones appear to be predominantly composed of calcium phosphate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38340/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal and pelvic ultrasound should be performed when an obstructing calculus is suspected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38340/abstract/2\">",
"     2",
"    </a>",
"    ]. This modality avoids exposure to radiation and is useful for detecting secondary signs of obstruction, such as hydronephrosis or hydroureter. However, physiological hydronephrosis of pregnancy must be distinguished from pathological hydronephrosis from obstruction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/32/24072?source=see_link\">",
"     \"Renal and urinary tract physiology in normal pregnancy\"",
"    </a>",
"    .) Rarely, pelvic ultrasound may identify a stone obstructing the distal ureter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38340/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ability of ultrasonography and other imaging modalities to detect nephrolithiasis was retrospectively evaluated in a study of 57 pregnant women with 73 admissions for symptomatic nephrolithiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38340/abstract/2\">",
"     2",
"    </a>",
"    ]. When performed as the initial examination, renal ultrasonography detected calculi in 21 of 35 cases (60 percent sensitivity).",
"   </p>",
"   <p>",
"    To avoid radiation exposure, transvaginal ultrasonography should be performed next in those in whom transabdominal ultrasonography is noninformative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38340/abstract/7\">",
"     7",
"    </a>",
"    ]. This modality can help detect distal ureteral stones. If the examination is negative, the patient may be treated symptomatically, with hydration and lying on her side, with the symptomatic side up. This can relieve pressure on the ureter from the gravid uterus. Doppler ultrasound has also been utilized to improve the diagnostic accuracy of identifying ureteral calculi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38340/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If further diagnosis is required following",
"    <span class=\"nowrap\">",
"     renal/pelvic",
"    </span>",
"    ultrasound, transvaginal ultrasonography, and a trial of symptomatic therapy, two additional options are available; they are listed in our order of preference:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MR urography, which is not associated with radiation exposure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28120?source=see_link&amp;anchor=H26#H26\">",
"       \"Diagnostic imaging procedures during pregnancy\", section on 'Magnetic resonance imaging'",
"      </a>",
"      .).",
"     </li>",
"     <li>",
"      Low dose CT can be used in the second and third trimester but not the first trimester, when the fetus is most susceptible to radiation induced injury. Some evidence suggests that low dose CT is highly sensitive and specific for the detection of renal and ureteral calculi in pregnant women, and confers a low risk of fetal harm if used judiciously [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38340/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28120?source=see_link&amp;anchor=H17#H17\">",
"       \"Diagnostic imaging procedures during pregnancy\", section on 'Computed tomography'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our recommendations are consistent with those made by the American Urological Association Technology Assessment on Imaging in the Management of Ureteral Calculus Disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38340/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most (75 to 85 percent) stones pass spontaneously, due in part to the normally dilated urinary tract in pregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38340/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/32/24072?source=see_link\">",
"     \"Renal and urinary tract physiology in normal pregnancy\"",
"    </a>",
"    .) If drugs are needed to relieve pain in such patients,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    is probably the safest choice. The use of nonsteroidal drugs and opioids in pregnant women are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42010?source=see_link&amp;anchor=H1702574#H1702574\">",
"     \"Initial prenatal assessment and patient education\", section on 'Treatment of pain and fever'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cystoscopy with insertion of a ureteral stent or ureteroscopy to remove or fragment the stone may be required in the patient who is septic, has persistent severe pain, or has obstruction in a solitary functioning kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38340/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Ureteral stenting or placement of a nephrostomy tube to relieve obstruction or pain is a valid option for managing pregnant patients. However, pregnancy significantly increases the risk of stent encrustation, necessitating the need for frequent ureteral stent exchange every four to six weeks until delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38340/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients who fail to spontaneously pass the stone and who develop urinary tract infection, persistent urinary obstruction, or persistent severe pain, ureteroscopy with lithotripsy may be an option. Small caliber ureteroscopes minimize or eliminate the need for concomitant fluoroscopic monitoring. If additional monitoring is needed, ultrasonography (no ionizing radiation) or pulsed fluoroscopy (minimal ionizing radiation) can be used. Another option to reduce radiation exposure to the fetus while performing ureteroscopy utilizes an inverted C-arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38340/abstract/16\">",
"     16",
"    </a>",
"    ]. Although shock wave lithotripsy has been inadvertently performed in only a few pregnant women, without complications, its use during pregnancy is contraindicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38340/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ureteroscopic stone removal appears to be similarly safe in pregnant and nonpregnant patients. A 2009 systematic review and meta-analysis of 14 reports noted nine complications with this technique among 108 pregnant patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38340/abstract/19\">",
"     19",
"    </a>",
"    ]. These included two patients with postoperative pain managed by analgesia, five with urinary tract infections, one with preterm uterine contractions treated by tocolytic, and one with a ureteral perforation managed by a stent. There were no life-threatening complications or deaths. The review also reported that the cases were from centers with operators that were highly skilled, a likely contributor to success with the technique. A similar rate of ureteral injury and urinary tract infection was reported in a multinational meta-analysis of ureteroscopy in nonpregnant patients.",
"   </p>",
"   <p>",
"    Holmium laser lithotripsy may be the preferred technique of stone fragmentation during ureteroscopy, as this device delivers energy to a localized area, can be used with flexible ureteroscopes, and is effective with stones of all compositions. The potential efficacy was illustrated in a report of eight pregnant women with 10 symptomatic ureteral calculi and two encrusted ureteral stents who underwent ureteroscopy and holmium:YAG laser lithotripsy at a mean gestational age of 22 weeks; the mean stone size was 8.1 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38340/abstract/20\">",
"     20",
"    </a>",
"    ]. Procedural success was achieved in all but one case (91 percent), with no obstetric or urologic complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27079?source=see_link\">",
"     \"Management of ureteral calculi\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/53/28499?source=see_link\">",
"       \"Patient information: Kidney stones in adults (Beyond the Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6997245\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic stones during pregnancy are rare, usually presenting in the second or third trimester with acute flank pain radiating to the groin or lower abdomen and hematuria. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H436313749\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Normal pregnancy is associated with a mild increase in urine calcium excretion and a rise in urine pH; these are risk factors for calcium phosphate stones, which appear to be the most common kidney stone in pregnancy. Urinary stasis, due both to increased progesterone and a diminished fluid intake associated with reduced bladder capacity, may also contribute to stone formation. (See",
"      <a class=\"local\" href=\"#H436313749\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal and pelvic ultrasound is the diagnostic test of choice in order to avoid radiation exposure. However, when invasive therapy to remove stones is considered, physiological hydronephrosis of pregnancy must first be distinguished from pathological hydronephrosis from obstruction. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Distal stones can be missed by renal and pelvic ultrasound. Thus, transvaginal or Doppler ultrasonography should be performed next when transabdominal ultrasonography is noninformative. If transvaginal ultrasound is negative, a trial of symptomatic therapy should be instituted before moving forward with further imaging. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If further diagnosis is required following",
"      <span class=\"nowrap\">",
"       renal/pelvic",
"      </span>",
"      ultrasound, transvaginal and Doppler ultrasonography, and a trial of symptomatic therapy, two additional options are available. In order of preference, they are: (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      MR urography",
"     </li>",
"     <li>",
"      Low dose CT (second and third trimester only)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most (75 to 85 percent) stones pass spontaneously, due in part to the normally dilated urinary tract in pregnant women. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Decompression of the kidney with placement of a ureteral stent or percutaneous nephrostomy tube, or ureteroscopy to remove the stone may be required in the patient who is septic, has persistent severe pain, or has persistent obstruction. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38340/abstract/1\">",
"      Stothers L, Lee LM. Renal colic in pregnancy. J Urol 1992; 148:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38340/abstract/2\">",
"      Butler EL, Cox SM, Eberts EG, Cunningham FG. Symptomatic nephrolithiasis complicating pregnancy. Obstet Gynecol 2000; 96:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38340/abstract/3\">",
"      Curhan GC, Willett WC, Knight EL, Stampfer MJ. Dietary factors and the risk of incident kidney stones in younger women: Nurses' Health Study II. Arch Intern Med 2004; 164:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38340/abstract/4\">",
"      Maikranz P, Holley JL, Parks JH, et al. Gestational hypercalciuria causes pathological urine calcium oxalate supersaturations. Kidney Int 1989; 36:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38340/abstract/5\">",
"      Ross AE, Handa S, Lingeman JE, Matlaga BR. Kidney stones during pregnancy: an investigation into stone composition. Urol Res 2008; 36:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38340/abstract/6\">",
"      Boridy IC, Maklad N, Sandler CM. Suspected urolithiasis in pregnant women: imaging algorithm and literature review. AJR Am J Roentgenol 1996; 167:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38340/abstract/7\">",
"      Laing FC, Benson CB, DiSalvo DN, et al. Distal ureteral calculi: detection with vaginal US. Radiology 1994; 192:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38340/abstract/8\">",
"      Elgamasy A, Elsherif A. Use of Doppler ultrasonography and rigid ureteroscopy for managing symptomatic ureteric stones during pregnancy. BJU Int 2010; 106:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38340/abstract/9\">",
"      Shokeir AA, Mahran MR, Abdulmaaboud M. Renal colic in pregnant women: role of renal resistive index. Urology 2000; 55:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38340/abstract/10\">",
"      White WM, Zite NB, Gash J, et al. Low-dose computed tomography for the evaluation of flank pain in the pregnant population. J Endourol 2007; 21:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38340/abstract/11\">",
"      White WM, Johnson EB, Zite NB, et al. Predictive value of current imaging modalities for the detection of urolithiasis during pregnancy: a multicenter, longitudinal study. J Urol 2013; 189:931.",
"     </a>",
"    </li>",
"    <li>",
"     Fulgham PF, Assimos DG, Pearle MS, Preminger GM. Clinical Effectiveness Protocols for Imaging in The Management Of Ureteral Calculous Disease: Aua Technology Assessment. American Urological Association Education and Research, Inc., &copy;2012. file://www.auanet.org/content/media/imaging_assessment.pdf (Accessed on July 17th, 2012)",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38340/abstract/13\">",
"      Scarpa RM, De Lisa A, Usai E. Diagnosis and treatment of ureteral calculi during pregnancy with rigid ureteroscopes. J Urol 1996; 155:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38340/abstract/14\">",
"      McAleer SJ, Loughlin KR. Nephrolithiasis and pregnancy. Curr Opin Urol 2004; 14:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38340/abstract/15\">",
"      Parulkar BG, Hopkins TB, Wollin MR, et al. Renal colic during pregnancy: a case for conservative treatment. J Urol 1998; 159:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38340/abstract/16\">",
"      Cocuzza M, Colombo JR Jr, Lopes RI, et al. Use of inverted fluoroscope's C-arm during endoscopic treatment of urinary tract obstruction in pregnancy: a practicable solution to cut radiation. Urology 2010; 75:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38340/abstract/17\">",
"      Asgari MA, Safarinejad MR, Hosseini SY, Dadkhah F. Extracorporeal shock wave lithotripsy of renal calculi during early pregnancy. BJU Int 1999; 84:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38340/abstract/18\">",
"      Deliveliotis CH, Argyropoulos B, Chrisofos M, Dimopoulos CA. Shockwave lithotripsy in unrecognized pregnancy: interruption or continuation? J Endourol 2001; 15:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38340/abstract/19\">",
"      Semins MJ, Trock BJ, Matlaga BR. The safety of ureteroscopy during pregnancy: a systematic review and meta-analysis. J Urol 2009; 181:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38340/abstract/20\">",
"      Watterson JD, Girvan AR, Beiko DT, et al. Ureteroscopy and holmium:YAG laser lithotripsy: an emerging definitive management strategy for symptomatic ureteral calculi in pregnancy. Urology 2002; 60:383.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7370 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-EA0AF42627-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_28_38340=[""].join("\n");
var outline_f37_28_38340=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6997245\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H436313749\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6997245\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42010?source=related_link\">",
"      Initial prenatal assessment and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27079?source=related_link\">",
"      Management of ureteral calculi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/53/28499?source=related_link\">",
"      Patient information: Kidney stones in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/32/24072?source=related_link\">",
"      Renal and urinary tract physiology in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_28_38341="Erectile dysfunction in diabetes mellitus";
var content_f37_28_38341=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Erectile dysfunction in diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/28/38341/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38341/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/28/38341/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38341/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/28/38341/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38341/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/28/38341/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inability to achieve and maintain an erection sufficient for satisfactory sexual intercourse is a distressing and common symptom, affecting up to one-third of adult men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38341/abstract/1\">",
"     1",
"    </a>",
"    ]. The prevalence of erectile dysfunction increases with age (",
"    <a class=\"graphic graphic_figure graphicRef81051 \" href=\"mobipreview.htm?32/46/33517\">",
"     figure 1",
"    </a>",
"    ), and it is common in men with systemic disorders such as hypertension, ischemic heart disease, or diabetes mellitus.",
"   </p>",
"   <p>",
"    Erectile dysfunction in men with diabetes mellitus will be reviewed here. A general discussion of normal erectile physiology and the treatment of male sexual dysfunction are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42696?source=see_link\">",
"     \"Overview of male sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/36/30282?source=see_link\">",
"     \"Treatment of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE AND NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of erectile dysfunction in diabetes was evaluated in a survey of 541 men aged 20 to 59 years with diabetes attending a large community diabetes clinic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38341/abstract/2\">",
"     2",
"    </a>",
"    ]. The prevalence of erectile dysfunction increased progressively with age, from 6 percent in men aged 20 to 24 years, to 52 percent in men aged 55 to 59 years. In addition to increasing age, the main factors associated with erectile dysfunction were peripheral or autonomic neuropathy, retinopathy, long duration of diabetes, and poor glycemic control.",
"   </p>",
"   <p>",
"    Five years later, new erectile dysfunction had developed in 75 of 275 men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38341/abstract/3\">",
"     3",
"    </a>",
"    ]. In contrast, only 11 of 128 men (9 percent) who initially had erectile dysfunction regained erectile function; these men were usually younger, had a shorter duration of diabetes, and had features suggesting psychogenic erectile dysfunction when first evaluated. Men in whom erectile dysfunction persisted were more likely to develop retinopathy or neuropathy than men with normal erectile function.",
"   </p>",
"   <p>",
"    In a similar population study of 1040 Israeli men with diabetes who completed a self-report questionnaire, erectile dysfunction severity increased with diabetes duration, poor glycemic control, diuretic therapy, and presence of microvascular or cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38341/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, observational studies suggest that the presence of erectile dysfunction is a predictor of cardiovascular events in men with diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38341/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], as it may be for men without diabetes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42696?source=see_link&amp;anchor=H189242040#H189242040\">",
"     \"Overview of male sexual dysfunction\", section on 'Association with cardiovascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Not surprisingly, men with diabetes who develop erectile dysfunction (ED) experience a significant decline in quality-of-life measures as well as an increase in depressive symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38341/abstract/7\">",
"     7",
"    </a>",
"    ]. Conversely, depression is a well-recognized contributor to ED. Unfortunately, ED may go undetected as many clinicians do not inquire about sexual health. As an example, a large epidemiologic survey reported that the majority of men with diabetes and erectile dysfunction had never been asked by their clinicians about their sexual function and, therefore, did not receive treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38341/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development and maintenance of a normal erection requires an increase in parasympathetic activity and a reduction in sympathetic activity; these changes increase blood flow into the corpora cavernosa of the penis and relax the trabecular smooth muscle within the corpora cavernosa, thereby decreasing venous drainage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38341/abstract/9\">",
"     9",
"    </a>",
"    ]. These neural pathways are activated by central tactile, visual, auditory, and imaginative stimuli and penile tactile stimuli, modified by psychologic factors such as libido. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42696?source=see_link\">",
"     \"Overview of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, erectile dysfunction can result from local nerve damage (eg, neuropathy or surgical trauma), impaired blood flow to the penis, or psychologic factors; several of these factors are present in most cases. Loss of trabecular smooth muscle has been found in cavernosal tissue removed from men with diabetes at the time of implantation of a penile prosthesis; it is not known if this is an early event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All men with diabetes should be asked about erectile function, because many are reluctant to volunteer information about their sexual function. If present, the clinician should not automatically assume it is caused by diabetes, but should seek information about other causes, such as drugs, vascular disease, endocrine dysfunction, depression, and alcohol consumption. The man should be examined for the possible presence of retinopathy, peripheral or autonomic neuropathy, hypertension, peripheral vascular disease, hypogonadism, and gynecomastia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32533?source=see_link\">",
"     \"Evaluation of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some expert groups suggest that men with diabetes and erectile dysfunction (ED) who are planning to start phosphodiesterase inhibitors should first undergo evaluation for coronary heart disease (CHD). However, there are no data demonstrating that this approach decreases the likelihood of coronary events related to sexual activity. Given that the prevalence of coronary events linked to sexual activity is very low, we do not routinely screen men with diabetes and ED for CHD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42696?source=see_link&amp;anchor=H189242040#H189242040\">",
"     \"Overview of male sexual dysfunction\", section on 'Association with cardiovascular disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32533?source=see_link&amp;anchor=H11#H11\">",
"     \"Evaluation of male sexual dysfunction\", section on 'Subsequent cardiovascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Depression is an important factor in the development of erectile dysfunction in men with diabetes. As an example, in a study of 1460 such men, the prevalence of mild or moderate and severe erectile dysfunction was 24 and 34 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38341/abstract/10\">",
"     10",
"    </a>",
"    ]. Severe erectile dysfunction was mainly related to the severity of diabetes, while mild-moderate dysfunction was only associated with the severity of depressive symptoms.",
"   </p>",
"   <p>",
"    Laboratory testing should include evaluation of glycemic control, including measurements of hemoglobin A1C, serum creatinine, cholesterol, testosterone, prolactin, thyrotropin, and urinary protein excretions.",
"   </p>",
"   <p>",
"    In one report of 1022 men (including nondiabetic men) with erectile dysfunction, persistently low serum testosterone concentrations (less than 300",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [10.4",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    were found in 4 percent of men under age 50 years and 9 percent of those age 50 years or older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38341/abstract/11\">",
"     11",
"    </a>",
"    ]. If testing had been restricted to those men with symptoms of low sexual desire or signs of hypoandrogenism, 40 percent of the men with low serum testosterone concentrations would have been missed, some of whom may respond to treatment with testosterone.",
"   </p>",
"   <p>",
"    Specific tests of peripheral or autonomic nerve function are usually not necessary. These tests are time-consuming, complex, and expensive, and are rarely indicated unless surgical therapy is being considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32533?source=see_link\">",
"     \"Evaluation of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluation for coronary heart disease in men with erectile dysfunction is reviewed separately. This is currently an area of controversy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42696?source=see_link&amp;anchor=H189242040#H189242040\">",
"     \"Overview of male sexual dysfunction\", section on 'Association with cardiovascular disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32533?source=see_link&amp;anchor=H11#H11\">",
"     \"Evaluation of male sexual dysfunction\", section on 'Subsequent cardiovascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several treatments for men with erectile dysfunction are available, none of which is specific for diabetes. These approaches are discussed in detail elsewhere, but will be briefly reviewed here with an emphasis on their value in men with diabetes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/36/30282?source=see_link\">",
"     \"Treatment of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Glycemic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intensive glycemic control reduces the development of erectile dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38341/abstract/12\">",
"     12",
"    </a>",
"    ]. However, there are no data to suggest intensive therapy can reverse or improve ED once it has developed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=see_link\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Psychosexual counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most men with diabetes have one or more organic causes for their erectile dysfunction, psychologic factors are also often present. It is important to discuss the quality and stability of the man's sexual relationship and to explore the expectations of both the man and his partner. Psychosexual counseling alone is not often effective in diabetic men with erectile dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38341/abstract/13\">",
"     13",
"    </a>",
"    ], but it may be helpful as an adjunct to drug therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Phosphodiesterase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;We consider the first-line therapy for erectile dysfunction to be a class of drugs that are cyclic GMP phosphodiesterase five (PDE -5) inhibitors (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    ) that prolong the vasodilatory effect of nitric oxide to initiate and maintain an erection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38341/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/36/30282?source=see_link\">",
"     \"Treatment of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A meta-analysis of eight trials with 976 diabetic men randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    reported improvement in several indices of erectile dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38341/abstract/17\">",
"     17",
"    </a>",
"    ]. As an example, the weighted mean difference between the percentage of successful attempts in the treatment and in the control arm was 26.7 (95% CI, 23.1-30.3).",
"   </p>",
"   <p>",
"    The risk of developing adverse effects was higher in the treatment group. The most common side effects were headache and flushing. Other side effects included upper respiratory and flu-like symptoms, dyspepsia, abnormal vision, and back pain.",
"   </p>",
"   <p>",
"    Side effects associated with PDE-5 inhibitors are related to their vasodilatory properties and are similar to those induced by nitrates. These include headache, lightheadedness, dizziness, flushing, distorted vision (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    ) and, in some cases, syncope. Men at highest risk for syncope are those who take other vasodilators such as nitrates. Thus, men should be cautioned against the combined use of sildenafil and a nitrate because of the risk of hypotension and syncope.",
"   </p>",
"   <p>",
"    PDE-5 inhibitors do not appear to have adverse effects on coronary hemodynamics, even in men with either stable or severe coronary disease. The consensus position of the American College of Cardiology and the American Heart Association is that PDE-5 inhibitors are safe for men with stable coronary artery disease who are not taking nitrates. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/36/30282?source=see_link\">",
"     \"Treatment of male sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/15/8442?source=see_link\">",
"     \"Sexual activity in patients with heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although there are no direct comparison studies,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    appear to be as effective as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The use of PDE-5 inhibitors for erectile dysfunction is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/36/30282?source=see_link&amp;anchor=H72305547#H72305547\">",
"     \"Treatment of male sexual dysfunction\", section on 'Phosphodiesterase 5 inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Intraurethral alprostadil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraurethral administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40966?source=see_link\">",
"     alprostadil",
"    </a>",
"    (prostaglandin E1) has proven effective in some men with erectile dysfunction. In a placebo-controlled study of 961 men (of whom 20 percent had diabetes), 65 percent treated with alprostadil had successful intercourse versus 19 percent of those given placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38341/abstract/18\">",
"     18",
"    </a>",
"    ]. The results in the subgroup with diabetes were not given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Intracavernosal injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracavernosal injections of several vasoactive drugs may be effective in men with erectile dysfunction. The drugs given for this purpose have included",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/2/37923?source=see_link\">",
"     papaverine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/43/34485?source=see_link\">",
"     phentolamine",
"    </a>",
"    , and prostaglandin E1 (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40966?source=see_link\">",
"     alprostadil",
"    </a>",
"    ), either alone or in combination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38341/abstract/19\">",
"     19",
"    </a>",
"    ]. They are now used less often because of the availability of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other therapies, now rarely used, include use of a constricting band at the base of the penis to maintain an erection (with or without prior use of a negative pressure device), microsurgical penile revascularization, and penile prostheses. Surgical complications, including erosion and infection, have been reported in 3 to 8 percent of men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38341/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Infection is more common in diabetic men, who may even develop penile gangrene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38341/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/36/30282?source=see_link\">",
"     \"Treatment of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our recommendations for diabetic men with erectile dysfunction are the same as those for men without diabetes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because of their efficacy, ease of use, and favorable side effect profile, we recommend the phosphodiesterase inhibitors as first-line therapy.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"       Sildenafil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/40/21127?source=see_link\">",
"       vardenafil",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/4/19528?source=see_link\">",
"       tadalafil",
"      </a>",
"      appear to be equally effective, but tadalafil has a longer duration of action.",
"     </li>",
"     <li>",
"      Second-line therapies include penile self-injectable drugs, intraurethral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40966?source=see_link\">",
"       alprostadil",
"      </a>",
"      , and vacuum devices.",
"     </li>",
"     <li>",
"      Surgical treatment should be reserved for men who cannot use or who have not responded to first and second-line therapies.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38341/abstract/1\">",
"      NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993; 270:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38341/abstract/2\">",
"      McCulloch DK, Campbell IW, Wu FC, et al. The prevalence of diabetic impotence. Diabetologia 1980; 18:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38341/abstract/3\">",
"      McCulloch DK, Young RJ, Prescott RJ, et al. The natural history of impotence in diabetic men. Diabetologia 1984; 26:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38341/abstract/4\">",
"      Kalter-Leibovici O, Wainstein J, Ziv A, et al. Clinical, socioeconomic, and lifestyle parameters associated with erectile dysfunction among diabetic men. Diabetes Care 2005; 28:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38341/abstract/5\">",
"      Gazzaruso C, Solerte SB, Pujia A, et al. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors. J Am Coll Cardiol 2008; 51:2040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38341/abstract/6\">",
"      Ma RC, So WY, Yang X, et al. Erectile dysfunction predicts coronary heart disease in type 2 diabetes. J Am Coll Cardiol 2008; 51:2045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38341/abstract/7\">",
"      De Berardis G, Pellegrini F, Franciosi M, et al. Longitudinal assessment of quality of life in patients with type 2 diabetes and self-reported erectile dysfunction. Diabetes Care 2005; 28:2637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38341/abstract/8\">",
"      Giuliano FA, Leriche A, Jaudinot EO, de Gendre AS. Prevalence of erectile dysfunction among 7689 patients with diabetes or hypertension, or both. Urology 2004; 64:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38341/abstract/9\">",
"      Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995; 75:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38341/abstract/10\">",
"      De Berardis G, Pellegrini F, Franciosi M, et al. Identifying patients with type 2 diabetes with a higher likelihood of erectile dysfunction: the role of the interaction between clinical and psychological factors. J Urol 2003; 169:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38341/abstract/11\">",
"      Buvat J, Lemaire A. Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 1997; 158:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38341/abstract/12\">",
"      Wessells H, Penson DF, Cleary P, et al. Effect of intensive glycemic therapy on erectile function in men with type 1 diabetes. J Urol 2011; 185:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38341/abstract/13\">",
"      McCulloch DK, Hosking DJ, Tobert A. A pragmatic approach to sexual dysfunction in diabetic men: psychosexual counselling. Diabet Med 1986; 3:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38341/abstract/14\">",
"      Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999; 281:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38341/abstract/15\">",
"      Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003; 26:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38341/abstract/16\">",
"      S&aacute;enz de Tejada I, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002; 25:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38341/abstract/17\">",
"      Vardi M, Nini A. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. Cochrane Database Syst Rev 2007; :CD002187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38341/abstract/18\">",
"      Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 1997; 336:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38341/abstract/19\">",
"      Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med 1996; 334:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38341/abstract/20\">",
"      Kearse WS Jr, Sago AL, Peretsman SJ, et al. Report of a multicenter clinical evaluation of the Dura-II penile prosthesis. J Urol 1996; 155:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38341/abstract/21\">",
"      Garber BB. Inflatable penile prosthesis: results of 150 cases. Br J Urol 1996; 78:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38341/abstract/22\">",
"      Bejany DE, Perito PE, Lustgarten M, Rhamy RK. Gangrene of the penis after implantation of penile prosthesis: case reports, treatment recommendations and review of the literature. J Urol 1993; 150:190.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7464 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-04D01F2D42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_28_38341=[""].join("\n");
var outline_f37_28_38341=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE AND NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Glycemic control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Psychosexual counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Phosphodiesterase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Intraurethral alprostadil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Intracavernosal injections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7464\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7464|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/46/33517\" title=\"figure 1\">",
"      Impotence in men by age",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32533?source=related_link\">",
"      Evaluation of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42696?source=related_link\">",
"      Overview of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/15/8442?source=related_link\">",
"      Sexual activity in patients with heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/36/30282?source=related_link\">",
"      Treatment of male sexual dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_28_38342="Nonmucinous BAC hobnail";
var content_f37_28_38342=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Non-mucinous bronchioloalveolar carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High magnification photomicrograph showing non-mucinous hobnail cells (arrow) in bronchioloalveolar carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_28_38342=[""].join("\n");
var outline_f37_28_38342=null;
var title_f37_28_38343="Epidemiology, transmission, natural history, and pathogenesis of HIV-2 infection";
var content_f37_28_38343=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, transmission, natural history, and pathogenesis of HIV-2 infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/28/38343/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38343/contributors\">",
"     Geoffrey S Gottlieb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/28/38343/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38343/contributors\">",
"     John A Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/28/38343/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38343/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/28/38343/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H13491378\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although HIV-1 infection is associated with most of the global AIDS pandemic, HIV-2 is an important cause of disease in certain regions of the world where it is endemic. HIV-2 infection has also been described in pockets of locations globally, so it is an important consideration in patients with an AIDS-like illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will address the epidemiology, transmission, natural history, and pathogenesis of HIV-2 infection. The clinical manifestations, diagnosis, and treatment of HIV-2 are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/46/13030?source=see_link\">",
"     \"Clinical manifestations and diagnosis of HIV-2 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/5/26713?source=see_link\">",
"     \"Treatment of HIV-2 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1426447\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As of 2009, the World Health Organization (WHO) estimates that approximately 33 million people are living with",
"    <span class=\"nowrap\">",
"     HIV/AIDS;",
"    </span>",
"    by crude estimates, approximately one to two million of these people are infected with HIV-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/2-4\">",
"     2-4",
"    </a>",
"    ], including some who are dually infected with both viruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/2-7\">",
"     2-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1427234\">",
"    <span class=\"h2\">",
"     Origin of the epidemic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic evidence of a second human immunodeficiency virus was first discovered in 1985 in Senegal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/8\">",
"     8",
"    </a>",
"    ] with subsequent isolation of HIV-2 documented in 1986 from a Cape Verdean patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/9\">",
"     9",
"    </a>",
"    ]. Similar to HIV-1, HIV-2 was initially a zoonosis, originally transmitted from West African Sooty mangabeys to humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Serologic data suggest that HIV-2 may have been circulating as early as 1966 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/13\">",
"     13",
"    </a>",
"    ] while phylogenetic evidence dates its introduction into humans during the first half of the 20",
"    <sup>",
"     th",
"    </sup>",
"    century [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/2/21546?source=see_link&amp;anchor=H2#H2\">",
"     \"The global human immunodeficiency virus pandemic\", section on 'Origin of the HIV epidemic'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1427152\">",
"    <span class=\"h2\">",
"     HIV-2 in West Africa",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-2 is endemic in West Africa, although data over the past decade suggest that epidemiologic trends may be shifting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Several African countries (eg, Senegal, Gambia, Cote D&rsquo;Ivoire, Guinea-Bissau) have reported declining prevalence rates of HIV-2 over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/16-19\">",
"     16-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, a cross-sectional survey performed from 1996 to 2006 among 3242 individuals living in Guinea-Bissau demonstrated that the incidence of HIV-2 was declining and was half that of HIV-1 infection, when compared with a similar serosurvey from 1987 to 1996 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/18,20\">",
"     18,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additionally, the prevalence of HIV-2 decreased among persons below 45 years of age, but not among older individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/18\">",
"     18",
"    </a>",
"    ]. This observation may be due to a cohort effect, where previously infected individuals are aging with HIV-2 infection, which is less pathogenic than HIV-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/18\">",
"     18",
"    </a>",
"    ]. Other explanations include: a) lower rates of sexual transmission of HIV-2 compared with HIV-1 and b) screening of the blood supply for HIV-2, which was initiated in 1987. (See",
"    <a class=\"local\" href=\"#H1427133\">",
"     'Transmission'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1427159\">",
"    <span class=\"h2\">",
"     HIV-2 outside West Africa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regions and countries outside of West Africa reporting HIV-2 infections include: North America (United States, Canada), South America (Brazil, Venezuela), Europe (France, Spain, Portugal, United Kingdom, Sweden, Germany, Italy, Switzerland, Netherlands, Belgium, Greece), the Middle East (Lebanon, Israel, Egypt), Asia-Oceana (India, Philippines, China, Nepal, Japan, Australia, New Zealand), and Southern Africa (Zimbabwe, Angola, Mozambique, South Africa) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, the first case of HIV-2 infection was reported in 1987 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/23\">",
"     23",
"    </a>",
"    ]. The total number of cases of HIV-2 in the United States is small, with only 166 cases reported to the CDC between 1987 and 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/24\">",
"     24",
"    </a>",
"    ]. However, most experts suspect this is a likely underestimate; there have been 62 cases of HIV-2 diagnosed in New York City alone since implementation of HIV reporting in 2000 and many urban areas (eg, Chicago, Boston, Washington, DC) include immigrants from West Africa where HIV-2 is endemic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/1,25\">",
"     1,25",
"    </a>",
"    ]. The prevalence of HIV-2 may also be underestimated since most patients with HIV-2 infection are asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1426891\">",
"    <span class=\"h2\">",
"     Dual infection with HIV-1 and HIV-2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dual infection with HIV-1 and HIV-2 can occur in locales where both viruses co-circulate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Dual infection has been reported most commonly in West Africa where it is estimated that approximately 5 to 10 percent of HIV-infected individuals are coinfected with HIV-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/4,19,26-29\">",
"     4,19,26-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although one observational study in Senegalese female sex workers suggested that HIV-2 infection may be protective against HIV acquisition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/30\">",
"     30",
"    </a>",
"    ], these results were not corroborated by subsequent reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1427133\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60762404\">",
"    <span class=\"h2\">",
"     Routes of transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-1 and HIV-2 share similar routes of transmission including sexual contact, blood-borne exposure (eg, blood transfusions, shared needles) and perinatal transmission.",
"   </p>",
"   <p>",
"    Screening of the blood supply has virtually eliminated transmissions via this route in developed countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/34\">",
"     34",
"    </a>",
"    ]. The risk of HIV-2 infection has also declined in some African countries, such as Guinea-Bissau, where HIV-1 screening of the blood supply was initiated in 1987 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/20\">",
"     20",
"    </a>",
"    ]. Such screening may have identified patients with dual HIV-1 and HIV-2 infection or may have identified those with HIV-2 monoinfection through serologic cross-reactivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60762411\">",
"    <span class=\"h2\">",
"     Risk of transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transmission of HIV-2 appears to be less efficient than HIV-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/35-41\">",
"     35-41",
"    </a>",
"    ]. This is particularly notable when comparing perinatal transmission rates for these two viruses. For example, in studies of pregnant women in The Gambia or the Ivory Coast, the relative risk of transmission was 6- to 21-fold lower among HIV-2 infected compared with HIV-1 infected women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/37,41\">",
"     37,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lower risk of transmission of HIV-2 may be related to lower levels of viremia that are seen among infected patients compared with those with HIV-1. Compared with HIV-1, lower levels of HIV-2 shedding have also been found in the genital tracts of men and women, which may also help to explain the lower rates of HIV-2 transmission through sexual contact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/35,39,42\">",
"     35,39,42",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13491385\">",
"     'Natural history'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13491385\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H151845\">",
"    <span class=\"h2\">",
"     HIV-2 is less pathogenic than HIV-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies suggest that HIV-2 is generally less pathogenic than HIV-1. Chronic HIV-1 infection is characterized by rising levels of viremia and progressive immunologic decline in association with opportunistic infections that eventually lead to death in the untreated host. Compared with HIV-1, HIV-2 infection is characterized by [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/35-40,42-50\">",
"     35-40,42-50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A longer asymptomatic stage of infection",
"     </li>",
"     <li>",
"      Slower declines of CD4+ T-cell counts",
"     </li>",
"     <li>",
"      Lower levels of plasma viremia in chronically-infected patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60761993\">",
"    <span class=\"h3\">",
"     Risk of AIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The slower natural history of HIV-2 infection was well illustrated in an observational study in Senegal; 46 HIV-1 infected and 103 HIV-2 infected commercial sex workers were recruited and followed serially from 1985 to 1993 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/44\">",
"     44",
"    </a>",
"    ]. Over the course of the study, the probability of AIDS-free survival was higher among HIV-2 compared with HIV-1 infected women (100 percent versus 67 percent). In addition, a subset of women with incident HIV-1 seroconversion (n = 32) were significantly more likely to have a decline in CD4 cell counts (&lt;400",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    than those with incident HIV-2 seroconversion (n = 33).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2601006\">",
"    <span class=\"h3\">",
"     Risk of death",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-2 infected patients with a CD4 cell count &gt;500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    appear to have a lower risk of dying compared with HIV-1 infected patients with a similar immune status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/51\">",
"     51",
"    </a>",
"    ]. However, mortality rates among HIV-1 and HIV-2 infected patients with advanced disease appear similar when adjusting for CD4 cell count, age, and sex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60762000\">",
"    <span class=\"h3\">",
"     Lower levels of viremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;When matched for disease stage, studies of HIV-2 infected patients demonstrate that plasma viremia is significantly lower compared with HIV-1 infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/52\">",
"     52",
"    </a>",
"    ]. Low levels of viremia are also associated with slower declines of CD4 cell counts and lower rates of viral evolution among individual patients with HIV-2 infection compared with those with HIV-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/53\">",
"     53",
"    </a>",
"    ]. Lower levels of viremia are also seen among recent HIV-2 seroconverters; in one study, the viral load set point was approximately 28-fold lower after seroconversion among those with HIV-2 than with HIV-1 infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/54\">",
"     54",
"    </a>",
"    ]. HIV-2-specific CD8+ T cells may help to control viremia in early stages of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/54-56\">",
"     54-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, for each logarithmic increase in viral load in HIV-2 infected patients, the rate of CD4 T cell decline is similar to that seen in HIV-1 infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/45\">",
"     45",
"    </a>",
"    ]. Thus, the level of viremia may influence the development of advanced immunodeficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2600297\">",
"    <span class=\"h2\">",
"     Natural history among dually infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data as to whether the natural history of HIV-1 infection is altered by coinfection with HIV-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/54,58-65\">",
"     54,58-65",
"    </a>",
"    ]. Two large studies performed in Guinea-Bissau gave disparate results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, there was no difference in mortality between 53",
"      <span class=\"nowrap\">",
"       dually-HIV-1/HIV-2-infected",
"      </span>",
"      and 117 mono-HIV-1-infected individuals followed for more than 15 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/65\">",
"       65",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      In contrast, in another observational cohort, the median time to AIDS was longer in 32 patients with dual infection compared with 119 patients with HIV-1 alone (104 months versus 68 months) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/64\">",
"       64",
"      </a>",
"      ]. In addition, CD4 T cell counts were higher and HIV-1 genetic diversity was lower among those with dual infection.",
"      <br/>",
"      <br/>",
"      Despite significant efforts to assess possible individual sources of confounding (eg, misclassification, interval-screening bias, patient selection, and lost to follow-up), the authors did not estimate how these combined effects might temper their results. Other limitations of the study include the absence of viral load data and the unusually rapid time to onset of AIDS (~5.7 years) observed in the HIV-1 group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the conflicting results on natural history, clinicians need to be aware that once advanced immunodeficiency develops, dually-infected patients have similarly high mortality rates as seen in those with HIV-1 alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60762064\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms underlying the divergent natural history patterns between HIV-1 and HIV-2 infections are unclear.",
"   </p>",
"   <p>",
"    In patients with HIV-1 infection, systemic immune activation is an independent marker of disease progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/66\">",
"     66",
"    </a>",
"    ]. Immune activation may result from microbial translocation of bacterial cell wall products (eg, lipopolysaccharide), which occurs secondary to HIV-related invasion and disruption of the gastrointestinal mucosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. Cross-sectional studies of HIV-infected patients in the United States have demonstrated that different stages of HIV disease are associated with higher levels of circulating lipopolysaccharide (LPS) and markers of monocyte activation (sCD14) and decreased endotoxin core antibody (EndoCAb) levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/66,69\">",
"     66,69",
"    </a>",
"    ]. However, one longitudinal study in Africa did not support a role for microbial translocation among African patients with HIV-1 infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/70\">",
"     70",
"    </a>",
"    ]. These opposing observations may be related to different modes of transmission or differences in baseline cytokine levels due to chronic intestinal infections, which could alter the immune response to HIV-1 infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/34/5674?source=see_link\">",
"     \"Immunology of HIV-1 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are few studies that have examined the role of microbial translocation or chronic immune activation and disease progression among HIV-1 and HIV-2 infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/52,67,71,72\">",
"     52,67,71,72",
"    </a>",
"    ]. These observational studies have demonstrated the following key findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some studies have suggested that HIV-2 infected patients may have lower levels of immune activation compared with those with HIV-1, thus accounting for slower rates of disease progression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/71\">",
"       71",
"      </a>",
"      ], while others have found comparable levels among patients with similar stages of clinical disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are also conflicting data as to whether there is a direct relationship between viral load and markers of T cell activation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/52,67,72\">",
"       52,67,72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      However, several studies do suggest that immune activation (as measured by the cellular expression of HLA-DR and CD38 on CD4+ and CD8+ T cells) is directly associated with CD4+ T cell depletion in HIV-2 infected patients, as previously described in HIV-1 infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/52,67,71\">",
"       52,67,71",
"      </a>",
"      ]. Another study that examined the role of microbial translocation found a direct correlation between increased LPS levels and loss of CD4 T cells among HIV-1 and HIV-2 infected patients alike [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38343/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H603396\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Similar to HIV-1, HIV-2 was initially a zoonosis, originally transmitted from West African Sooty mangabeys to humans. (See",
"      <a class=\"local\" href=\"#H1427234\">",
"       'Origin of the epidemic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-2 is endemic in West Africa, but has also been reported in more than two dozen countries in multiple continents. Accurate estimates on the number of cases worldwide are lacking. (See",
"      <a class=\"local\" href=\"#H1427159\">",
"       'HIV-2 outside West Africa'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dual infection with HIV-1 and HIV-2 can occur in locales where both viruses cocirculate. (See",
"      <a class=\"local\" href=\"#H1426891\">",
"       'Dual infection with HIV-1 and HIV-2'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-1 and HIV-2 share similar routes of transmission including sexual contact, blood-borne exposure (eg, blood transfusions, shared needles) and perinatal transmission. (See",
"      <a class=\"local\" href=\"#H1427133\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transmission of HIV-2 appears to be less efficient than HIV-1. This observation may be related to the lower levels of plasma viremia and genital shedding that is observed among HIV-2 infected patients. (See",
"      <a class=\"local\" href=\"#H1427133\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple studies suggest that HIV-2 is generally less pathogenic than HIV-1. Compared with HIV-1, HIV-2 infection is characterized by a longer asymptomatic stage of infection, slower declines of CD4 cell counts and lower levels of plasma viremia. (See",
"      <a class=\"local\" href=\"#H13491385\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/1\">",
"      Campbell-Yesufu OT, Gandhi RT. Update on human immunodeficiency virus (HIV)-2 infection. Clin Infect Dis 2011; 52:780.",
"     </a>",
"    </li>",
"    <li>",
"     file://data.unaids.org/pub/Report/2009/JC1700_Epi_Update_2009_en.pdf (Accessed on March 01, 2011).",
"    </li>",
"    <li>",
"     file://www.cdc.gov/hiv/resources/factsheets/hiv2.htm (Accessed on March 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/4\">",
"      Ari&euml;n KK, Abraha A, Qui&ntilde;ones-Mateu ME, et al. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol 2005; 79:8979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/5\">",
"      Cot MC, Poulain M, Delagneau JF, et al. Dual HIV-1 and HIV-2 infection in West Africa supported by synthetic peptide analysis. AIDS Res Hum Retroviruses 1988; 4:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/6\">",
"      Evans LA, Moreau J, Odehouri K, et al. Simultaneous isolation of HIV-1 and HIV-2 from an AIDS patient. Lancet 1988; 2:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/7\">",
"      Rayfield M, De Cock K, Heyward W, et al. Mixed human immunodeficiency virus (HIV) infection in an individual: demonstration of both HIV type 1 and type 2 proviral sequences by using polymerase chain reaction. J Infect Dis 1988; 158:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/8\">",
"      Barin F, M'Boup S, Denis F, et al. Serological evidence for virus related to simian T-lymphotropic retrovirus III in residents of west Africa. Lancet 1985; 2:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/9\">",
"      Clavel F, Gu&eacute;tard D, Brun-V&eacute;zinet F, et al. Isolation of a new human retrovirus from West African patients with AIDS. Science 1986; 233:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/10\">",
"      Gao F, Yue L, Robertson DL, et al. Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J Virol 1994; 68:7433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/11\">",
"      Gao F, Bailes E, Robertson DL, et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 1999; 397:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/12\">",
"      Gao F, Yue L, White AT, et al. Human infection by genetically diverse SIVSM-related HIV-2 in west Africa. Nature 1992; 358:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/13\">",
"      Kawamura M, Yamazaki S, Ishikawa K, et al. HIV-2 in west Africa in 1966. Lancet 1989; 1:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/14\">",
"      Lemey P, Pybus OG, Wang B, et al. Tracing the origin and history of the HIV-2 epidemic. Proc Natl Acad Sci U S A 2003; 100:6588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/15\">",
"      Wertheim JO, Worobey M. Dating the age of the SIV lineages that gave rise to HIV-1 and HIV-2. PLoS Comput Biol 2009; 5:e1000377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/16\">",
"      van der Loeff MF, Awasana AA, Sarge-Njie R, et al. Sixteen years of HIV surveillance in a West African research clinic reveals divergent epidemic trends of HIV-1 and HIV-2. Int J Epidemiol 2006; 35:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/17\">",
"      Eholi&eacute; S, Anglaret X. Commentary: decline of HIV-2 prevalence in West Africa: good news or bad news? Int J Epidemiol 2006; 35:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/18\">",
"      da Silva ZJ, Oliveira I, Andersen A, et al. Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing? AIDS 2008; 22:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/19\">",
"      Hamel DJ, Sankal&eacute; JL, Eisen G, et al. Twenty years of prospective molecular epidemiology in Senegal: changes in HIV diversity. AIDS Res Hum Retroviruses 2007; 23:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/20\">",
"      Larsen O, da Silva Z, Sandstr&ouml;m A, et al. Declining HIV-2 prevalence and incidence among men in a community study from Guinea-Bissau. AIDS 1998; 12:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/21\">",
"      Remy G. HIV-2 infection throughout the world. A geographical perspective. Sante 1998; 8:440.",
"     </a>",
"    </li>",
"    <li>",
"     UNAIDS AIDS epidemic update 2006. In: Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO) 2004; 2006. p.1-94.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/23\">",
"      Centers for Disease Control (CDC). AIDS due to HIV-2 infection--New Jersey. MMWR Morb Mortal Wkly Rep 1988; 37:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/24\">",
"      Centers for Disease Control and Prevention (CDC). HIV-2 Infection Surveillance--United States, 1987-2009. MMWR Morb Mortal Wkly Rep 2011; 60:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/25\">",
"      Torian LV, Eavey JJ, Punsalang AP, et al. HIV type 2 in New York City, 2000-2008. Clin Infect Dis 2010; 51:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/26\">",
"      L&eacute;onard G, Chaput A, Courgnaud V, et al. Characterization of dual HIV-1 and HIV-2 serological profiles by polymerase chain reaction. AIDS 1993; 7:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/27\">",
"      Walther-Jallow L, Andersson S, da Silva Z, Biberfeld G. High concordance between polymerase chain reaction and antibody testing of specimens from individuals dually infected with HIV types 1 and 2 in Guinea-Bissau, West Africa. AIDS Res Hum Retroviruses 1999; 15:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/28\">",
"      Sarr AD, Hamel DJ, Thior I, et al. HIV-1 and HIV-2 dual infection: lack of HIV-2 provirus correlates with low CD4+ lymphocyte counts. AIDS 1998; 12:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/29\">",
"      Ishikawa K, Fransen K, Ariyoshi K, et al. Improved detection of HIV-2 proviral DNA in dually seroreactive individuals by PCR. AIDS 1998; 12:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/30\">",
"      Travers K, Mboup S, Marlink R, et al. Natural protection against HIV-1 infection provided by HIV-2. Science 1995; 268:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/31\">",
"      Sarr AD, Sankal&eacute; JL, Hamel DJ, et al. Interaction with human immunodeficiency virus (HIV) type 2 predicts HIV type 1 genotype. Virology 2000; 268:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/32\">",
"      Kokkotou EG, Sankale JL, Mani I, et al. In vitro correlates of HIV-2-mediated HIV-1 protection. Proc Natl Acad Sci U S A 2000; 97:6797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/33\">",
"      G&uuml;nthard HF, Huber M, Kuster H, et al. HIV-1 superinfection in an HIV-2-infected woman with subsequent control of HIV-1 plasma viremia. Clin Infect Dis 2009; 48:e117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/34\">",
"      U.S. Public Health Service guidelines for testing and counseling blood and plasma donors for human immunodeficiency virus type 1 antigen. MMWR Recomm Rep 1996; 45:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/35\">",
"      Kanki PJ, Travers KU, MBoup S, et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994; 343:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/36\">",
"      Comparison of vertical human immunodeficiency virus type 2 and human immunodeficiency virus type 1 transmission in the French prospective cohort. The HIV Infection in Newborns French Collaborative Study Group. Pediatr Infect Dis J 1994; 13:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/37\">",
"      Adjorlolo-Johnson G, De Cock KM, Ekpini E, et al. Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. JAMA 1994; 272:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/38\">",
"      Prazuck T, Yameogo JM, Heylinck B, et al. Mother-to-child transmission of human immunodeficiency virus type 1 and type 2 and dual infection: a cohort study in Banfora, Burkina Faso. Pediatr Infect Dis J 1995; 14:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/39\">",
"      Gottlieb GS, Hawes SE, Agne HD, et al. Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission. AIDS 2006; 20:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/40\">",
"      Burgard M, Jasseron C, Matheron S, et al. Mother-to-child transmission of HIV-2 infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO1. Clin Infect Dis 2010; 51:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/41\">",
"      O'Donovan D, Ariyoshi K, Milligan P, et al. Maternal plasma viral RNA levels determine marked differences in mother-to-child transmission rates of HIV-1 and HIV-2 in The Gambia. MRC/Gambia Government/University College London Medical School working group on mother-child transmission of HIV. AIDS 2000; 14:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/42\">",
"      Hawes SE, Sow PS, Stern JE, et al. Lower levels of HIV-2 than HIV-1 in the female genital tract: correlates and longitudinal assessment of viral shedding. AIDS 2008; 22:2517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/43\">",
"      Simon F, Matheron S, Tamalet C, et al. Cellular and plasma viral load in patients infected with HIV-2. AIDS 1993; 7:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/44\">",
"      Marlink R, Kanki P, Thior I, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994; 265:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/45\">",
"      Gottlieb GS, Sow PS, Hawes SE, et al. Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. J Infect Dis 2002; 185:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/46\">",
"      Gilbert PB, McKeague IW, Eisen G, et al. Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal. Stat Med 2003; 22:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/47\">",
"      MacNeil A, Sarr AD, Sankal&eacute; JL, et al. Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. J Virol 2007; 81:5325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/48\">",
"      Popper SJ, Sarr AD, Travers KU, et al. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J Infect Dis 1999; 180:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/49\">",
"      Poulsen AG, Aaby P, Larsen O, et al. 9-year HIV-2-associated mortality in an urban community in Bissau, west Africa. Lancet 1997; 349:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/50\">",
"      Martinez-Steele E, Awasana AA, Corrah T, et al. Is HIV-2- induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic. AIDS 2007; 21:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/51\">",
"      Schim van der Loeff MF, Jaffar S, Aveika AA, et al. Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in The Gambia. AIDS 2002; 16:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/52\">",
"      Sousa AE, Carneiro J, Meier-Schellersheim M, et al. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol 2002; 169:3400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/53\">",
"      MacNeil A, Sankale JL, Meloni ST, et al. Long-term intrapatient viral evolution during HIV-2 infection. J Infect Dis 2007; 195:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/54\">",
"      Andersson S, Norrgren H, da Silva Z, et al. Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. Arch Intern Med 2000; 160:3286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/55\">",
"      Leligdowicz A, Yindom LM, Onyango C, et al. Robust Gag-specific T cell responses characterize viremia control in HIV-2 infection. J Clin Invest 2007; 117:3067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/56\">",
"      Duvall MG, Jaye A, Dong T, et al. Maintenance of HIV-specific CD4+ T cell help distinguishes HIV-2 from HIV-1 infection. J Immunol 2006; 176:6973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/57\">",
"      Matheron S, Pueyo S, Damond F, et al. Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort. AIDS 2003; 17:2593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/58\">",
"      Nkengasong JN, Kestens L, Ghys PD, et al. Dual infection with human immunodeficiency virus type 1 and type 2: impact on HIV type 1 viral load and immune activation markers in HIV-seropositive female sex workers in Abidjan, Ivory Coast. AIDS Res Hum Retroviruses 2000; 16:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/59\">",
"      Greenberg AE. Possible protective effect of HIV-2 against incident HIV-1 infection: review of available epidemiological and in vitro data. AIDS 2001; 15:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/60\">",
"      Alabi AS, Jaffar S, Ariyoshi K, et al. Plasma viral load, CD4 cell percentage, HLA and survival of HIV-1, HIV-2, and dually infected Gambian patients. AIDS 2003; 17:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/61\">",
"      Koblavi-D&egrave;me S, Kestens L, Hanson D, et al. Differences in HIV-2 plasma viral load and immune activation in HIV-1 and HIV-2 dually infected persons and those infected with HIV-2 only in Abidjan, C&ocirc;te D'Ivoire. AIDS 2004; 18:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/62\">",
"      Borget MY, Diallo K, Adje-Toure C, et al. Virologic and immunologic responses to antiretroviral therapy among HIV-1 and HIV-2 dually infected patients: case reports from Abidjan, C&ocirc;te d'Ivoire. J Clin Virol 2009; 45:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/63\">",
"      Landman R, Damond F, Gerbe J, et al. Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients. AIDS 2009; 23:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/64\">",
"      Esbj&ouml;rnsson J, M&aring;nsson F, Kvist A, et al. Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection. N Engl J Med 2012; 367:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/65\">",
"      van Tienen C, Schim van der Loeff M, Peterson I, et al. HTLV-1 and HIV-2 infection are associated with increased mortality in a rural West African community. PLoS One 2011; 6:e29026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/66\">",
"      Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/67\">",
"      Leligdowicz A, Feldmann J, Jaye A, et al. Direct relationship between virus load and systemic immune activation in HIV-2 infection. J Infect Dis 2010; 201:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/68\">",
"      Levy JA. HIV pathogenesis: 25 years of progress and persistent challenges. AIDS 2009; 23:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/69\">",
"      Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One 2008; 3:e2516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/70\">",
"      Redd AD, Dabitao D, Bream JH, et al. Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa. Proc Natl Acad Sci U S A 2009; 106:6718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/71\">",
"      Michel P, Balde AT, Roussilhon C, et al. Reduced immune activation and T cell apoptosis in human immunodeficiency virus type 2 compared with type 1: correlation of T cell apoptosis with beta2 microglobulin concentration and disease evolution. J Infect Dis 2000; 181:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38343/abstract/72\">",
"      Nowroozalizadeh S, M&aring;nsson F, da Silva Z, et al. Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections. J Infect Dis 2010; 201:1150.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13966 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-A161942C46-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_28_38343=[""].join("\n");
var outline_f37_28_38343=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H603396\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13491378\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1426447\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1427234\">",
"      Origin of the epidemic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1427152\">",
"      HIV-2 in West Africa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1427159\">",
"      HIV-2 outside West Africa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1426891\">",
"      Dual infection with HIV-1 and HIV-2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1427133\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60762404\">",
"      Routes of transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60762411\">",
"      Risk of transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13491385\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H151845\">",
"      HIV-2 is less pathogenic than HIV-1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H60761993\">",
"      - Risk of AIDS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2601006\">",
"      - Risk of death",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H60762000\">",
"      - Lower levels of viremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2600297\">",
"      Natural history among dually infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H60762064\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H603396\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/46/13030?source=related_link\">",
"      Clinical manifestations and diagnosis of HIV-2 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/34/5674?source=related_link\">",
"      Immunology of HIV-1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/2/21546?source=related_link\">",
"      The global human immunodeficiency virus pandemic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/5/26713?source=related_link\">",
"      Treatment of HIV-2 infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_28_38344="Taxane-induced pulmonary toxicity";
var content_f37_28_38344=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Taxane-induced pulmonary toxicity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/28/38344/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38344/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38344/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/28/38344/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38344/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38344/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/28/38344/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38344/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38344/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/28/38344/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The taxanes,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (Taxol) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    (Taxotere), are anti-microtubulin drugs that have a broad range of antitumor activity. Both drugs have the potential to induce pulmonary injury through a variety of mechanisms.",
"   </p>",
"   <p>",
"    Acute infusion reactions (both mast",
"    <span class=\"nowrap\">",
"     cell/basophil",
"    </span>",
"    and cytokine-mediated) are common manifestations of chemotherapy and are seen with both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    . The most common pulmonary toxicity, interstitial pneumonitis, can develop within days to weeks of receiving either drug, or later in the course of therapy. A syndrome of capillary leakage resulting in peripheral edema, noncardiogenic pulmonary edema, and pleural effusions has been reported with docetaxel.",
"   </p>",
"   <p>",
"    The range of pulmonary toxicity seen with use of the taxanes will be reviewed here. An overview of chemotherapy-induced infusion reactions and general issues related to interstitial pneumonitis in adults are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=see_link\">",
"     \"Infusion reactions to systemic chemotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22792?source=see_link\">",
"     \"Acute interstitial pneumonia (Hamman-Rich syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/23/4474?source=see_link\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACUTE INFUSION REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactions that occur during or shortly after infusion of an antineoplastic agent can be categorized as",
"    <span class=\"nowrap\">",
"     hypersensitivity/allergic",
"    </span>",
"    reactions (associated with mast",
"    <span class=\"nowrap\">",
"     cell/basophil",
"    </span>",
"    activation) and standard infusion reactions (cytokine-mediated) (",
"    <a class=\"graphic graphic_table graphicRef76456 \" href=\"mobipreview.htm?35/54/36715\">",
"     table 1",
"    </a>",
"    ). The clinical signs and symptoms associated with these reactions overlap, although the mechanisms are different. The important reason to differentiate these reactions is that patients with symptoms and signs to suggest mast",
"    <span class=\"nowrap\">",
"     cell/basophil",
"    </span>",
"    mediation (eg, urticaria, angioedema, wheezing, stridor) are at risk for life-threatening anaphylaxis should rechallenge be undertaken (",
"    <a class=\"graphic graphic_table graphicRef72225 \" href=\"mobipreview.htm?22/43/23228\">",
"     table 2",
"    </a>",
"    ). The evaluation of reactions during or shortly after infusion and the clinical manifestations of anaphylaxis (from all causes) are presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=see_link\">",
"     \"Infusion reactions to systemic chemotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute infusion reactions to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    usually develop within the first 10 to 15 minutes of drug infusion, and nearly 95 percent occur during the first or second drug infusion. Symptoms may include dyspnea (with or without bronchospasm), urticaria, back pain, hypotension (or sometimes hypertension), and an erythematous rash, which may not begin until after the patient has returned home following drug infusion.",
"   </p>",
"   <p>",
"    The timing of these reactions suggests that they are mediated by nonimmunologic release of histamine or histamine-like compounds. However, reactions can occur with later infusions, even if they have not occurred with previous doses. It is uncertain whether the taxanes themselves or the vehicles in which they are dissolved (Cremophor [polyoxyethylated castor oil] for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , polysorbate 80 for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ) are responsible for the majority of infusion reactions.",
"   </p>",
"   <p>",
"    In early trials, acute infusion reactions developed in up to 30 percent of patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    . After the introduction of methods to diminish the incidence and severity of infusion reactions (eg, prolonging the drug infusion, and premedication with antihistamines and glucocorticoids), the rate of severe reactions was reduced to 2 to 4 percent. Premedication is now a standard component of paclitaxel administration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=see_link&amp;anchor=H36#H36\">",
"     \"Infusion reactions to systemic chemotherapy\", section on 'Premedication regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Novel taxane formulations (nanoparticle albumin-bound",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , paclitaxel polyglutamate) have been developed in an effort to shorten infusion times, decrease the incidence of infusion reactions, and reduce the need for glucocorticoid premedication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Nanoparticle albumin-bound paclitaxel (Abraxane) is Cremophor-free and can be administered by rapid infusion without premedication; infusion reactions are only rarely observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild to moderate standard infusion reactions (ie, infusion reactions that do not involve symptoms of anaphylaxis) can usually be overcome by stopping the infusion for 30 minutes, and then restarting at a slower rate. Reactions with ANY features of anaphylaxis (",
"    <a class=\"graphic graphic_table graphicRef72225 \" href=\"mobipreview.htm?22/43/23228\">",
"     table 2",
"    </a>",
"    ) as well as severe infusion reactions (grade 3 or 4, (",
"    <a class=\"graphic graphic_table graphicRef57843 \" href=\"mobipreview.htm?28/31/29179\">",
"     table 3",
"    </a>",
"    )) require discontinuation of drug infusion; anaphylaxis requires immediate treatment with epinephrine and antihistamines. This subject is addressed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=see_link&amp;anchor=H32#H32\">",
"     \"Infusion reactions to systemic chemotherapy\", section on 'Taxanes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Successful rechallenge with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    following desensitization has been reported. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=see_link&amp;anchor=H40#H40\">",
"     \"Infusion reactions to systemic chemotherapy\", section on 'Rechallenge'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INTERSTITIAL PNEUMONITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple reports of acute or subacute bilateral interstitial lung disease developing within hours or a few weeks after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/5-10\">",
"     5-10",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Symptoms include exertional dyspnea, dry cough, malaise, and low-grade fever.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       Paclitaxel",
"      </a>",
"      has been associated with acute diffuse interstitial pneumonia (which may progress to respiratory failure), subacute diffuse interstitial pneumonia (with a pattern similar to but often less severe as the acute form), pulmonary opacities with peripheral eosinophilia, and acute noncardiogenic pulmonary edema [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       Docetaxel",
"      </a>",
"      has been associated with acute or subacute diffuse interstitial pneumonia, acute permeability edema with or without a pattern of adult respiratory distress syndrome, and pleural effusions; the last two are thought to reflect a capillary leakage phenomenon. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Capillary leakage and docetaxel'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The interstitial pneumonitis induced by taxanes is thought to represent an immune-mediated delayed hypersensitivity reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/12,14\">",
"     12,14",
"    </a>",
"    ]. In one case report, the patient underwent bronchoalveolar lavage (BAL), and the BAL lymphocytes showed a positive leukocyte migration inhibition test to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/15\">",
"     15",
"    </a>",
"    ]. Based on this finding, paclitaxel (rather than its vehicle Cremophor) was judged responsible, via a cell-mediated (type IV) delayed reaction (",
"    <a class=\"graphic graphic_table graphicRef71375 \" href=\"mobipreview.htm?13/23/13692\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although most cases follow intravenous use of the taxane, fatal acute interstitial pneumonitis has also been described in patients after insertion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    -eluting intracoronary stents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43702?source=see_link&amp;anchor=H21#H21\">",
"     \"Drug-eluting intracoronary stents: General principles\", section on 'Hypersensitivity reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interstitial lung disease may rarely occur with more chronic dosing, and progression to pulmonary fibrosis has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/16\">",
"     16",
"    </a>",
"    ]. Whether the mechanism underlying chronic interstitial pneumonitis is similar to that responsible for the",
"    <span class=\"nowrap\">",
"     acute/subacute",
"    </span>",
"    presentation is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Incidence and impact of dose and schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 1 to 4 percent of patients receiving conventional-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    on an every three week schedule develop pneumonitis of grade 3 or higher (",
"    <a class=\"graphic graphic_table graphicRef61493 \" href=\"mobipreview.htm?18/50/19243\">",
"     table 5",
"    </a>",
"    ) severity during therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/16-23\">",
"     16-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a modest dose effect within the range of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    doses that are used in the clinic. This was shown in a phase III trial conducted in women with advanced breast cancer, in which there was a slightly but significantly higher incidence of grade 3 or 4 (",
"    <a class=\"graphic graphic_table graphicRef61493 \" href=\"mobipreview.htm?18/50/19243\">",
"     table 5",
"    </a>",
"    ) pulmonary toxicity with docetaxel doses of 100",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    as compared to 60",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    (2.2 versus 0.7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No difference in rates of pulmonary toxicity have been reported in trials comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    doses within a range that does not require growth factor or hematopoietic stem cell support (eg, 175 versus 225 or 250",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    of paclitaxel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]). However, interstitial pneumonitis has been seen more commonly with higher paclitaxel doses that require growth factor or hematopoietic stem cell support [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In fact, acute pneumonitis has been dose limiting in phase I trials of paclitaxel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is some evidence to suggest that weekly as compared to every three week dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    increases the incidence or severity of pulmonary toxicity. In a phase III trial directly comparing both paclitaxel administration schedules in women with advanced breast cancer, rates of grade 3 or higher (",
"    <a class=\"graphic graphic_table graphicRef61493 \" href=\"mobipreview.htm?18/50/19243\">",
"     table 5",
"    </a>",
"    ) dyspnea during therapy were 7 and 4 percent, respectively, with weekly or every three week treatment. There were two deaths due to pneumonia on the weekly schedule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/22\">",
"     22",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Another comparative trial also suggests a higher rate of pneumonitis in patients receiving weekly as compared to every three week",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/23\">",
"     23",
"    </a>",
"    ]. Of the 60 patients receiving weekly therapy, interstitial pneumonia developed in 16 (27 percent), and it was grade 1 or 2 (",
"    <a class=\"graphic graphic_table graphicRef61493 \" href=\"mobipreview.htm?18/50/19243\">",
"     table 5",
"    </a>",
"    ) in 13, and grade 3 or 4 in three (5 percent). By comparison, interstitial pneumonia only developed in 2 of the 33 patients receiving standard every three week therapy (6 percent), only one of which was grade 3.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Concomitant drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of taxane-induced pulmonary toxicity seems to be higher when taxanes are combined with other cytotoxic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/10,18,29-36\">",
"     10,18,29-36",
"    </a>",
"    ]. In particular, the combination of taxanes plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    appears to result in significantly more pulmonary toxicity than seen with a taxane alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/10,18,29-34,36,37\">",
"     10,18,29-34,36,37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, 4 of 12 patients (33 percent) with non-small cell lung cancer who were treated with the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      developed grade 2 or worse (",
"      <a class=\"graphic graphic_table graphicRef61493 \" href=\"mobipreview.htm?18/50/19243\">",
"       table 5",
"      </a>",
"      ) pneumonitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/10\">",
"       10",
"      </a>",
"      ]. The diagnosis was made on the basis of high-resolution CT scanning, and all patients responded to high-dose glucocorticoids within a week or less. No patient had received thoracic radiotherapy at any time during the course of the illness.",
"     </li>",
"     <li>",
"      In two other reports, grade 3 or worse interstitial lung disease was observed in 4 of 39 (10 percent) and 7 of 63 (11 percent) patients treated with the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      plus gemcitabine, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/30,38\">",
"       30,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a meta-analysis, the incidence of severe (grade 3 or worse) lung toxicity with combined",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      was 2.7 percent (95% CI 2.26 to 3.14); the proportion of fatal cases was 0.35 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/37\">",
"       37",
"      </a>",
"      ]. Patients treated for lung cancer were at a higher risk for severe pulmonary toxicity than were those treated for breast cancer (4 versus 0.8 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Concomitant radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Taxanes are often used in conjunction with radiotherapy (RT) and they are considered radiosensitizers. Thoracic RT is associated with lung damage, but concomitant therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    and lung irradiation can cause pulmonary disease beyond that attributable to RT alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24090?source=see_link\">",
"     \"Radiation-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial of concurrent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      and thoracic RT for non-small cell lung cancer, pneumonitis of grade 3 or greater severity (",
"      <a class=\"graphic graphic_table graphicRef61493 \" href=\"mobipreview.htm?18/50/19243\">",
"       table 5",
"      </a>",
"      ) was observed in 4 of 34 (12 percent) patients, while 44 percent had grade 1 or 2 pneumonitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A trial of concurrent RT and weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      in stage III non-small cell lung cancer reported a 47 percent rate of grade 3 or worse pneumonitis; the high rate was thought related to a large volume of irradiated lung [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of sequential rather than concurrent administration of taxanes and chest wall radiotherapy appears to reduce, although not eliminate, the excess risk of pneumonitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/35,43-48\">",
"     35,43-48",
"    </a>",
"    ]. As an example, a North American trial reported grade 3 to 5 (",
"    <a class=\"graphic graphic_table graphicRef61493 \" href=\"mobipreview.htm?18/50/19243\">",
"     table 5",
"    </a>",
"    ) pneumonitis in 10 percent of 73 patients (one death) treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    consolidation chemotherapy after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    plus concurrent chest irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Radiographic appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radiographic features of taxane-induced pulmonary toxicity are nonspecific and similar to other cases of drug-induced pneumonitis. Chest radiographs and high-resolution CT scans typically show an increase in reticular markings in a patchy or diffuse pattern with or without ground glass opacities (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51035 \" href=\"mobipreview.htm?12/20/12612\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/14,49,50\">",
"     14,49,50",
"    </a>",
"    ]. Pulmonary parenchymal infiltration with eosinophils or organizing pneumonia-type reactions may lead to focal opacities or dense",
"    <span class=\"nowrap\">",
"     nodules/consolidation",
"    </span>",
"    with or without air bronchograms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/29/16858?source=see_link&amp;anchor=H4#H4\">",
"     \"High resolution computed tomography of the lungs\", section on 'HRCT patterns'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis includes infectious agents, and lung involvement from the primary malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/9\">",
"     9",
"    </a>",
"    ]. There is no reliable radiographic pattern that serves to distinguish drug-induced pulmonary toxicity from either opportunistic infections or pulmonary infiltration with malignant cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Findings at BAL and biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main purpose of bronchoalveolar lavage (BAL) is to exclude other processes such as infection, alveolar hemorrhage, or metastatic spread of the underlying cancer. Patients with acute taxane-induced pneumonitis often have lymphocytosis in the BAL specimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/36/16968?source=see_link\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lung biopsy is indicated when the patient has progressive or severe disease and the cause of the pneumonitis is uncertain. Histopathology of biopsy specimens in taxane-induced pneumonitis shows nonspecific interstitial pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/424?source=see_link\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, treatment of taxane-induced pulmonary disease is empiric rather than evidence based and consists of supportive care and avoidance of additional taxane therapy until evidence of pneumonitis has resolved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/52\">",
"     52",
"    </a>",
"    ]. The rationale for using systemic glucocorticoid therapy in selected patients is based upon case reports suggesting an immunologic mechanism (eg, hypersensitivity pneumonitis) and anecdotal observation of benefit, particularly in cases that have an acute or subacute presentation. Bronchoconstriction, if present, is typically treated with inhaled bronchodilators (eg, beta agonists) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glucocorticoids are generally reserved for patients with severe pulmonary toxicity (eg, dyspnea at rest, a decrease in oxygen saturation below 90 percent or more than 4 percent decrease from baseline, or worsening clinical status). When considering systemic glucocorticoid therapy, it is mandatory to exclude an infectious etiology with appropriate cultures, often including BAL. Empiric antimicrobial therapy directed at likely pathogens is often indicated while diagnostic procedures and cultures are performed.",
"   </p>",
"   <p>",
"    There is no established glucocorticoid treatment schedule, but severe respiratory compromise is often treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    40 to 60 mg daily; intravenous glucocorticoids may be used in patients who have impending respiratory failure. In patients with an acute or subacute onset of pneumonitis, treatment with glucocorticoids usually rapidly reverses the pneumonitis and improves oxygenation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/7\">",
"     7",
"    </a>",
"    ]. If the patient's response permits, tapering of the dose can be carried out over one to two months.",
"   </p>",
"   <p>",
"    Rarely, patients will develop taxane-associated acute interstitial pneumonitis with biopsy evidence of diffuse alveolar damage and progress to life-threatening respiratory failure despite glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/11,12,54\">",
"     11,12,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22792?source=see_link\">",
"     \"Acute interstitial pneumonia (Hamman-Rich syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CAPILLARY LEAKAGE AND DOCETAXEL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    develop serious problems with fluid retention, attributed to capillary leakage. Clinically, this is usually manifest as peripheral edema, although pulmonary vascular leak can also occur, leading to noncardiogenic pulmonary edema,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pleural effusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/34,55\">",
"     34,55",
"    </a>",
"    ]. This side effect appears to be most closely related to the total dose of docetaxel administered; it appears at an average cumulative dose of 400",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    when docetaxel is given without glucocorticoid premedication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glucocorticoid premedication (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    8 mg twice daily for 24 hours before and 48 hours following each",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    dose, when the drug is administered on an every three week schedule) reduces the incidence of severe cases of fluid retention from 20 to 6 percent, reduces the number of patients discontinuing treatment because of this adverse effect from 32 to 3 percent, and increases the median cumulative dose to onset of moderate to severe fluid retention from 490",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    to 790",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal schedule of glucocorticoid administration in patients receiving weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    is unclear. At least two studies report a low incidence of infusion reactions with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    8 mg the night before, just prior to, and the evening after the weekly dose (24 mg per week). Alternatively, others have successfully used a single dose of 4 to 8 mg of dexamethasone prior to each weekly dose of docetaxel. This subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=see_link&amp;anchor=H35#H35\">",
"     \"Infusion reactions to systemic chemotherapy\", section on 'Other idiosyncratic reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When it does occur, the first sign of fluid retention is body weight gain. Early treatment with diuretics appears to be effective in limiting the severity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    -induced fluid retention. If the docetaxel is continued and the fluid retention not treated, it may progress to pleural",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pericardial effusions, pulmonary edema, and ascites. The diagnosis of noncardiogenic pulmonary edema is suggested by the time course, concomitant peripheral edema, and the lack of fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RADIATION RECALL",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     Paclitaxel",
"    </a>",
"    has also been occasionally reported to cause a recall pneumonitis in a patient who previously received radiation therapy for a non-small cell lung cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38344/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=see_link&amp;anchor=H20#H20\">",
"     \"Cutaneous complications of conventional chemotherapy agents\", section on 'Radiation recall and enhancement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Taxanes are widely used chemotherapeutic agents with the potential to induce pulmonary injury through a variety of mechanisms. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Infusion reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms and signs of acute infusion reactions to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    usually develop within the first 10 to 15 minutes of the first or second drug infusion (",
"    <a class=\"graphic graphic_table graphicRef76456 \" href=\"mobipreview.htm?35/54/36715\">",
"     table 1",
"    </a>",
"    ). The incidence can be reduced with routine premedication using a glucocorticoid and antihistamines. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Acute infusion reactions'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=see_link&amp;anchor=H36#H36\">",
"     \"Infusion reactions to systemic chemotherapy\", section on 'Premedication regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild to moderate standard infusion reactions (ie, infusion reactions that do not involve symptoms of anaphylaxis) can usually be overcome by stopping the infusion for 30 minutes, and then restarting at a lower rate. More severe reactions require more aggressive treatment, such as intravenous fluids, vasopressor medication. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=see_link&amp;anchor=H12#H12\">",
"     \"Infusion reactions to systemic chemotherapy\", section on 'Principles of treatment and rechallenge'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reactions that have features of mast",
"    <span class=\"nowrap\">",
"     cell/basophil",
"    </span>",
"    mediation require discontinuation of the medication and appropriate treatment with epinephrine and antihistamines. Successful rechallenge following desensitization has been reported. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=see_link&amp;anchor=H40#H40\">",
"     \"Infusion reactions to systemic chemotherapy\", section on 'Rechallenge'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Diffuse interstitial pneumonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving taxanes are at risk of diffuse interstitial pneumonitis, which may present within days to weeks of starting either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    , or later in the course of therapy. The incidence and severity depend on dose, schedule, use of concurrent chemotherapy agents, and use of concurrent or sequential radiation therapy. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Interstitial pneumonitis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Taxane-induced pulmonary toxicity needs to be considered in the differential diagnosis when patients receiving these agents present with respiratory symptoms. Clinical and radiographic features are nonspecific, and the diagnosis is usually one of exclusion. The main purpose of bronchoalveolar lavage (BAL) is to exclude other processes such as infection, alveolar hemorrhage, or metastatic spread of the underlying cancer. A lung biopsy is indicated when the patient has progressive or severe disease and the cause of the pneumonitis is uncertain. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Findings at BAL and biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of taxane-induced interstitial pneumonitis is generally supportive with discontinuation of the drug. For patients with severe pulmonary toxicity (eg, dyspnea at rest, a decrease in oxygen saturation below 90 percent or more than 4 percent decrease from baseline, or worsening clinical status), we suggest initiating systemic glucocorticoid therapy rather than observation alone (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). We generally use oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    40 to 60 mg daily; intravenous glucocorticoids may be used initially in patients who have impending respiratory failure. If the clinical response permits, tapering of the dose can be carried out over one to two months. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Most cases will resolve with observation or treatment with glucocorticoids, although fatalities have been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Docetaxel-related capillary leakage",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     Docetaxel",
"    </a>",
"    has been associated with fluid retention that is attributed to capillary leakage. The usual initial symptom is peripheral edema and weight gain, followed by pleural effusions and pulmonary edema, particularly if edema is untreated.",
"   </p>",
"   <p>",
"    For all patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    , we recommend glucocorticoid premedication to reduce the incidence and severity of fluid retention (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients receiving every three week therapy, the dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      is 8 mg twice daily the day before chemotherapy, the day of chemotherapy, and the day after chemotherapy.",
"     </li>",
"     <li>",
"      The optimal schedule of glucocorticoids for patients receiving weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      is not established. Options include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      8 mg the night before, just prior to, and the evening after the weekly dose (24 mg per week), or a single dose of 4 to 8 mg of dexamethasone prior to each weekly dose of docetaxel. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Capillary leakage and docetaxel'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=see_link&amp;anchor=H35#H35\">",
"       \"Infusion reactions to systemic chemotherapy\", section on 'Other idiosyncratic reactions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who develop peripheral edema while receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    , we suggest early treatment with daily diuretics to limit the severity of fluid retention (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/1\">",
"      Edelman MJ. Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancer. Clin Lung Cancer 2009; 10 Suppl 1:S30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/2\">",
"      Hennenfent KL, Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle? Ann Oncol 2006; 17:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/3\">",
"      Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23:7794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/4\">",
"      Socinski MA, Manikhas GM, Stroyakovsky DL, et al. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2010; 5:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/5\">",
"      Goldberg HL, Vannice SB. Pneumonitis related to treatment with paclitaxel. J Clin Oncol 1995; 13:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/6\">",
"      Ramanathan RK, Belani CP. Transient pulmonary infiltrates: a hypersensitivity reaction to paclitaxel. Ann Intern Med 1996; 124:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/7\">",
"      Khan A, McNally D, Tutschka PJ, Bilgrami S. Paclitaxel-induced acute bilateral pneumonitis. Ann Pharmacother 1997; 31:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/8\">",
"      Yasuda K, Igishi T, Kawasaki Y, et al. Phase II trial of weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. Oncology 2003; 65:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/9\">",
"      Ayoub JP, North L, Greer J, et al. Pulmonary changes in patients with lymphoma who receive paclitaxel. J Clin Oncol 1997; 15:2476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/10\">",
"      Thomas AL, Cox G, Sharma RA, et al. Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study. Eur J Cancer 2000; 36:2329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/11\">",
"      Read WL, Mortimer JE, Picus J. Severe interstitial pneumonitis associated with docetaxel administration. Cancer 2002; 94:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/12\">",
"      Wang GS, Yang KY, Perng RP. Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere). Br J Cancer 2001; 85:1247.",
"     </a>",
"    </li>",
"    <li>",
"     Foucher P, Camus P, and the GEPPI (Groupe d'Etude de la Pathologie Pulmonaire Iatrogene). www.pneumotox.com (Accessed on May 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/14\">",
"      Ramanathan RK, Reddy VV, Holbert JM, Belani CP. Pulmonary infiltrates following administration of paclitaxel. Chest 1996; 110:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/15\">",
"      Fujimori K, Yokoyama A, Kurita Y, et al. Paclitaxel-induced cell-mediated hypersensitivity pneumonitis. Diagnosis using leukocyte migration test, bronchoalveolar lavage and transbronchial lung biopsy. Oncology 1998; 55:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/16\">",
"      Ostoros G, Pretz A, Fillinger J, et al. Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature. Int J Gynecol Cancer 2006; 16 Suppl 1:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/17\">",
"      Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol 2006; 17:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/18\">",
"      Harries M, Moss C, Perren T, et al. A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer. Br J Cancer 2004; 91:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/19\">",
"      Graziano SL, Herndon JE 2nd, Socinski MA, et al. Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901. J Thorac Oncol 2008; 3:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/20\">",
"      Yasuda K, Igishi T, Kawasaki Y, et al. Phase II study of weekly paclitaxel in patients with non-small cell lung cancer who have failed previous treatments. Oncology 2004; 66:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/21\">",
"      Maruyama R, Nishiwaki Y, Tamura T, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008; 26:4244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/22\">",
"      Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008; 26:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/23\">",
"      Chen YM, Shih JF, Perng RP, et al. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest 2006; 129:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/24\">",
"      Harvey V, Mouridsen H, Semiglazov V, et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 2006; 24:4963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/25\">",
"      Winer EP, Berry DA, Woolf S, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 2004; 22:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/26\">",
"      Bolis G, Scarfone G, Polverino G, et al. Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial. J Clin Oncol 2004; 22:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/27\">",
"      Stemmer SM, Cagnoni PJ, Shpall EJ, et al. High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial. J Clin Oncol 1996; 14:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/28\">",
"      McNeish IA, Kanfer EJ, Haynes R, et al. Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours. Br J Cancer 2004; 90:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/29\">",
"      Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 2008; 109:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/30\">",
"      Katakami N, Takiguchi Y, Yoshimori K, et al. Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group. J Thorac Oncol 2006; 1:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/31\">",
"      Dunsford ML, Mead GM, Bateman AC, et al. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol 1999; 10:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/32\">",
"      Li J, Juliar B, Yiannoutsos C, et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol 2005; 23:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/33\">",
"      Takeda K, Negoro S, Tamura T, et al. Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol 2009; 20:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/34\">",
"      Briasoulis E, Froudarakis M, Milionis HJ, et al. Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support. Respiration 2000; 67:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/35\">",
"      Yu TK, Whitman GJ, Thames HD, et al. Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients. J Natl Cancer Inst 2004; 96:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/36\">",
"      Kalmadi S, McNeill G, Davis M, et al. Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer. Med Oncol 2006; 23:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/37\">",
"      Binder D, H&uuml;bner RH, Temmesfeld-Wollbr&uuml;ck B, Schlattmann P. Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials. Cancer Chemother Pharmacol 2011; 68:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/38\">",
"      Akerley W, Safran H, Zaner K, et al. Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer. Cancer 2006; 107:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/39\">",
"      Reckzeh B, Merte H, Pfl&uuml;ger KH, et al. Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. J Clin Oncol 1996; 14:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/40\">",
"      Nakamura M, Koizumi T, Hayasaka M, et al. Cisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage III non-small-cell lung cancer. Cancer Chemother Pharmacol 2009; 63:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/41\">",
"      Onishi H, Kuriyama K, Yamaguchi M, et al. Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis. Lung Cancer 2003; 40:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/42\">",
"      Hanna YM, Baglan KL, Stromberg JS, et al. Acute and subacute toxicity associated with concurrent adjuvant radiation therapy and paclitaxel in primary breast cancer therapy. Breast J 2002; 8:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/43\">",
"      Sekine I, Nokihara H, Sumi M, et al. Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer. J Thorac Oncol 2006; 1:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/44\">",
"      Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008; 26:5755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/45\">",
"      Taghian AG, Assaad SI, Niemierko A, et al. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst 2001; 93:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/46\">",
"      Beal K, Hudis C, Norton L, et al. Radiation pneumonitis in breast cancer patients treated with taxanes: does sequential radiation therapy lower the risk? Breast J 2005; 11:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/47\">",
"      Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003; 21:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/48\">",
"      Wang S, Liao Z, Wei X, et al. Association between systemic chemotherapy before chemoradiation and increased risk of treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy. J Thorac Oncol 2008; 3:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/49\">",
"      Cleverley JR, Screaton NJ, Hiorns MP, et al. Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol 2002; 57:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/50\">",
"      Wong P, Leung AN, Berry GJ, et al. Paclitaxel-induced hypersensitivity pneumonitis: radiographic and CT findings. AJR Am J Roentgenol 2001; 176:718.",
"     </a>",
"    </li>",
"    <li>",
"     Camus P, White DA. Drugs and the lungs. In: Clinical Respiratory Medicine, 3rd, Albert RK, Spiro SG, Jett JR (Eds), Mosby Elsevier, Philadelphia 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/52\">",
"      Limper AH. Chemotherapy-induced lung disease. Clin Chest Med 2004; 25:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/53\">",
"      Lee C, Gianos M, Klaustermeyer WB. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol 2009; 102:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/54\">",
"      Suzaki N, Hiraki A, Takigawa N, et al. Severe interstitial pneumonia induced by paclitaxel in a patient with adenocarcinoma of the lung. Acta Med Okayama 2006; 60:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/55\">",
"      Amathieu R, Tual L, Fessenmeyer C, Dhonneur G. [Docetaxel-induced acute pulmonary capillary-leak syndrome mimicking cardiogenic oedema]. Ann Fr Anesth Reanim 2007; 26:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/56\">",
"      Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995; 13:2643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/57\">",
"      Burris HA. Optimal use of docetaxel (Taxotere): maximizing its potential. Anticancer Drugs 1996; 7 Suppl 2:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38344/abstract/58\">",
"      Schweitzer VG, Juillard GJ, Bajada CL, Parker RG. Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel. Cancer 1995; 76:1069.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4355 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-F35B292492-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_28_38344=[""].join("\n");
var outline_f37_28_38344=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACUTE INFUSION REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INTERSTITIAL PNEUMONITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Incidence and impact of dose and schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Concomitant drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Concomitant radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Radiographic appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Findings at BAL and biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CAPILLARY LEAKAGE AND DOCETAXEL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RADIATION RECALL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Infusion reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Diffuse interstitial pneumonitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Docetaxel-related capillary leakage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4355\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4355|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?12/20/12612\" title=\"diagnostic image 1\">",
"      Paclitaxel pneumonitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4355|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/54/36715\" title=\"table 1\">",
"      Chemotherapy infusion reaction types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/43/23228\" title=\"table 2\">",
"      Anaphylaxis diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/31/29179\" title=\"table 3\">",
"      Grade of infusion related reactions NCI CTCAE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/23/13692\" title=\"table 4\">",
"      Types of allergic reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/50/19243\" title=\"table 5\">",
"      NCI CTCAE pneumonitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22792?source=related_link\">",
"      Acute interstitial pneumonia (Hamman-Rich syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/20/22856?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/18/16681?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=related_link\">",
"      Cutaneous complications of conventional chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43702?source=related_link\">",
"      Drug-eluting intracoronary stents: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/23/4474?source=related_link\">",
"      Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=related_link\">",
"      Infusion reactions to systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24090?source=related_link\">",
"      Radiation-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/36/16968?source=related_link\">",
"      Role of bronchoalveolar lavage in diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_28_38345="Valvar aortic stenosis in children";
var content_f37_28_38345=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Valvar aortic stenosis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/28/38345/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38345/contributors\">",
"     David W Brown, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38345/contributors\">",
"     John F Keane, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/28/38345/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38345/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/28/38345/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38345/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/28/38345/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular outflow tract (LVOT) obstructive lesions account for approximately 6 percent of cases of congenital heart disease in children; in one series, the incidence was estimated to be 3.8 in 10,000 live births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Obstruction can occur at valvar, subvalvar, and supravalvar levels.",
"   </p>",
"   <p>",
"    The most common form of LVOT in children is valvar aortic stenosis (AS), accounting for as many as 71 to 86 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. More than three-quarters of affected patients are male [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Valvar aortic stenosis will be reviewed here. Subvalvar and supravalvar aortic stenosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/27/33207?source=see_link\">",
"     \"Subvalvar aortic stenosis (subaortic stenosis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40774?source=see_link\">",
"     \"Supravalvar aortic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among children with valvar AS, the most common cause is a bicommissural or bicuspid aortic valve, that is, only two leaflets are present rather than the normal three. Bicommissural aortic valve is associated with both congenital and acquired aortic stenosis. It is also the most common cause of acquired aortic stenosis in adults. As an example, a review of 932 adults who underwent operative excision of an aortic stenotic valve reported that two thirds of the patients had a bicommissural aortic valve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/5\">",
"     5",
"    </a>",
"    ]. The severity of AS progressed with age, with the majority of patients requiring surgical intervention after 50 years of age. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6169?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon large retrospective autopsy studies, bicommissural aortic valve had been estimated to occur in 1 to 2 percent of the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. This is likely to be an overestimation as demonstrated by two echocardiographic screening studies, which reported a lower prevalence of 0.5 percent in both neonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/9\">",
"     9",
"    </a>",
"    ] and school-age children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/10\">",
"     10",
"    </a>",
"    ]. In each of these studies, bicommissural aortic valves were more common among males than females (0.7 versus 0.2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Familial clustering has also been observed, as approximately 35 percent of patients with a bicommissural aortic valve have at least one additional family member with a bicommissural aortic valve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with congenital AS are slightly more likely to have offspring with congenital heart disease. This was illustrated in a report from the Second Natural History Study of Congenital Heart Defects in which congenital heart disease occurred in three offspring of 251 (1.2 percent) males with AS and one of 72 females (1.4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/12\">",
"     12",
"    </a>",
"    ]; these values are somewhat higher than the 0.5 to 0.8 percent incidence of congenital heart disease in live births in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/1,13\">",
"     1,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Associated cardiovascular anomalies have been noted in as many as 20 percent of children with congenital AS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/14\">",
"     14",
"    </a>",
"    ]. Among patients with a bicommissural aortic valve, coexisting coarctation of the aorta is seen in approximately 6 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/8\">",
"     8",
"    </a>",
"    ]; on the other hand, as many as 30 to 40 percent of patients with coarctation have a bicommissural aortic valve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/15\">",
"     15",
"    </a>",
"    ]. Dilated ascending aorta is commonly associated with bicommissural aortic valve. Less common concomitant congenital anomalies include patent ductus arteriosus, bicommissural pulmonic valve, and congenital mitral regurgitation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6169?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23385?source=see_link\">",
"     \"Clinical manifestations and diagnosis of coarctation of the aorta\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less common forms of congenital AS include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unicommissural or unicuspid aortic valves, in which two of the three commissures are fused [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/16,17\">",
"       16,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Aortic annular hypoplasia, which may be an isolated abnormality or may be seen in association with leaflet abnormalities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/18,19\">",
"       18,19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These rarer forms of congenital aortic stenosis are often associated with severe obstruction to left ventricular outflow and heart failure in infancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal aortic valve has three commissures, which results in three leaflets of approximately equal size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/20\">",
"     20",
"    </a>",
"    ]. The free margins of the leaflets have a semilunar shape. Normal leaflets are smooth and pliable. In older patients, a fibrous nodule may be located at the center of their free margins.",
"   </p>",
"   <p>",
"    Mild AS from a bicommissural aortic valve commonly progresses as the patient ages, although the rate is variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/21\">",
"     21",
"    </a>",
"    ]. In the majority of patients with bicommissural aortic valves, the size of the valve leaflets is unequal, which is thought to result from the fusion or absence of one of the three valve commissures; a false commissure or raphe is frequently present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/8\">",
"     8",
"    </a>",
"    ]. With absence of the right-left (intercoronary) commissure, the most common form, the leaflets are oriented anterior and posterior, the raphe is usually in the anterior leaflet, and both coronary arteries arise from the aortic sinuses above the anterior leaflet. In a series of 1135 patients, this orientation was found in 70 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Less commonly, there is absence of the right-noncoronary commissure, and the leaflets are oriented to the right and left; the raphe is usually in the right leaflet, and the coronary arteries arise from the aortic sinuses above each leaflet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/20\">",
"     20",
"    </a>",
"    ]. Absence or fusion of the left-noncoronary commissure is exceedingly rare. The free margins of a bicommissural valve are relatively straight rather than semilunar. This configuration limits their mobility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bicommissural valve morphology has clinical and prognostic importance as illustrated in the review of 1135 patients cited above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/22\">",
"     22",
"    </a>",
"    ]. Patients with fusion of the right-noncoronary commissure had a higher incidence of moderate or greater aortic stenosis, and moderate or greater aortic regurgitation (AR). In contrast, patients with the more common absence of the right-left commissure had lesser degrees of aortic stenosis and regurgitation. Coarctation of the aorta was highly associated with absence from the right-left commissure, with 89 percent of patients with coarctation and a bicommissural aortic valve having this morphology.",
"   </p>",
"   <p>",
"    In a subsequent nested cohort longitudinal study of 310 patients selected from the above study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/22\">",
"     22",
"    </a>",
"    ], patients with the right-noncoronary commissural absence compared to those with right-left commissural absence were more likely to require intervention because of more rapid progression of aortic stenosis and regurgitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A unicommissural or unicuspid aortic valve results from the absence of two of the three commissures. Most commonly, the patent commissure is the left-noncoronary commissure, which results in a valve with an eccentric, teardrop-shaped opening that may extend leftward and posteriorly to the annulus. The valve is thus described as having a single \"cusp.\" Absence of all three commissures results in aortic atresia and usually in the hypoplastic left heart syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases of valvar AS, systemic blood pressure and cardiac output remain normal because left ventricular (LV) systolic pressure and total cardiac work are elevated. Despite the increase in total cardiac work, wall stress remains normal or even reduced, presumably because of the compensatory increase in left ventricular wall thickness. In a study of LV mechanics, the ejection fraction (0.88 versus 0.64) and mean velocity of fiber shortening (1.80 versus 1.22",
"    <span class=\"nowrap\">",
"     circ/s)",
"    </span>",
"    were higher in children with AS than normal subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important physiologic derangement in valvar AS is the relative reduction in coronary blood supply to a hypertrophied, hypertensive left ventricle with increased myocardial oxygen demand. This may lead to subendocardial ischemia and infarction. The imbalance between supply and demand is due to a decrease in coronary perfusion pressure and a shortened diastolic filling period (due to prolonged systolic ejection across the stenotic orifice). This imbalance is exaggerated by exercise, which further shortens the diastolic filling period, decreases coronary perfusion, increases the gradient across the stenotic aortic valve, and results in both increased myocardial oxygen demand and decreased myocardial oxygen delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children with congenital valvar AS, even to moderate degrees, are relatively asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients with bicommissural valves and no stenosis still require long-term follow-up, because progressive stenosis develops in approximately 75 percent of adults. Thickening and focal calcification of the bicommissural valve can be detected pathologically and on echocardiography as early as the second decade of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More severe disease in childhood is not uncommon, as approximately 10 percent develop heart failure during the first year after birth. Of these, about two-thirds become symptomatic by two months of age, and most present before six months. Infants with critical AS, the most severe form, present with signs of severe heart failure or cardiogenic shock in the neonatal period or shortly thereafter, following closure of the ductus arteriosus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Critical AS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Critical AS is often well tolerated in utero because LV output is decreased and the right ventricle (RV) supports a greater share of the fetal cardiac output via the ductus arteriosus. However, there are reports of in utero cardiac dysfunction, hydrops fetalis, and endocardial fibroelastosis due to critical AS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In particular, the rare combination of severe fetal AS and mitral regurgitation results in left heart dilation and compression of the right ventricle causing poor cardiac output and hydrops fetalis, and a poor outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, severely restricted forward flow from critical AS may lead to hypoplastic left heart syndrome (HLHS) with small left-sided heart structures in utero [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/31\">",
"     31",
"    </a>",
"    ]. Fetal echocardiography may be helpful in predicting which fetuses with AS will develop HLHS. Identification of these fetuses becomes increasingly important with the possible development of in utero intervention to prevent the progression of AS to HLHS. In one study from a tertiary center, fetuses at midgestation (16 to 30 weeks gestation) who were more likely to develop HLHS had echographic findings of reversed blood flow in the transverse aortic arch, left to right blood flow across the foramen ovale, monophasic mitral valve inflow, and moderate to severe left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/32\">",
"     32",
"    </a>",
"    ]. However, the ability to detect these changes are dependent on operator expertise and in other clinical settings the ability to detect prenatal heart disease is low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/54/4968?source=see_link\">",
"     \"Prenatal sonographic diagnosis of fetal cardiac anomalies\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H21\">",
"     'Fetus'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/27/41401?source=see_link\">",
"     \"Hypoplastic left heart syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following delivery, the ductus arteriosus closes, pulmonary vascular resistance falls, and venous return to the left atrium increases. If the LV cannot fill or eject a sufficient volume of blood, cardiac output cannot be maintained, leading to signs and symptoms of heart failure or even cardiogenic shock [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/33\">",
"     33",
"    </a>",
"    ]. This condition is fatal without intervention.",
"   </p>",
"   <p>",
"    Infants with critical AS may present at birth with poor peripheral perfusion and cyanosis. Physical examination reveals a hyperactive precordium and poor pulses. A cardiac murmur is frequently not heard because of the poor cardiac output. Although a gallop rhythm may be appreciated, an ejection click is almost never present. Distal pulses are often poor or inappreciable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Infantile AS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with severe but not critical AS present in infancy with heart failure. They typically have tachypnea, poor feeding, and growth failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9466?source=see_link&amp;anchor=H23884780#H23884780\">",
"     \"Etiology and diagnosis of heart failure in infants and children\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A hyperactive precordium is usually present on physical examination. Most have a characteristic ejection murmur along the upper left sternal border that radiates to the neck, although it may be very soft if heart failure is severe. An ejection click may be heard. Many patients have hepatomegaly and peripheral edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Older children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older children with AS are rarely symptomatic. Nearly all have appropriate growth and development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/26,34\">",
"     26,34",
"    </a>",
"    ]. Some patients report fatigability, which appears to be unrelated to the severity of AS. Angina and syncope occur in less than 5 percent of children with valvar AS, and are more common in those with higher gradients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Older children typically have normal vital signs, including blood pressure. Auscultation and palpation may reveal one or more of the following (",
"    <a class=\"graphic graphic_table graphicRef51024 \" href=\"mobipreview.htm?42/11/43196\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Visible apical activity and an increased LV impulse on palpation are common with severe stenosis.",
"     </li>",
"     <li>",
"      The first heart sound is usually normal, and the second heart sound is normally split unless stenosis is severe.",
"     </li>",
"     <li>",
"      Approximately 60 to 90 percent of children with valvar AS have an ejection click, which is usually loudest at the apex or lower left sternal border (",
"      <a class=\"graphic graphic_movie graphicRef72877 \" href=\"mobipreview.htm?43/6/44128\">",
"       movie 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A systolic ejection murmur is present; its intensity is proportional to the extent of stenosis. The murmur typically has a harsh, loud, crescendo-decrescendo quality (",
"      <a class=\"graphic graphic_movie graphicRef77091 \" href=\"mobipreview.htm?39/8/40065\">",
"       movie 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Approximately one-third of patients also have a diastolic regurgitant murmur [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/33/1559?source=see_link\">",
"       \"Aortic regurgitation in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As the severity of stenosis increases, the following auscultatory changes occur (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ejection click may disappear.",
"     </li>",
"     <li>",
"      The ejection murmur becomes harsh, longer, and peaks later with increasing obstruction. The late peak is associated with a delay in the carotid upstroke.",
"     </li>",
"     <li>",
"      The intensity of the aortic component of the second sound decreases, and paradoxical splitting of the second sound may occur.",
"     </li>",
"     <li>",
"      A systolic thrill may be palpable at the right base or suprasternal notch.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with congenital valvar AS often have progressive obstruction and are at substantial risk for infectious endocarditis and sudden death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/26,35,36\">",
"     26,35,36",
"    </a>",
"    ]. The long-term outcome of this disorder was evaluated in the Second Natural History Study of Congenital Heart Defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/36\">",
"     36",
"    </a>",
"    ]. This report included 371 patients with AS, mostly children, who had undergone cardiac catheterization from 1958 to 1969; 92 percent were asymptomatic. Most with gradients across the aortic valve &ge;80 mmHg underwent valvotomy, while most with gradients &lt;50 mmHg were treated medically. Those with intermediate gradients had either medical or surgical therapy. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The probability of 25-year survival was 92.4 and 81 percent for patients with initial peak systolic ejection gradients &lt;50 or &ge;50 mmHg, respectively.",
"     </li>",
"     <li>",
"      In 32 percent of 212 patients who were treated medically, obstruction progressed to a severe gradient, especially in the younger patients.",
"     </li>",
"     <li>",
"      The likelihood of needing surgery in 25 years was 20, 40, and 60 percent for patients with initial gradients of &lt;25, 25 to 49, and 50 to 79 mmHg, respectively.",
"     </li>",
"     <li>",
"      Sudden death occurred in 25 patients (5 percent) and accounted for more than one-half of cardiac deaths. These patients were almost all older than 10 years and had significant obstruction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      aortic regurgitation (AR); 19 had prior surgery.",
"     </li>",
"     <li>",
"      Infectious endocarditis occurred in 3 percent. In another report from this registry, the overall risk of endocarditis was 0.27 percent per year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/35\">",
"       35",
"      </a>",
"      ]. The risk was greater in patients treated surgically (0.41 versus 0.16 percent per year in those with less severe disease who were treated medically). The applicability of these findings to current practice is uncertain since the data were obtained before widespread use of antimicrobial prophylaxis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"       \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A study of patients with mild aortic stenosis (initial systolic gradient between 10 to 25 mmHg) reported that a low gradient-slope of &lt;1.2",
"    <span class=\"nowrap\">",
"     mmHg/year",
"    </span>",
"    (change gradient over time in years) was associated with a low risk of increasing obstruction and need for surgical correction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/37\">",
"     37",
"    </a>",
"    ]. Based upon their results, the authors suggested that followup echocardiography could be performed every four to five years in this low-risk group, but in children with higher gradient-slope (&ge;1.2",
"    <span class=\"nowrap\">",
"     mmHg/year),",
"    </span>",
"    echocardiography should be performed every one to two years.",
"   </p>",
"   <p>",
"    Similar finding of a slow progression of obstruction in children with mild disease was reported in a retrospective study of 245 children with valvar AS followed over a mean of 9 years (range 0.1 to 19.4 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/38\">",
"     38",
"    </a>",
"    ]. The rates of intervention and mortality were greatest in patients diagnosed in infancy with more severe disease. Deaths in infants were mostly due to progressive left ventricular dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of valvar AS is almost always made by physical examination and echocardiography. Cardiac catheterization is performed if the diagnosis remains uncertain, if there are associated defects that cannot be completely evaluated noninvasively, or if balloon aortic valvuloplasty is anticipated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is confirmed by two-dimensional echocardiography with Doppler analysis. This technique is used to estimate the severity of obstruction and evaluate LV function, valve morphology, and the degree of aortic regurgitation (AR). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1082?source=see_link\">",
"     \"Echocardiographic evaluation of the aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    M-mode and two-dimensional echocardiography are useful for demonstrating reduced valve leaflet mobility and making measurements of valve orifice area, as well as documenting the presence of poststenotic dilation of the supravalvar aortic root (",
"    <a class=\"graphic graphic_movie graphicRef66664 \" href=\"mobipreview.htm?21/52/22351\">",
"     movie 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef59607 \" href=\"mobipreview.htm?27/17/27921\">",
"     movie 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Using Doppler echocardiography and Bernoulli's equation, the maximum instantaneous gradient across the stenotic valve can be estimated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/39\">",
"     39",
"    </a>",
"    ]. This value is usually higher than the phase shifted peak-to-peak gradient between the left ventricle and aorta measured at catheterization. Mean gradient values estimated by Doppler correlate better with those measured at catheterization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/11/1208?source=see_link\">",
"     \"Aortic valve area in aortic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECG is of limited use in children with AS. It is typically abnormal in infants with critical AS, although rarely diagnostic. The majority of older infants have evidence of LV hypertrophy and inverted T waves, although these findings may be absent and cannot be used to estimate the extent of severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ECG also has limited utility in distinguishing mild from severe obstruction in older affected children (more than two years of age) because of the lack of a close correlation between the ECG and the transvalvar pressure gradient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/26,36\">",
"     26,36",
"    </a>",
"    ]. In children with less severe initial disease, the ECG is often normal until the later stages. On the other hand, evidence of left ventricular hypertrophy, with or without repolarization abnormality, has been described in approximately 30 percent of children with a significant degree of stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiographs in symptomatic infants typically show cardiomegaly that may be severe. In general, cardiac enlargement in older patients does not correlate with the severity of stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/20\">",
"     20",
"    </a>",
"    ]. Dilation of the ascending aorta may be seen in older patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Exercise testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise testing is not usually performed in children. In adults with AS, the ST segment change during exercise correlates with the echocardiographic Doppler maximum transaortic gradient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/41\">",
"     41",
"    </a>",
"    ]. However, in children and young adults, the false positive rate (ST changes with less severe stenosis) for exercise testing may be as high as 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cardiac catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac catheterization is performed if the diagnosis remains uncertain, if there are associated defects that cannot be completely evaluated by echocardiography, or if balloon aortic valvuloplasty is anticipated. Catheterization provides both hemodynamic and anatomic data, such as the gradient across the valve, ventricular end-diastolic pressure, cardiac output, and anatomy and competency of the valve. Associated lesions, such as aortic coarctation, can also be defined. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/41/3737?source=see_link&amp;anchor=H2#H2\">",
"     \"Hemodynamics of valvular disorders as measured by cardiac catheterization\", section on 'Valvular aortic stenosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As part of this procedure, balloon valvotomy can be performed if indicated. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Balloon valvotomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive therapy consists of reducing the degree of valvar stenosis. The treatment of choice is balloon valvuloplasty, which has largely replaced surgery. Surgical options include valvotomy and valve replacement, which is now rarely performed for valvar AS in children. However, patients who develop severe AR following balloon dilation require surgical treatment. In such patients, valve repair is effective and usually preferred to valve replacement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/33/1559?source=see_link\">",
"     \"Aortic regurgitation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Indications for intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific treatment for AS depends upon the degree of obstruction and is independent of the age of the patient. Those with severe obstruction require intervention, which is especially urgent in the critically ill newborn. Transitional support of the systemic circulation can be achieved by intravenous administration of prostaglandin E1 (also known as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/57/23445?source=see_link\">",
"     alprostadil",
"    </a>",
"    ) to open or maintain the patency of the ductus arteriosus, which allows the right ventricle to support the systemic circulation.",
"   </p>",
"   <p>",
"    Data from the Second Natural History Study of Congenital Heart Defects on 371 patients with congenital aortic stenosis provide some guidelines for therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/36\">",
"     36",
"    </a>",
"    ]. All gradients in this study were measured at cardiac catheterization.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a peak systolic gradient of 25 mmHg or less at catheterization or on echocardiogram have a low mortality and a low overall risk of requiring surgery (20 percent) over a 25-year period. These patients can be followed medically with annual evaluation. A recent follow-up study of this cohort with very mild stenosis demonstrated that the slope of the transaortic gradient (change of",
"      <span class=\"nowrap\">",
"       gradient/time",
"      </span>",
"      [years]) was predictive of outcome, so that those with gradient slope &gt;1.2 merited annual follow-up, and those with slope &lt;1.1 could be followed somewhat less frequently [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Those with peak systolic gradients greater than 50 mmHg are at high risk for ventricular arrhythmias and sudden death, and have a 71 percent likelihood of requiring intervention. It seems prudent, therefore, to proceed with intervention immediately in these patients, whether or not they have symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more difficult decision is faced with the patient whose gradient is between 25 and 50 mmHg. These patients are at intermediate risk for both sudden death and the long-term likelihood of requiring surgery. Given the morbidity and mortality of intervention, however small, it has been suggested these patients be treated medically and followed closely for a worsening gradient or the development of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Balloon valvotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since balloon dilation was first reported in 1983, percutaneous balloon aortic valvotomy (or valvuloplasty, BAV) has become the therapy of choice for valvar AS in children. The aortic valve leaflets in children are typically pliable and usually easy to dilate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tear. This is in contrast to adult patients with AS, in whom calcific changes in the valve make them less amenable to effective dilation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/8/31881?source=see_link&amp;anchor=H6#H6\">",
"     \"Indications for valve replacement in aortic stenosis in adults\", section on 'Indications for surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    BAV results in a 50 percent reduction in gradients in the majority of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/43-47\">",
"     43-47",
"    </a>",
"    ]. Most patients have new or increased aortic regurgitation (AR), which is moderate to severe in approximately 10 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Children and adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term outcome of BAV was evaluated in 509 children and adolescents with congenital AS who underwent the procedure at a median age of 2.4 years (age range from one day to 40.5 years) from 1985 to 2008 at Children&rsquo;s Hospital Boston [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/48\">",
"     48",
"    </a>",
"    ]. The following observations were noted at a median follow-up of 9.3 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      About 75 percent of patients had isolated native AS.",
"     </li>",
"     <li>",
"      Survival based on Kaplan-Meier analysis was 95, 93, and 88 percent at 5, 10, and 20 years, respectively.",
"     </li>",
"     <li>",
"      Peak AS gradients decreased significantly after dilatation with a median decrease of 35 mmHg.",
"     </li>",
"     <li>",
"      Moderate to severe AR was present in 14 percent of patients following BAV. Patients older than 11 years of age were more likely to have AR than younger patients. Repeat interventions were performed in 44 percent of patients (n=225) including repeat BAV in 115 patients (23 percent), aortic valve repair in 65 (13 percent), and aortic valve replacement in 116 (23 percent). Survival rates free from any aortic valve intervention was 89, 72, 65, and 27 percent at 1,5,10, and 20 years, respectively.",
"     </li>",
"     <li>",
"      In multivariate analysis, a longer time period prior to aortic valve replacement was associated with lower post-dilatation AS gradient and lower grade of post-dilation AR but not age, pre-dilation AS severity, or the year BAV was performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings were noted in a case series of 272 patients (age range 1 day to 30.5 years) who underwent BAV from 1985 to 2009 at Texas Children&rsquo;s Hospital [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/49\">",
"     49",
"    </a>",
"    ]. Survival without transplantation based on Kaplan-Meier analysis was 89, 87, and 81 percent, 10, 15, and 20 years after initial BAV, respectively at an average follow-up of 5.8 years. Death (n = 22) and transplantation (n = 2) occurred at a median time of 0.44 after BAV. Other outcomes included aortic valve replacement in 15 percent of patients, repeat BAV in 15 percent of patients, and the presence of moderate or severe aortic insufficiency in 31 percent of patients. &nbsp;",
"   </p>",
"   <p>",
"    In an older multicenter case series of 630 balloon aortic valvotomies in 606 children and adolescents (median age 6.8 years) from the Valvuloplasty and Angioplasty of Congenital Anomalies Registry, BAV was successful in 83 percent of procedures, and the mean reduction in the peak transvalvular gradient was 60 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the specific outcomes of BAV in neonates are from retrospective review from single tertiary centers.",
"   </p>",
"   <p>",
"    In the first study, the clinical outcome was evaluated in 113 infants who underwent BAV at &le;60 days of age who were treated from 1985 to 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/47\">",
"     47",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The early mortality rate fell significantly from 22 percent between 1985 and 1993 to 4 percent between 1994 and 2002.",
"     </li>",
"     <li>",
"      In the short-term, the relative gradient reduction was 54 percent and significant AR developed in 15 percent.",
"     </li>",
"     <li>",
"      The patients with initially small left heart structures (aortic annulus, left ventricular end-diastolic dimension) normalized within one to two years.",
"     </li>",
"     <li>",
"      Among 91 early survivors with a biventricular circulation, the five-year rates of freedom from moderate to severe AR, reintervention for residual or recurrent AS or for AR, and valve replacement were 65 percent, 48 percent, and 84 percent, respectively. Most reinterventions occurred in the first year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the second study, 53 neonates who underwent BAV at or before 30 days of age from 1994 to 2004 were evaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/50\">",
"     50",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The median age of intervention was 3.5 days (range 1 to 30 days).",
"     </li>",
"     <li>",
"      During a median follow-up of 3.2 years, there were 7 deaths (21 percent). The presence of moderate or severe LV endocardial fibroelastosis was associated with an increased risk of death.",
"     </li>",
"     <li>",
"      During the follow-up period, there were 31 reinterventions, for a similar rate of reintervention to the study above. Patients with a small aortic annulus were at an increased risk for aortic valve replacement.",
"     </li>",
"     <li>",
"      There was catch-up growth of the left-sided heart structures with increases in the aortic valve annulus, aortic sinus, and LV dimensions as previously reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/47\">",
"       47",
"      </a>",
"      ], but the size of the mitral valve remained below the normal range for body surface area.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A procedure-related complication noted in neonates undergoing BAV, aortic wall injury, was recently described in a large retrospective series, with little demonstrable associated mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Fetus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal intervention has the potential to change the course of severe and possibly fatal cardiac lesions. As an example, fetal balloon valvuloplasty may reverse the development of hypoplastic left heart syndrome in patients with critical AS. In these fetuses, balloon valvuloplasty would increase forward flow to the left ventricle allowing its continued growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/52\">",
"     52",
"    </a>",
"    ]. In a retrospective review, balloon valvuloplasty improved forward flow in 20 of 26 fetuses with severe AS and left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition, the increased flow was associated with growth of the left heart structures. The procedure was performed at a median gestational age of 24 weeks (range 21 to 31 weeks). After dilatation, seven patients had mild AR, three with moderate AR, and two with severe AR. There was one fetal death due to balloon rupture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Recurrent obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repeat balloon dilation is often effective in patients who develop recurrent obstruction, with gradient reduction of at least 50 percent in most patients. In one report, repeat BAV was performed in 34 patients from an initial series of 298 patients, including 70 neonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/54\">",
"     54",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repeat intervention was required more often in newborns than older patients (26 versus 8 percent)",
"     </li>",
"     <li>",
"      The mean peak-to-peak gradient was significantly reduced (67 to 36 mmHg)",
"     </li>",
"     <li>",
"      AR increased immediately in 26 percent of patients and was at least moderate in 24 percent",
"     </li>",
"     <li>",
"      Among 33 survivors (one surgery-related death occurred), 27 (81 percent) were asymptomatic and six had surgery for residual stenosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      AR",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Surgical valvotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major alternative to BAV for congenital valvar AS is surgical valvotomy. The efficacy of this approach was evaluated in 51 children between one and 18 years of age who underwent surgery between 1956 and 1986 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/55\">",
"     55",
"    </a>",
"    ]. The operative mortality was 3.9 percent, and mean transvalvular gradient fell from 91 to 27 mmHg. Mean survival was 94 percent at 10 and 15 years and 82 percent at 20 and 25 years. The reoperation rate was 2 percent at 10 years and 3.3 percent per year in the next 10 years. In the Second Natural History Study of Congenital Heart Defects cited above, 27 percent of patients required a second operation within 20 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are limited comparative data between surgical valvotomy and BAV. These procedures were compared in an observational series of 110 newborns with critical valvar AS, in which the initial procedure was surgical valvotomy in 28 and BAV in 82 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/56\">",
"     56",
"    </a>",
"    ]. Survival (72 percent) and freedom from reintervention (48 percent) at five years were similar in both groups. BAV resulted in a greater reduction in systolic gradient (65 versus 41 percent), a lower mean residual postoperative gradient (20 versus 36 mmHg), and more frequent clinically important AR (18 versus 3 percent). The overall risk was increased by associated hypoplasia of the left ventricular outflow tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Valve replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic valve replacement (AVR) is usually reserved for adults with congenital AS, in whom balloon dilation is generally ineffective. Mechanical prosthetic valves are preferred because of better long-term durability even though they require systemic anticoagulation. Bioprosthetic valves reduce the need for anticoagulation, but have a failure rate in children as high as 20 percent from progressive calcification with as short a follow-up period as six years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25497?source=see_link\">",
"     \"Complications of prosthetic heart valves\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7078?source=see_link\">",
"     \"Treatment of bicuspid aortic valve stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children who undergo AVR, mortality and repeat valve replacement are common. In a review of 160 children who underwent AVR from a single center between the years 1974 to 2004, 19 percent of children died without a second AVR, 34 percent received a second AVR, and 47 percent remained alive without replacement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/58\">",
"     58",
"    </a>",
"    ]. A younger age at initial AVR was a risk factor for both death and repeat valve replacement. A younger age was associated with the presence of other cardiac anomalies, which increased the risk of death, and with outgrowth of the original prosthetic valve requiring subsequent replacement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Pulmonary autograft (Ross procedure)",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative to valve replacement in children with congenital valvar AS is the Ross or",
"    <span class=\"nowrap\">",
"     Ross/Konno",
"    </span>",
"    procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. With this procedure, the pulmonary valve is transplanted to the aortic position, and a homograft conduit is implanted from the right ventricle to the pulmonary artery. Use of this technique has been limited by the high rates of failure of the pulmonary autograft and deterioration of the right heart homografts. A meta-analysis of published studies on the Ross procedure observed that compared to adults, children had a high early mortality rate (4.2 versus 3.2",
"    <span class=\"nowrap\">",
"     percent/patient-year)",
"    </span>",
"    and slightly higher rates of autograft deterioration (1.4 versus 0.8",
"    <span class=\"nowrap\">",
"     percent/patient-year)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/62\">",
"     62",
"    </a>",
"    ]. The higher rate of autograft deterioration in patients with predominantly aortic regurgitation, presumably due to progressive annular dilation, has led some to avoid the Ross procedure in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/8/31881?source=see_link\">",
"     \"Indications for valve replacement in aortic stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88515812\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88515889\">",
"    <span class=\"h2\">",
"     Sports participation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Bethesda guidelines for sports participation recommend restricted participation in competitive sports for patients with valvar AS and avoidance of strenuous activity in more severe degrees of obstruction because of concerns of an increased risk for sudden unexpected death (SUD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/63\">",
"     63",
"    </a>",
"    ]. However, there is evidence that these guidelines may be too restrictive in patients following successful balloon aortic valvotomy (BAV). This was illustrated by a retrospective review of 528 patients who underwent BAV at our tertiary center from 1984 to 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38345/abstract/64\">",
"     64",
"    </a>",
"    ]. At a median follow-up, there were 63 deaths including SUD in six patients, five of which occurred &le;18 months of age. In patients greater than four years of age, exercise restriction was prescribed in 43 percent and included the one patient with SUD. As a result, we conclude that SUD is extremely rare after BAV, and there is no beneficial effect for exercise restriction in these patients. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88515896\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 2007 American Heart Association guidelines, antibiotic prophylaxis to prevent bacterial endocarditis is",
"    <strong>",
"     no",
"    </strong>",
"    longer recommended in patients with valvar AS except in those with a prior history of endocarditis or who require prosthetic heart valves. Patients with valvar AS are at increased risk of endocarditis; however, as there is considerable uncertainty regarding the efficacy of the practice of SBE prophylaxis, the latest guidelines emphasize prophylaxis only for those patients at greatest risk from the sequelae of endocarditis, a group most patients with native AS do not fall into. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/53/36690?source=see_link\">",
"       \"Patient information: Aortic stenosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13529287\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common congenital left ventricular outflow tract obstructive lesion is valvar aortic stenosis (AS).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In valvar AS, the most common morphology is a bicommissural or bicuspid aortic valve, which is associated with both congenital and acquired AS. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In adults with AS, bicuspid aortic valve is the most common valve anomaly. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6169?source=see_link\">",
"       \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with congenital AS due to bicuspid aortic valve are at-risk for other cardiovascular anomalies, especially coarctation of the aorta. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical findings vary depending on the severity of the stenotic lesion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Most children with valvar AS, even those with moderate disease, are relatively asymptomatic.",
"     </li>",
"     <li>",
"      Critical AS in the neonate results in severe restricted outward flow and is fatal in patients without intervention. Neonates with critical AS will present with poor peripheral perfusion and cyanosis as the ductus arteriosus closes. Physical findings include a hyperactive precordium and poor peripheral pulses, A cardiac murmur is frequently not heard because of poor cardiac output. A gallop rhythm may also be present. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Critical AS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants with severe but not critical AS may present with heart failure, which is characterized by poor feeding, growth failure and tachypnea, and physical findings including hyperactive precordium, ejection murmur, and often hepatomegaly and peripheral edema. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Infantile AS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Older children with AS are rarely symptomatic and are generally identified by the presence of the characteristic harsh ejection murmur, which may be accompanied by an ejection click. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Older children'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with congenital valvar AS often have progressive obstruction and are at increased risk for infectious endocarditis and sudden death. The risk of mortality is greater in patients with more severe disease who have significant obstruction and aortic regurgitation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of valvar AS may be made on physical findings and generally confirmed by echocardiography. Cardiac catheterization is performed if the",
"      <span class=\"nowrap\">",
"       severity/diagnosis",
"      </span>",
"      remains uncertain, if there are associated defects that cannot be completely evaluated noninvasively, or if balloon aortic valvuloplasty (BAV) is anticipated. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment is indicated for patients who present with severe obstruction, which is especially urgent in the critically ill neonate and infant with heart failure. In other patients, the decision to treat is based on the peak systolic gradient obtained during cardiac catheterization (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Indications for intervention'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with a peak systolic gradient &gt;50 mmHg should be treated as they are at high risk for ventricular arrhythmias and sudden death due to progressive obstruction from their lesions.",
"     </li>",
"     <li>",
"      Patients with a peak systolic gradient &lt;25 mmHg can be followed medically on a regular basis as they have mild disease and are at low risk for mortality and morbidity.",
"     </li>",
"     <li>",
"      Data are less conclusive of patients with a peak systolic gradient between 25 and 50 mmHg, as they are at intermediate risk for poor outcome. In our practice, we monitor their clinical status closely and intervene if there is a worsening of the gradient or development of symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Definitive therapy consists of reducing the degree of valvar stenosis. The treatment of choice is balloon valvuloplasty, regardless of the age and size of the patient, which has largely replaced surgical valvotomy. Aortic valve replacement is usually reserved for adults with congenital AS in whom balloon dilation is generally ineffective. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/8/31881?source=see_link\">",
"       \"Indications for valve replacement in aortic stenosis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antibiotic prophylaxis to prevent bacterial endocarditis is",
"      <strong>",
"       no",
"      </strong>",
"      longer recommended in patients with valvar AS except in those with a prior history of endocarditis or who require prosthetic heart valves. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"       \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/1\">",
"      Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol 2002; 39:1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/2\">",
"      Kitchiner D, Jackson M, Malaiya N, et al. Incidence and prognosis of obstruction of the left ventricular outflow tract in Liverpool (1960-91): a study of 313 patients. Br Heart J 1994; 71:588.",
"     </a>",
"    </li>",
"    <li>",
"     Keane JF, Fyler DC. Aortic outflow abnormalities. In: Nadas' Pediatric Cardiology, Keane JF, Lock JE, Fyler DC (Eds), Saunders/Elsevier, Philadelphia 2006. p.581.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/4\">",
"      Liu CW, Hwang B, Lee BC, et al. Aortic stenosis in children: 19-year experience. Zhonghua Yi Xue Za Zhi (Taipei) 1997; 59:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/5\">",
"      Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation 2005; 111:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/6\">",
"      Larson EW, Edwards WD. Risk factors for aortic dissection: a necropsy study of 161 cases. Am J Cardiol 1984; 53:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/7\">",
"      Pauperio HM, Azevedo AC, Ferreira CS. The aortic valve with two leaflets--a study in 2,000 autopsies. Cardiol Young 1999; 9:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/8\">",
"      Roberts WC. The congenitally bicuspid aortic valve. A study of 85 autopsy cases. Am J Cardiol 1970; 26:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/9\">",
"      Tutar E, Ekici F, Atalay S, Nacar N. The prevalence of bicuspid aortic valve in newborns by echocardiographic screening. Am Heart J 2005; 150:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/10\">",
"      Basso C, Boschello M, Perrone C, et al. An echocardiographic survey of primary school children for bicuspid aortic valve. Am J Cardiol 2004; 93:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/11\">",
"      Huntington K, Hunter AG, Chan KL. A prospective study to assess the frequency of familial clustering of congenital bicuspid aortic valve. J Am Coll Cardiol 1997; 30:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/12\">",
"      Driscoll DJ, Michels VV, Gersony WM, et al. Occurrence risk for congenital heart defects in relatives of patients with aortic stenosis, pulmonary stenosis, or ventricular septal defect. Circulation 1993; 87:I114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/13\">",
"      Todros T, Faggiano F, Chiappa E, et al. Accuracy of routine ultrasonography in screening heart disease prenatally. Gruppo Piemontese for Prenatal Screening of Congenital Heart Disease. Prenat Diagn 1997; 17:901.",
"     </a>",
"    </li>",
"    <li>",
"     Friedman WF. Congenital aortic stenosis. In: Moss and Adams' Heart Disease in Infants, Children, and Adolescents, 5th ed, Emmanoulides GC, Riemenschneider TA, Allen HD, et al (Eds), Williams and Wilkins, Baltimore 1994. p.1087.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/15\">",
"      Nihoyannopoulos P, Karas S, Sapsford RN, et al. Accuracy of two-dimensional echocardiography in the diagnosis of aortic arch obstruction. J Am Coll Cardiol 1987; 10:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/16\">",
"      ROBERTS WC, MORROW AG. CONGENITAL AORTIC STENOSIS PRODUCED BY A UNICOMMISSURAL VALVE. Br Heart J 1965; 27:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/17\">",
"      Stephan PJ, Henry AC 3rd, Hebeler RF Jr, et al. Comparison of age, gender, number of aortic valve cusps, concomitant coronary artery bypass grafting, and magnitude of left ventricular-systemic arterial peak systolic gradient in adults having aortic valve replacement for isolated aortic valve stenosis. Am J Cardiol 1997; 79:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/18\">",
"      Jonas RA. Radical aortic root enlargement in the infant and child. J Card Surg 1994; 9:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/19\">",
"      Ohye RG, Kagisaki K, Lee LA, et al. Biventricular repair for aortic atresia or hypoplasia and ventricular septal defect. J Thorac Cardiovasc Surg 1999; 118:648.",
"     </a>",
"    </li>",
"    <li>",
"     Latson LA. Aortic stenosis: valvar, supravalvar, and fibromuscular subvalvar. In: The Science and Practice of Pediatric Cardiology, Garson A, Bricker JT, Fisher DJ, Neish SR (Eds), Williams and Wilkins, Baltimore 1998. p.1257.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/21\">",
"      Kitchiner D, Jackson M, Walsh K, et al. The progression of mild congenital aortic valve stenosis from childhood into adult life. Int J Cardiol 1993; 42:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/22\">",
"      Fernandes SM, Sanders SP, Khairy P, et al. Morphology of bicuspid aortic valve in children and adolescents. J Am Coll Cardiol 2004; 44:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/23\">",
"      Fernandes SM, Khairy P, Sanders SP, Colan SD. Bicuspid aortic valve morphology and interventions in the young. J Am Coll Cardiol 2007; 49:2211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/24\">",
"      Donner R, Carabello BA, Black I, Spann JF. Left ventricular wall stress in compensated aortic stenosis in children. Am J Cardiol 1983; 51:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/25\">",
"      Lewis AB, Heymann MA, Stanger P, et al. Evaluation of subendocardial ischemia in valvar aortic stenosis in children. Circulation 1974; 49:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/26\">",
"      Wagner HR, Weidman WH, Ellison RC, Miettinen OS. Indirect assessment of severity in aortic stenosis. Circulation 1977; 56:I20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/27\">",
"      Beppu S, Suzuki S, Matsuda H, et al. Rapidity of progression of aortic stenosis in patients with congenital bicuspid aortic valves. Am J Cardiol 1993; 71:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/28\">",
"      McCaffrey FM, Sherman FS. Prenatal diagnosis of severe aortic stenosis. Pediatr Cardiol 1997; 18:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/29\">",
"      Mielke G, Mayer R, Hassberg D, Breuer J. Sequential development of fetal aortic valve stenosis and endocardial fibroelastosis during the second trimester of pregnancy. Am Heart J 1997; 133:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/30\">",
"      Vogel M, McElhinney DB, Wilkins-Haug LE, et al. Aortic stenosis and severe mitral regurgitation in the fetus resulting in giant left atrium and hydrops: pathophysiology, outcomes, and preliminary experience with pre-natal cardiac intervention. J Am Coll Cardiol 2011; 57:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/31\">",
"      Hornberger LK, Sanders SP, Rein AJ, et al. Left heart obstructive lesions and left ventricular growth in the midtrimester fetus. A longitudinal study. Circulation 1995; 92:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/32\">",
"      M&auml;kikallio K, McElhinney DB, Levine JC, et al. Fetal aortic valve stenosis and the evolution of hypoplastic left heart syndrome: patient selection for fetal intervention. Circulation 2006; 113:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/33\">",
"      Mody MR, Nadas AS, Bernhard WF. Aortic stenosis in infants. N Engl J Med 1967; 276:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/34\">",
"      Ellison RC, Wagner HR, Weidman WH, Miettinen OS. Congenital valvular aortic stenosis: clinical detection of small pressure gradient. Prepared for the joint study on the joint study on the natural history of congenital heart defects. Am J Cardiol 1976; 37:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/35\">",
"      Gersony WM, Hayes CJ, Driscoll DJ, et al. Bacterial endocarditis in patients with aortic stenosis, pulmonary stenosis, or ventricular septal defect. Circulation 1993; 87:I121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/36\">",
"      Keane JF, Driscoll DJ, Gersony WM, et al. Second natural history study of congenital heart defects. Results of treatment of patients with aortic valvar stenosis. Circulation 1993; 87:I16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/37\">",
"      Bartz PJ, Driscoll DJ, Keane JF, et al. Management strategy for very mild aortic valve stenosis. Pediatr Cardiol 2006; 27:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/38\">",
"      Ten Harkel AD, Berkhout M, Hop WC, et al. Congenital valvular aortic stenosis: limited progression during childhood. Arch Dis Child 2009; 94:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/39\">",
"      Bengur AR, Snider AR, Meliones JN, Vermilion RP. Doppler evaluation of aortic valve area in children with aortic stenosis. J Am Coll Cardiol 1991; 18:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/40\">",
"      Zoghbi WA, Farmer KL, Soto JG, et al. Accurate noninvasive quantification of stenotic aortic valve area by Doppler echocardiography. Circulation 1986; 73:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/41\">",
"      Driscoll DJ, Wolfe RR, Gersony WM, et al. Cardiorespiratory responses to exercise of patients with aortic stenosis, pulmonary stenosis, and ventricular septal defect. Circulation 1993; 87:I102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/42\">",
"      Alpert BS, Moes DM, Durant RH, et al. Hemodynamic responses to ergometer exercise in children and young adults with left ventricular pressure or volume overload. Am J Cardiol 1983; 52:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/43\">",
"      Sholler GF, Keane JF, Perry SB, et al. Balloon dilation of congenital aortic valve stenosis. Results and influence of technical and morphological features on outcome. Circulation 1988; 78:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/44\">",
"      Moore P, Egito E, Mowrey H, et al. Midterm results of balloon dilation of congenital aortic stenosis: predictors of success. J Am Coll Cardiol 1996; 27:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/45\">",
"      McCrindle BW. Independent predictors of immediate results of percutaneous balloon aortic valvotomy in children. Valvuloplasty and Angioplasty of Congenital Anomalies (VACA) Registry Investigators. Am J Cardiol 1996; 77:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/46\">",
"      Rocchini AP, Beekman RH, Ben Shachar G, et al. Balloon aortic valvuloplasty: results of the Valvuloplasty and Angioplasty of Congenital Anomalies Registry. Am J Cardiol 1990; 65:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/47\">",
"      McElhinney DB, Lock JE, Keane JF, et al. Left heart growth, function, and reintervention after balloon aortic valvuloplasty for neonatal aortic stenosis. Circulation 2005; 111:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/48\">",
"      Brown DW, Dipilato AE, Chong EC, et al. Aortic valve reinterventions after balloon aortic valvuloplasty for congenital aortic stenosis intermediate and late follow-up. J Am Coll Cardiol 2010; 56:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/49\">",
"      Maskatia SA, Ing FF, Justino H, et al. Twenty-five year experience with balloon aortic valvuloplasty for congenital aortic stenosis. Am J Cardiol 2011; 108:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/50\">",
"      Han RK, Gurofsky RC, Lee KJ, et al. Outcome and growth potential of left heart structures after neonatal intervention for aortic valve stenosis. J Am Coll Cardiol 2007; 50:2406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/51\">",
"      Brown DW, Chong EC, Gauvreau K, et al. Aortic wall injury as a complication of neonatal aortic valvuloplasty: incidence and risk factors. Circ Cardiovasc Interv 2008; 1:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/52\">",
"      Latson LA. Aortic valvuloplasty in the fetus: technically possible but is it ready for prime time? J Pediatr 2005; 147:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/53\">",
"      Marshall AC, Tworetzky W, Bergersen L, et al. Aortic valvuloplasty in the fetus: technical characteristics of successful balloon dilation. J Pediatr 2005; 147:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/54\">",
"      Satou GM, Perry SB, Lock JE, et al. Repeat balloon dilation of congenital valvar aortic stenosis: immediate results and midterm outcome. Catheter Cardiovasc Interv 1999; 47:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/55\">",
"      DeBoer DA, Robbins RC, Maron BJ, et al. Late results of aortic valvotomy for congenital valvar aortic stenosis. Ann Thorac Surg 1990; 50:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/56\">",
"      McCrindle BW, Blackstone EH, Williams WG, et al. Are outcomes of surgical versus transcatheter balloon valvotomy equivalent in neonatal critical aortic stenosis? Circulation 2001; 104:I152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/57\">",
"      Walker WE, Duncan JM, Frazier OH Jr, et al. Early experience with the ionescu-shiley pericardial xenograft valve. Accelerated calcification in children. J Thorac Cardiovasc Surg 1983; 86:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/58\">",
"      Karamlou T, Jang K, Williams WG, et al. Outcomes and associated risk factors for aortic valve replacement in 160 children: a competing-risks analysis. Circulation 2005; 112:3462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/59\">",
"      Ohye RG, Gomez CA, Ohye BJ, et al. The Ross/Konno procedure in neonates and infants: intermediate-term survival and autograft function. Ann Thorac Surg 2001; 72:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/60\">",
"      Schoof PH, Cromme-Dijkhuis AH, Bogers JJ, et al. Aortic root replacement with pulmonary autograft in children. J Thorac Cardiovasc Surg 1994; 107:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/61\">",
"      Laudito A, Brook MM, Suleman S, et al. The Ross procedure in children and young adults: a word of caution. J Thorac Cardiovasc Surg 2001; 122:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/62\">",
"      Takkenberg JJ, Klieverik LM, Schoof PH, et al. The Ross procedure: a systematic review and meta-analysis. Circulation 2009; 119:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/63\">",
"      Graham TP Jr, Driscoll DJ, Gersony WM, et al. Task Force 2: congenital heart disease. J Am Coll Cardiol 2005; 45:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38345/abstract/64\">",
"      Brown DW, Dipilato AE, Chong EC, et al. Sudden unexpected death after balloon valvuloplasty for congenital aortic stenosis. J Am Coll Cardiol 2010; 56:1939.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5775 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-9EF4B3CCD6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_28_38345=[""].join("\n");
var outline_f37_28_38345=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13529287\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Critical AS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Infantile AS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Older children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Exercise testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Indications for intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Balloon valvotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Neonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Fetus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Recurrent obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Surgical valvotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Valve replacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Pulmonary autograft (Ross procedure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88515812\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88515889\">",
"      Sports participation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88515896\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13529287\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5775\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5775|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?43/6/44128\" title=\"movie 1\">",
"      Phonocardiogram of bicuspid AS at apex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?39/8/40065\" title=\"movie 2\">",
"      Phonocardiogram bicusid AS at 2nd R ICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?21/52/22351\" title=\"movie 3\">",
"      M-mode echocardiogram of AR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?27/17/27921\" title=\"movie 4\">",
"      Bicuspid aortic valve short axis echocardiogram 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5775|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/11/43196\" title=\"table 1\">",
"      Causes LV outflow obstruction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/33/1559?source=related_link\">",
"      Aortic regurgitation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/11/1208?source=related_link\">",
"      Aortic valve area in aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6169?source=related_link\">",
"      Clinical manifestations and diagnosis of bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25497?source=related_link\">",
"      Complications of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1082?source=related_link\">",
"      Echocardiographic evaluation of the aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9466?source=related_link\">",
"      Etiology and diagnosis of heart failure in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/41/3737?source=related_link\">",
"      Hemodynamics of valvular disorders as measured by cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/27/41401?source=related_link\">",
"      Hypoplastic left heart syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/8/31881?source=related_link\">",
"      Indications for valve replacement in aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/53/36690?source=related_link\">",
"      Patient information: Aortic stenosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/54/4968?source=related_link\">",
"      Prenatal sonographic diagnosis of fetal cardiac anomalies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/27/33207?source=related_link\">",
"      Subvalvar aortic stenosis (subaortic stenosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40774?source=related_link\">",
"      Supravalvar aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7078?source=related_link\">",
"      Treatment of bicuspid aortic valve stenosis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_28_38346="AIDS-related lymphomas: Treatment of systemic lymphoma";
var content_f37_28_38346=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   AIDS-related lymphomas: Treatment of systemic lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/28/38346/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38346/contributors\">",
"     Lawrence D Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38346/contributors\">",
"     Wei Ai, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/28/38346/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38346/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/28/38346/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/28/38346/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/28/38346/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV infection results in impaired cellular immunity, a condition known to predispose persons to develop neoplasms. As the lifespan of HIV-infected patients has increased, malignancies have become a known cause of morbidity and mortality in this population.",
"   </p>",
"   <p>",
"    Non-Hodgkin lymphoma (NHL) of high-grade pathologic type and of B cell or unknown immunologic phenotype is an AIDS-defining malignancy. AIDS-related non-Hodgkin lymphoma (NHL) can be divided into three general categories based on location:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Systemic NHL",
"     </li>",
"     <li>",
"      Primary central nervous system (CNS) lymphoma",
"     </li>",
"     <li>",
"      Primary effusion (or body cavity) lymphoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Systemic NHL accounts for the great majority of AIDS-related lymphomas. In contrast, primary central nervous system (CNS) lymphoma, in which disease is limited to the CNS, comprises about 10 percent of AIDS-related lymphomas, while primary effusion lymphoma is much less common. The latter disorder is characterized by its predilection for body cavities such as the peritoneal, pleural, and pericardial spaces without an identifiable tumor mass.",
"   </p>",
"   <p>",
"    The treatment of systemic NHL in the setting of HIV is complicated by the patient&rsquo;s immunocompromised state and also requires specific treatment for the HIV. The treatment of AIDS-related systemic NHL will be reviewed here. The treatment of aggressive and highly aggressive non-Hodgkin lymphoma in the absence of HIV is presented separately, as are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epidemiology and pathobiology of AIDS-related lymphoma (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/36/20042?source=see_link\">",
"       \"AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Clinical manifestations, diagnosis, and staging of AIDS-related lymphoma (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/4/7242?source=see_link\">",
"       \"AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Primary CNS lymphoma (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7321?source=see_link\">",
"       \"AIDS-related lymphomas: Primary central nervous system lymphoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Primary effusion lymphoma (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30969?source=see_link\">",
"       \"AIDS-related lymphomas: Primary effusion lymphoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Other AIDS-defining malignancies (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/36/27206?source=see_link\">",
"       \"HIV infection and malignancy: Epidemiology and pathogenesis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6051206\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 70 to 90 percent of the lymphomas encountered in HIV-infected patients are clinically aggressive diffuse large B cell lymphomas (DLBCLs) or highly aggressive Burkitt-like lymphomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/1\">",
"     1",
"    </a>",
"    ]. At least 80 percent of these patients with systemic lymphoma have stage IV disease at the time of presentation (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"mobipreview.htm?36/59/37819\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/2\">",
"     2",
"    </a>",
"    ], with the most common extranodal sites of involvement being the gastrointestinal tract, liver, lung, bone marrow, and the central nervous system. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/36/20042?source=see_link\">",
"     \"AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/4/7242?source=see_link\">",
"     \"AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although few patients diagnosed early in the HIV epidemic were cured of their lymphoma, the introduction of highly active antiretroviral therapy (HAART) in the late 1990s resulted in a marked improvement in the ability of these patients to tolerate standard chemotherapy regimens and in their clinical outcomes that now approach those in the general population.",
"   </p>",
"   <p>",
"    There are factors associated with HIV infection that make the management of patients with HIV and lymphoma considerably more complex:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Historically, doses of chemotherapy were restricted by the baseline cellular immunodeficiency and limited bone marrow reserve of patients with advanced HIV infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/3\">",
"       3",
"      </a>",
"      ]. However, the standard concomitant administration of HAART may improve bone marrow function by decreasing the adverse effects of the HIV infection on hematopoiesis, thereby allowing for full dosing of chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chemotherapy produces a significant and sustained reduction in CD4 cell counts and an increased risk (twofold in one study) of opportunistic infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. The immunosuppression induced by chemotherapy exceeds the duration of exposure to these drugs by many months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Medications taken to control the HIV infection may have side effects that overlap with chemotherapy side effects (eg, myelosuppression). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link\">",
"       \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3370?source=see_link\">",
"       \"Considerations prior to initiating antiretroviral therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A key component of the treatment of all HIV infected patients with an AIDS-related NHL is the administration of an effective HAART regimen. Recent experience in the HAART era strongly suggests that HIV-associated aggressive lymphomas can be treated successfully with standard chemotherapy regimens without unusually severe toxicities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/7\">",
"     7",
"    </a>",
"    ]. Even high-dose chemotherapy with autologous stem cell support (hematopoietic cell transplantation) has been well-tolerated in this patient population and is becoming more widely used. (See",
"    <a class=\"local\" href=\"#H4261248\">",
"     'Autologous transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Prior to the advent of HAART, randomized studies did not show any advantage in those treated with more intensive chemotherapy versus standard or reduced-dose regimens, in terms of response rates, time to progression, and median survival among patients with HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. However, a potential benefit from intensive chemotherapy may have been masked by an increase in opportunistic infections in those receiving intensive therapy. Opportunistic infections are less common in this setting now that the underlying HIV infection can be better controlled with HAART. (See",
"    <a class=\"local\" href=\"#H62463420\">",
"     'Incorporating HAART'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6237308\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;To best treat patients with NHL, the initial evaluation must establish the precise histologic subtype, the extent and sites of disease, and the performance status of the patient. General approaches to the diagnostic work-up and staging of non-Hodgkin lymphoma are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15658?source=see_link\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pretreatment evaluation both determines the extent of the disease and provides information about the individual's comorbidities that are likely to have an impact on treatment options. In addition to a history and physical examination, it is our practice to perform the following pretreatment studies in patients with AIDS-related systemic NHL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory studies include a complete blood count with differential, chemistries with liver and renal function and electrolytes, lactate dehydrogenase (LDH), uric acid, phosphate, CD4 count, viral load, hepatitis B and C screening, and pregnancy test (in women). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=see_link\">",
"       \"Hepatitis B virus reactivation associated with immunosuppression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Unilateral bone marrow biopsy is recommended for all patients.",
"     </li>",
"     <li>",
"      Lumbar puncture is indicated in a subset of patients. Cerebrospinal fluid should be sent for both cytology and flow cytometry. (See",
"      <a class=\"local\" href=\"#H1701337\">",
"       'CNS directed therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      A study of cardiac ejection fraction (eg, echocardiogram or MUGA) should be performed for most patients and is necessary prior to regimens that include highly cardiotoxic drugs (eg, anthracyclines).",
"     </li>",
"     <li>",
"      A contrast-enhanced computed tomography (CT) scan of the neck, chest, abdomen, and pelvis should be performed. This study provides critical information on the measurement of disease prior to treatment and aids in staging [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/10\">",
"       10",
"      </a>",
"      ]. When available, we suggest obtaining a combined positron emission tomography",
"      <span class=\"nowrap\">",
"       (PET)/CT",
"      </span>",
"      scan as a measure of disease activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15658?source=see_link&amp;anchor=H13#H13\">",
"       \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Routine imaging studies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1226113\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal initial therapy for lymphomas in the setting of HIV has yet to be defined. Highly active antiretroviral therapy (HAART) is started or modified (if already begun) to control the HIV infection and allow for the administration of chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy. As in the HIV-seronegative population, the choice of therapy is principally determined by the subtype of non-Hodgkin lymphoma and the stage of disease. Modifications are made based upon the degree of immunosuppression from HIV as measured by the CD4 count.",
"   </p>",
"   <p>",
"    As in the HIV-seronegative population, attention needs to be given to serum uric acid levels and other potential complications of the tumor lysis syndrome at the time of diagnosis and with the first cycle of cytotoxic chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62463420\">",
"    <span class=\"h2\">",
"     Incorporating HAART",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reduction in HIV viral load and improvement in immune function associated with highly active antiretroviral therapy (HAART) is expected to result in better tolerance of chemotherapy, fewer opportunistic infections, and improvement in overall treatment outcome. These expectations have largely been borne out in retrospective and prospective clinical data collected since the advent of HAART. HAART is an essential component to the treatment of patients with AIDS-related lymphoma. HAART should be continued during chemotherapy, with an undetectable blood viral load being the targeted goal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the incorporation of HAART, there has been a decrease in the number of AIDS-defining opportunistic infections that develop during or shortly after completing chemotherapy. As an example, approximately 20 percent of patients treated with chemotherapy for AIDS-related NHL in a large prospective trial conducted in the pre-HAART era developed AIDS-defining opportunistic infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/8\">",
"     8",
"    </a>",
"    ]. In contrast, opportunistic infections have been infrequently reported in more recent clinical trials in which HAART has been administered with chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/9,14-18\">",
"     9,14-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concomitant administration of HAART during chemotherapy for AIDS-related lymphoma also appears to improve overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/9,14-22\">",
"     9,14-22",
"    </a>",
"    ]. Improvements in immune function rendered by HAART diminish the effects of HIV on survival allowing the prognostic features of the lymphoma to become relatively more important to overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In studies conducted in the HAART era, advanced disease, as determined by stage or International Prognostic Index score (IPI) (",
"    <a class=\"graphic graphic_table graphicRef70850 \" href=\"mobipreview.htm?17/21/17757\">",
"     table 2",
"    </a>",
"    ), appears to have greater prognostic value than factors associated with HIV disease such as immune function and prior opportunistic infection. Most clinical trials, however, continue to identify a CD4 count",
"    <span class=\"nowrap\">",
"     &lt;100/microL",
"    </span>",
"    as a negative prognostic finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study evaluated patients with AIDS-related lymphoma treated either with one of two combinations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/22\">",
"       22",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      CHOP chemotherapy plus HAART (CHOP-HAART, 24 patients)",
"     </li>",
"     <li>",
"      CHOP or a CHOP-like regimen with no antiretroviral therapy or AZT monotherapy (CHOP, 80 patients)",
"      <br/>",
"      <br/>",
"      At a median follow-up of 7 to 8.5 months, the incidence of AIDS-defining opportunistic infection was significantly lower in the CHOP-HAART group (18 versus 52 percent), and overall survival was significantly longer (median survival not reached versus seven months).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A German study demonstrated treatment outcomes using CHOP and concurrent HAART that were similar to those observed in non-HIV patients with diffuse large B cell lymphoma, with a complete response rate of 79 percent and median survival not reached after a median of 47 months follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/14\">",
"       14",
"      </a>",
"      ]. Although these results are comparable to those observed in non-immunocompromised patients, it should be pointed out that this patient population had a higher median CD4 count",
"      <span class=\"nowrap\">",
"       (223/microL)",
"      </span>",
"      and lower IPI score than other studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The response to HAART has been shown to be an independent risk factor for survival in patients with AIDS-related, non-Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/20,27\">",
"     20,27",
"    </a>",
"    ]. In a study of 44 patients from two Italian treatment centers, virologic response to HAART was the only variable independently associated with attainment of complete remission following chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/28\">",
"     28",
"    </a>",
"    ]. Overall one-year survival for the entire group was 49 percent, increasing to 78 percent for virologic responders, and 84 percent among those who achieved immunologic restoration. Other studies support the importance of HAART as a prognostic factor with respect to complete response rate and event-free survival of those treated with CHOP chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1225504\">",
"     'Effect of HAART'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    With few exceptions, studies have shown that concomitant HAART and antineoplastic chemotherapy have no clinically adverse effects on the metabolism of drugs in either the antiretroviral or conventional-dose antineoplastic regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/13,29,30\">",
"     13,29,30",
"    </a>",
"    ]. There are little data to support one antiretroviral regimen over another. However, use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    is strongly discouraged due to the risk of overlapping myelotoxicity.",
"   </p>",
"   <p>",
"    Studies that have evaluated interactions between protease inhibitors and chemotherapy have had mixed results. One study has shown no statistically significant difference between HAART regimens containing protease inhibitors versus those not containing protease inhibitors with respect to response rates or survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/31\">",
"     31",
"    </a>",
"    ]. However, protease inhibitor containing regimens may potentiate the myelotoxicity of the chemotherapy regimen compared with antiretroviral regimens that do not contain a protease inhibitor. This is likely due to CYP3A inhibition by specific protease inhibitors. Even at lower doses,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    is a potent CYP3A inhibitor that can be used to &ldquo;boost&rdquo; levels of other protease inhibitors. Although use of these agents concomitantly with conventional dose chemotherapy is not contraindicated, alternatives might be considered, especially if more aggressive or high-dose chemotherapy regimens are to be utilized. The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    -based regimens (integrase inhibitor) might represent a good alternative as it does not have hepatic metabolism and thus the potential for drug interactions may be lessened [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link&amp;anchor=H28#H28\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\", section on 'Raltegravir'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The CD4 count may decline by at least 50 percent from the baseline during chemotherapy for AIDS-related non-Hodgkin lymphomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/33\">",
"     33",
"    </a>",
"    ], necessitating the use of prophylaxis for opportunistic infections in all patients. Although this effect on the CD4 counts may exceed the duration of the chemotherapy by several months, those patients receiving HAART concurrent with chemotherapy reconstitute CD4 counts more rapidly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/33\">",
"     33",
"    </a>",
"    ]. In one study the cohort of 20 patients with AIDS-related NHL treated with chemotherapy and concomitant HAART recovered CD4 and NK cells counts to baseline within one month after completion of chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/33\">",
"     33",
"    </a>",
"    ]. In contrast, 12 months were required for recovery following treatment with EPOCH without concomitant HAART [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/25\">",
"     25",
"    </a>",
"    ]. The combination of HAART with chemotherapy maintains the virologic response in the majority of patients, while the development of resistance mutations in the HIV does not seem to be increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62464350\">",
"    <span class=\"h2\">",
"     Prophylaxis for opportunistic infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;During treatment with combination chemotherapy, HAART should be continued along with prophylaxis for Pneumocystis jiroveci pneumonia (PCP, previously Pneumocystis carinii pneumonia). Mycobacterium avium complex (MAC) prophylaxis may be appropriate for selected patients with severe immunocompromise (ie, CD4",
"    <span class=\"nowrap\">",
"     &lt;50/microL).",
"    </span>",
"    Antibiotic prophylaxis for enteric organisms during neutropenia is strongly encouraged. Given the high incidence of recurrent Herpes simplex, Herpes zoster, and Candida infections in this population, many clinicians also advise instituting antiviral and antifungal prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3001?source=see_link\">",
"     \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/4/19530?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1700389\">",
"    <span class=\"h2\">",
"     Standard chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, first-line chemotherapy regimens that are effective for lymphomas of similar histology in the HIV-seronegative population have been associated with lower rates and durability of complete response in patients with AIDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/35\">",
"     35",
"    </a>",
"    ]. This may be related, in part, to increased expression of the multidrug-resistance gene (MDR-1) in the lymphocytes of AIDS-related lymphomas compared with the lymphocytes in the HIV-seronegative population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/36\">",
"     36",
"    </a>",
"    ]. This gene codes for the P-glycoprotein on the cell membrane, a transporter protein that promotes efflux from the cytoplasm of a wide variety of drugs and other molecules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As mentioned above, the vast majority of patients with AIDS-related NHL have advanced stage diffuse large B cell lymphoma (DLBCL) or Burkitt",
"    <span class=\"nowrap\">",
"     lymphoma/leukemia",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/38\">",
"     38",
"    </a>",
"    ]. The following sections investigate these NHL subtypes in more detail.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Diffuse large B cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of diffuse large B cell lymphoma (DLBCL) in the HIV seronegative population is based upon the stage of disease at diagnosis. Limited stage disease is generally treated with the combination of chemotherapy (eg, CHOP), immunotherapy (eg, directed at CD-20), and involved-field radiation therapy, while advanced stage disease is commonly treated with chemotherapy plus immunotherapy. In the HIV positive population, the majority of cases are of advanced stage. In this setting, the best choice of chemotherapy regimen and the role of immunotherapy are less clear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/45/26330?source=see_link\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our approach is to modify our choice of initial chemotherapy and the decision to use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    based upon prognostic factors and the CD4 count (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Role of Rituximab'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most patients with advanced stage HIV-associated DLBCL, we suggest combination chemotherapy with CHOP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with CD20-positive disease and a CD4 count over",
"      <span class=\"nowrap\">",
"       50/microL,",
"      </span>",
"      we suggest the addition of immunotherapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (eg, R-CHOP). The decision whether to use rituximab in a patient with a CD20-positive disease and a CD4 count &lt;50",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      must be individualized. For patients with a CD4 count over",
"      <span class=\"nowrap\">",
"       50/microL",
"      </span>",
"      who also have high growth fraction disease (Ki 67 &gt;80 percent), or plasmablastic histology, we suggest dose-adjusted EPOCH rather than CHOP, each in combination with rituximab for CD20-positive disease.",
"     </li>",
"     <li>",
"      Patients with limited stage DLBCL are those with disease that can be contained within one radiation field. Such patients may be considered for abbreviated chemotherapy or chemoimmunotherapy (as determined by CD4 count) followed by involved-field radiation therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h4\">",
"     CHOP chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not without controversy, the \"standard\" chemotherapy for most cases of AIDS-related DLBCL is CHOP (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ). CHOP alone (in the absence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ), as well as other CHOP-like regimens, were used predominantly in the pre-HAART era and were associated with complete response (CR) rates of 30 to 50 percent and two-year survival rates of less than 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/5,8,13,35\">",
"     5,8,13,35",
"    </a>",
"    ]. When administered in combination with HAART, CR rates with CHOP alone in two studies were 47 and 62 percent, with corresponding overall survival rates at two years in both studies of approximately 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/23,39\">",
"     23,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/45/26330?source=see_link\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite initial reports suggesting a benefit to the incorporation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    into the CHOP regimen over standard",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/37,40\">",
"     37,40",
"    </a>",
"    ], follow-up studies in the HIV-seronegative populations failed to confirm this benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In addition,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"     liposomal doxorubicin",
"    </a>",
"    substitution for doxorubicin in R-CHOP (DR-COP) in 40 HIV-seropositive patients with DLBCL was associated with a complete remission rate of 47.5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/39\">",
"     39",
"    </a>",
"    ], comparable to that observed in patients treated with standard R-CHOP.",
"   </p>",
"   <p>",
"    Treatment of DLBCL in the HIV-seronegative population has shown that the amount of anthracycline that is given in the first 12 weeks of therapy is an important factor in overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/43\">",
"     43",
"    </a>",
"    ]. Those patients who receive less than 75 percent of the standard doses of anthracycline in the first 12 weeks of therapy have inferior survival. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/45/26330?source=see_link&amp;anchor=H326785256#H326785256\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Older adults'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal duration of therapy is unknown. In the HIV-seronegative population, there is a paucity of data showing that eight cycles of chemotherapy with CHOP is any more effective than six cycles. Therefore, we usually give six courses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/45/26330?source=see_link&amp;anchor=H6#H6\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Number of treatment cycles'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6236970\">",
"    <span class=\"h4\">",
"     Dose-adjusted EPOCH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dose-adjusted infusional",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and bolus dose-escalated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    chemotherapy (daEPOCH (",
"    <a class=\"graphic graphic_table graphicRef88411 \" href=\"mobipreview.htm?30/9/30878\">",
"     table 3",
"    </a>",
"    )) is an alternative chemotherapy regimen for patients with a CD4 count",
"    <span class=\"nowrap\">",
"     &gt;50/microL",
"    </span>",
"    thought to have high risk disease as defined by a &gt;80 percent growth fraction, or plasmablastic histology. In this approach, vincristine, doxorubicin and etoposide are administered as a 96-hour continuous infusion, followed by bolus administration of cyclophosphamide. Dosages are adjusted based upon nadir neutrophil counts in the preceding treatment cycle.",
"   </p>",
"   <p>",
"    A prospective single arm trial evaluated the daEPOCH regimen in 39 patients with newly diagnosed AIDS-related lymphoma (80 percent DLBCL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/25\">",
"     25",
"    </a>",
"    ]. Antiretroviral therapy was deferred until completion of chemotherapy. A complete response was achieved in 74 percent. At a median follow-up of 53 months, estimated rates of progression-free and overall survival at five years were 73 and 60 percent, respectively. Five-year overall survival rates for patients with CD4 counts",
"    <span class=\"nowrap\">",
"     &gt;100/microL",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     &le;100/micro",
"    </span>",
"    were 87 and 16 percent, respectively.",
"   </p>",
"   <p>",
"    A multicenter trial to confirm these results and to examine incorporation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    into this regimen (R-daEPOCH) was completed within the United States AIDS Malignancy Consortium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/44\">",
"     44",
"    </a>",
"    ]. Results are discussed below. A randomized intergroup study (CALGB 50302) is comparing R-CHOP to R-daEPOCH in HIV-seronegative patients with DLBCL. Results of this study should be informative regarding the role of this regimen in HIV-associated lymphomas as well. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Dose-adjusted EPOCH plus rituximab'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h4\">",
"     Other regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other chemotherapy regimens, such as M-BACOD (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ), with granulocyte-macrophage colony-stimulating factor support, have not been shown to substantially increase the rates of complete response or median survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/8,21,45,46\">",
"     8,21,45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1224044\">",
"    <span class=\"h3\">",
"     Burkitt lymphoma/leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no agreed upon standard treatment for Burkitt",
"    <span class=\"nowrap\">",
"     lymphoma/leukemia",
"    </span>",
"    in the HIV seronegative population. These lymphomas are known to be highly aggressive tumors characterized by dysregulation of the c-MYC oncogene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/47\">",
"     47",
"    </a>",
"    ]. They are poorly-responsive to moderate-dose chemotherapy (eg, CHOP) that is used for other types of lymphomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/48\">",
"     48",
"    </a>",
"    ]. This is true not only in the HIV-infected population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/24,49\">",
"     24,49",
"    </a>",
"    ], but also in the HIV-seronegative population. HIV-seronegative patients with Burkitt",
"    <span class=\"nowrap\">",
"     lymphoma/leukemia",
"    </span>",
"    are typically treated with intensive, short-duration combination chemotherapy with central nervous system (CNS) prophylaxis. The most commonly used regimens in the HIV-seronegative population are",
"    <span class=\"nowrap\">",
"     CODOX-M/IVAC",
"    </span>",
"    (Magrath) (",
"    <a class=\"graphic graphic_table graphicRef72511 \" href=\"mobipreview.htm?35/40/36493\">",
"     table 4",
"    </a>",
"    ) and CALGB-9251 protocol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Alternatively, infusional chemotherapy with dose-adjusted EPOCH plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    may be considered for patients with HIV and Burkitt",
"    <span class=\"nowrap\">",
"     lymphoma/leukemia.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36217?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of Burkitt leukemia/lymphoma in adults\", section on 'Choice of chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are limited data regarding the use of these regimens in the setting of HIV. A retrospective study of the",
"    <span class=\"nowrap\">",
"     CODOX-M/IVAC",
"    </span>",
"    (Magrath) regimen in 14 HIV-positive adults with Burkitt lymphoma reported a complete response rate of 63 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/49\">",
"     49",
"    </a>",
"    ]. Although only in abstract form, the AIDS Malignancy Consortium reported outcomes for the first 31 patients with HIV and Burkitt lymphoma enrolled in a prospective trial (AMC 048) of a modified CODOX-M",
"    <span class=\"nowrap\">",
"     /IVAC",
"    </span>",
"    regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/52\">",
"     52",
"    </a>",
"    ]. These data demonstrate the regimen to be well-tolerated with a one-year overall survival rate of 86 percent. The addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    did not appear to increase toxicity. The preliminary results of this study compare favorably with results in non-immunocompromised patients treated with the same regimen in previous trials.",
"   </p>",
"   <p>",
"    A randomized phase II trial of dose-adjusted infusional chemotherapy with the EPOCH regimen plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (R-daEPOCH) conducted by the AIDS Malignancies Consortium included 27 patients with Burkitt lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/44\">",
"     44",
"    </a>",
"    ]. These patients did well with this regimen in conjunction with concurrent rituximab. However, further study of this regimen is required before definitive recommendations regarding its use in Burkitt",
"    <span class=\"nowrap\">",
"     lymphoma/leukemia",
"    </span>",
"    can be made. One concern is the lack of CNS-penetrating systemic chemotherapy in the daEPOCH regimen given the high risk of leptomeningeal involvement in HIV patients with Burkitt lymphoma. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Dose-adjusted EPOCH plus rituximab'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    CNS prophylaxis is a key component to the treatment of patients with Burkitt",
"    <span class=\"nowrap\">",
"     lymphoma/leukemia.",
"    </span>",
"    In the absence of CNS prophylaxis, up to 30 percent of patients with Burkitt",
"    <span class=\"nowrap\">",
"     lymphoma/leukemia",
"    </span>",
"    will develop leptomeningeal",
"    <span class=\"nowrap\">",
"     involvement/recurrence",
"    </span>",
"    regardless of HIV status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/47\">",
"     47",
"    </a>",
"    ]. The more successful treatment regimens, like",
"    <span class=\"nowrap\">",
"     CODOX-M/IVAC,",
"    </span>",
"    include the use of systemic CNS-penetrating chemotherapeutic agents and intrathecal chemotherapy administration as an integral part of treatment. (See",
"    <a class=\"local\" href=\"#H1701337\">",
"     'CNS directed therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     CODOX-M/IVAC",
"    </span>",
"    and CALGB-9251 protocols are complex to administer and there are possible interactions between the antineoplastic agents and the components of the HAART regimen. In particular, it is recommended that HAART be interrupted during the administration of high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . This decision should be individualized based upon the specific HAART combination used. During treatment, HAART should be continued if tolerated, however, if significant gastrointestinal toxicity is observed and resulting in the inconsistent use of antivirals, HAART therapy may be discontinued for the duration of chemotherapy and restarted once chemotherapy is completed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1224066\">",
"    <span class=\"h3\">",
"     Plasmablastic lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasmablastic lymphoma is a less common but highly aggressive lymphoma observed in the setting of HIV disease. These tumors infrequently express CD20 and usually display strong expression of CD138, a marker commonly associated with plasma cell malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/53\">",
"     53",
"    </a>",
"    ]. Plasmablastic lymphoma typically demonstrates Epstein Barr virus (EBV) and commonly arise in the oral cavity of HIV-positive patients. They are associated with a poor prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. A review of 157 cases of plasmablastic lymphoma reported in the literature suggests that early clinical stage and complete response to chemotherapy are associated with better outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/54\">",
"     54",
"    </a>",
"    ]. The best approach to therapy is unclear, with one study suggesting better outcome using more aggressive chemotherapy (eg,",
"    <span class=\"nowrap\">",
"     CODOX-M/IVAC)",
"    </span>",
"    such as that used for Burkitt",
"    <span class=\"nowrap\">",
"     lymphoma/leukemia",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/56\">",
"     56",
"    </a>",
"    ]. An alternative is dose-adjusted EPOCH. (See",
"    <a class=\"local\" href=\"#H1224044\">",
"     'Burkitt lymphoma/leukemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Role of Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of the recombinant anti-CD20 antibody",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    has revolutionized the treatment of CD 20-positive lymphomas in the HIV-negative population. However, the role of rituximab in AIDS-related lymphoma is not as clearly defined, given the profound cellular and humoral immunodeficiency that this agent can cause. The combination of rituximab with chemotherapy may cause a temporarily decrease the CD4, CD8, and CD19 (B cell) cell populations but does not appear to change the natural killer cell population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. In addition, panhypogammaglobulinemia of varying magnitude and duration typically follows the use of R-CHOP chemotherapy, leading to a decrease in humoral immunity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/59\">",
"     59",
"    </a>",
"    ]. The loss of humoral immunity in addition to the underlying destruction of the cellular immune system by HIV may increase the risk of infection above that which is normally seen with either HIV infection or rituximab therapy alone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/45/26330?source=see_link&amp;anchor=H4#H4\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Rituximab containing regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, our use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    for patients with AIDS-related CD20 positive lymphoma (eg, DLBCL, Burkitt",
"    <span class=\"nowrap\">",
"     lymphoma/leukemia)",
"    </span>",
"    depends upon the extent to which the underlying HIV is controlled, as manifest by the CD4 count. For most patients with AIDS-related CD20 positive lymphoma, we suggest the addition of rituximab to the treatment regimen if the CD4 count is over",
"    <span class=\"nowrap\">",
"     50/microL.",
"    </span>",
"    This preference places some emphasis on the known benefit of rituximab in the HIV-negative population despite recognizing the more profound cellular and humoral immunodeficiency that this agent can cause.",
"   </p>",
"   <p>",
"    The decision whether to use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in a patient with a CD20-positive disease and a CD4 count &lt;50",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    must be individualized. For patients who have not been treated with HAART previously, it is reasonable to begin chemotherapy with rituximab and HAART with the expectation that viral load will be controlled. Such patients should be followed closely and given enteric antibiotic prophylaxis. On the other hand, for a patient on HAART who has end stage AIDS, who is unlikely to have an increase in the CD4 count during subsequent therapy, we favor chemotherapy alone.",
"   </p>",
"   <p>",
"    Randomized trials are not available to guide the choice of chemotherapy along with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . The studies that have used rituximab with chemotherapy in the HIV-positive and HIV-negative populations have generally supported its addition to chemotherapy regimens for aggressive B cell lymphoma. However, this decision must take into consideration the patient's CD4 count. We use R-CHOP (",
"    <a class=\"graphic graphic_table graphicRef63586 \" href=\"mobipreview.htm?22/2/22574\">",
"     table 5",
"    </a>",
"    ) in average risk patients with CD20-positive AIDS-related diffuse large B cell lymphoma. In contrast, we prefer dose-adjusted EPOCH plus concurrent rituximab in patients with higher risk DLBCL, such as those with high growth fraction (&gt;80 percent) or non-germinal center DLBCL. For patients with Burkitt histology, we favor the",
"    <span class=\"nowrap\">",
"     CODOX-M/IVAC",
"    </span>",
"    (Magrath) regimen with the addition of rituximab. EPOCH plus concurrent rituximab is a possible alternative (",
"    <a class=\"graphic graphic_table graphicRef88411 \" href=\"mobipreview.htm?30/9/30878\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Rituximab plus CHOP or CDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prospective trials have investigated the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in combination with CHOP (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) or CDE (infusional cyclophosphamide, doxorubicin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ) for the treatment of AIDS-related lymphoma, with mixed results.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In results pooled from three phase II trials using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      plus infusional CDE (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ) chemotherapy in 74 patients with AIDS-related lymphoma, complete remission was achieved in 70 percent, with two-year failure-free and overall survival rates of 59 and 64 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/60\">",
"       60",
"      </a>",
"      ]. Not all patients received HAART therapy. Serious infections, including opportunistic infections, were noted in 31 percent, with 8 percent of the patients dying of infection.",
"     </li>",
"     <li>",
"      A phase II nonrandomized trial evaluated R-CHOP in a highly select group of 61 patients with high-grade lymphoma of B cell origin and no more than one of the following adverse characteristics: CD4 count less than 100",
"      <span class=\"nowrap\">",
"       cells/microL(3),",
"      </span>",
"      prior AIDS, or an ECOG performance status less than two [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/61\">",
"       61",
"      </a>",
"      ]. About one-half of the patients on this trial received HAART prior to starting chemotherapy. Treatment was well tolerated with an estimated two-year overall survival rate of 75 percent. Only two patients developed sepsis and one death was possibly related to both treatment and infection in a patient with progressive lymphoma.",
"     </li>",
"     <li>",
"      A nonrandomized phase II trial administered six cycles of R-CHOP plus HAART to 81 HIV-positive patients with diffuse large B cell lymphoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/62,63\">",
"       62,63",
"      </a>",
"      ]. Patients were eligible if they had an ECOG performance status &lt;3 and had no active opportunistic infections.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"       Granulocyte colony-stimulating factor",
"      </a>",
"      (G-CSF) was given if severe neutropenia had been observed on the previous cycle. Prophylaxis for pneumocystis jiroveci pneumonia (PCP, previously pneumocystis carinii pneumonia) was standard. Sixty-nine percent achieved a complete response. Three-year disease-free and overall survival rates were 77 versus 56 percent, respectively. Six patients died of infections during treatment.",
"     </li>",
"     <li>",
"      A multicenter German trial studied the use of standard R-CHOP with HAART in 72 patients with AIDS-related lymphoma and zero or one of the following risk factors:",
"      <span class=\"nowrap\">",
"       CD4&lt;50/microL,",
"      </span>",
"      prior opportunistic infection,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a ECOG performance score &gt;3 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/14\">",
"       14",
"      </a>",
"      ]. The rates of complete response and three-year overall survival were 72 and 60 percent, respectively, and are comparable to outcomes seen in the HIV-negative population.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to these initially favorable results from uncontrolled trials, benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    could not be shown in a subsequent randomized multicenter phase III trial conducted by the AIDS Malignancy Consortium (AMC 010) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/26\">",
"     26",
"    </a>",
"    ]. In this trial, 150 patients with AIDS-related aggressive or highly aggressive CD20 positive NHL were randomly assigned in a two to one ratio to R-CHOP or CHOP. All patients received G-CSF, HAART, and PCP prophylaxis. Antibiotic prophylaxis for enteric organisms was not required. Median follow-up was 137 weeks. When compared with CHOP alone, R-CHOP followed by rituximab maintenance resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A nonsignificant trend towards higher overall complete remission (58 versus 47 percent)",
"     </li>",
"     <li>",
"      A nonsignificant reduction in disease progression (8.1 versus 21.6 percent)",
"     </li>",
"     <li>",
"      Similar median overall survival (2.6 versus 2.1 years)",
"     </li>",
"     <li>",
"      A greater incidence of grade IV neutropenia (62 versus 48 percent)",
"     </li>",
"     <li>",
"      A significantly increased incidence of death due to infection (14 versus 2 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sixty percent of infection-related deaths occurred in patients with CD4 counts less than 50",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    In an analysis that excluded patients with CD4 counts less than 50",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    death rates due to infection were not significantly different between those patients who received or did not receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . It is noteworthy, however, that this study was not powered to detect the level of difference in outcome that was observed in the original GELA trial of CHOP versus R-CHOP in non-immunocompromised patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A greater incidence of grade IV neutropenia (62 versus 48 percent) and a significantly increased incidence of death due to infection in the R-CHOP arm of this study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/26\">",
"     26",
"    </a>",
"    ] as well as in patients treated with infusional R-CDE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/60\">",
"     60",
"    </a>",
"    ] raises serious concerns regarding the safety of adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to standard dose chemotherapy in HIV positive patients with poor performance status",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    low CD4 counts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/26,61,65\">",
"     26,61,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Dose-adjusted EPOCH plus rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, dose-adjusted EPOCH (daEPOCH; infusional",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and bolus dose-escalated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef88411 \" href=\"mobipreview.htm?30/9/30878\">",
"     table 3",
"    </a>",
"    )) may be preferred for patients with AIDS-related diffuse large B cell lymphoma and certain markers of poor prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/66\">",
"     66",
"    </a>",
"    ]. The combination of daEPOCH plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    has also been studied in patients with HIV, with mixed results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/44,67,68\">",
"     44,67,68",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6236970\">",
"     'Dose-adjusted EPOCH'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter randomized phase II trial from the AIDS Malignancies Consortium (AMC034) explored da-EPOCH plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in combination with antibiotic prophylaxis for enteric organisms in 101 patients with AIDS-related B cell NHL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/44\">",
"       44",
"      </a>",
"      ]. All patients received da-EPOCH and were randomly assigned to rituximab given either concurrently (375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      prior to starting each 21-day cycle of EPOCH) or sequentially (weekly for six weeks following completion of chemotherapy). The starting dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      was based upon the baseline CD4 count and dosage adjustments in subsequent cycles were based on nadir neutrophil counts. Tumor histology was diffuse large B cell lymphoma in 71 percent, and Burkitt or Burkitt-like lymphoma in 29 percent. When compared with sequential rituximab, concurrent rituximab resulted in:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A higher complete response rate (73 versus 55 percent)",
"     </li>",
"     <li>",
"      Similar rates of two-year progression-free (66 and 63 percent) and overall survival (70 and 67 percent)",
"     </li>",
"     <li>",
"      Similar numbers of treatment-associated deaths (5 versus 4 cases)",
"     </li>",
"     <li>",
"      Comparable toxicity",
"      <br/>",
"      <br/>",
"      The most common severe (grade 3 or 4) toxicities included neutropenia (42 percent), infection (28 percent), anemia (16 percent), thrombocytopenia (12 percent), and febrile neutropenia (12 percent). Patients with a baseline CD4 count",
"      <span class=\"nowrap\">",
"       &lt;50/microL",
"      </span>",
"      had a high infectious death rate in the concurrent arm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Another phase II trial of 33 patients with AIDS-related lymphoma treated with short-course EPOCH plus dose-dense",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      for a minimum of three cycles reported five-year rates of progression-free and overall survival of 84 and 68 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/67\">",
"       67",
"      </a>",
"      ]. Patients had a median CD4 cell count of 208 with 42 percent having a CD4 count less than 100. There were no treatment-related deaths or new opportunistic infections during treatment.",
"      <br/>",
"      <br/>",
"      Unlike most other studies, no clinical prognostic characteristics including International Prognostic Index (",
"      <a class=\"graphic graphic_table graphicRef70850 \" href=\"mobipreview.htm?17/21/17757\">",
"       table 2",
"      </a>",
"      ) were associated with progression-free or overall survival. However, tumor histogenesis was significantly associated with lymphoma-specific outcome with 95 percent of germinal center B cell (GCB) and 44 percent of 17 non-GCB DLBCL progression-free at five years. Tumor histogenesis and CD4 cell count were independently associated with survival, reflecting both lymphoma and HIV-specific deaths. These results mirror the importance of tumor histogenesis in the outcome of HIV-negative DLBCL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/69\">",
"       69",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15658?source=see_link&amp;anchor=H334141054#H334141054\">",
"       \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Prognosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1701337\">",
"    <span class=\"h2\">",
"     CNS directed therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AIDS-related NHL have an increased risk of central nervous system (CNS) involvement both at the time of diagnosis and during the course of disease. The incidence of CNS involvement varies with NHL subtype. All patients Burkitt",
"    <span class=\"nowrap\">",
"     lymphoma/leukemia",
"    </span>",
"    and a subset of patients with diffuse large B cell lymphoma (defined below) should undergo lumbar puncture with studies to rule out occult CNS spread at the time of diagnosis. Cerebrospinal fluid should be evaluated with flow cytometric studies in addition to CSF cytology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/17/39194?source=see_link&amp;anchor=H6053884#H6053884\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\", section on 'Lumbar puncture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study of 176 patients with systemic, AIDS-related non-Hodgkin lymphoma, 10 percent had meningeal involvement at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/71\">",
"     71",
"    </a>",
"    ]. This is likely due to the high frequency of lymphomatous involvement of multiple extranodal sites of disease in patients with HIV-related lymphoma. For those with diffuse large B cell lymphoma (DLBCL), lumbar puncture at diagnosis should be performed (as in non-immunocompromised patients) in the setting of &gt;2 extranodal sites of disease accompanied by elevated LDH, or specific high-risk sites such as paranasal sinuses, testes, epidural space, and bone marrow. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/45/26330?source=see_link&amp;anchor=H15#H15\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'AIDS-related lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with Burkitt",
"    <span class=\"nowrap\">",
"     lymphoma/leukemia",
"    </span>",
"    have an up to 30 percent risk of leptomeningeal",
"    <span class=\"nowrap\">",
"     involvement/recurrence",
"    </span>",
"    regardless of HIV status. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/47\">",
"     47",
"    </a>",
"    ]. All should have lumbar puncture performed at diagnosis. The more successful treatment regimens, like",
"    <span class=\"nowrap\">",
"     CODOX-M/IVAC,",
"    </span>",
"    include the use of systemic CNS-penetrating chemotherapeutic agents and intrathecal chemotherapy administration as an integral part of treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36217?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of Burkitt leukemia/lymphoma in adults\", section on 'CNS involvement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Those patients who have leptomeningeal involvement with systemic lymphoma should have treatment directed at the CNS, either with intrathecal chemotherapy or the systemic administration of high doses of antineoplastic agents that cross the blood-brain barrier [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/47\">",
"     47",
"    </a>",
"    ]. The agents used for this purpose include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/5,72\">",
"     5,72",
"    </a>",
"    ]. A liposomal preparation of the latter has become available and has the advantage of less frequent dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/12,73\">",
"     12,73",
"    </a>",
"    ]. However, severe and potentially fatal CNS toxicity was reported when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/53/34645?source=see_link\">",
"     liposomal cytarabine",
"    </a>",
"    was combined with high-dose CNS-penetrating systemic therapies, such as those used in the treatment of Burkitt lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/74\">",
"     74",
"    </a>",
"    ]. As such, liposomal cytarabine in combination with high-dose CNS-penetrating systemic therapies should be avoided outside of a clinical trial setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/17/39194?source=see_link&amp;anchor=H6053447#H6053447\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\", section on 'Treatment and prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1227497\">",
"    <span class=\"h1\">",
"     PATIENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;After completion of the initially planned treatment, patients should be evaluated to determine the disease response to treatment and should be followed longitudinally for relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1227504\">",
"    <span class=\"h2\">",
"     Response evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;One month following the completion of planned therapy (or sooner if the outcome is unfavorable), the response to treatment should be documented by history, physical examination, and laboratory studies (complete blood count, lactate dehydrogenase, and biochemical profile). The post-treatment imaging study of choice is a combined positron emission",
"    <span class=\"nowrap\">",
"     tomography/computed",
"    </span>",
"    tomography",
"    <span class=\"nowrap\">",
"     (PET/CT)",
"    </span>",
"    scan, which provides information on the size and activity of residual masses and allows for the distinction between active disease and fibrosis.",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    should be obtained six to eight weeks after completion of chemotherapy and 12 weeks after the completion of radiation therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/75\">",
"     75",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    imaging obtained earlier than this is likely to demonstrate increased uptake due to an inflammatory reaction to treatment.",
"   </p>",
"   <p>",
"    Using information gathered from the history, physical, and",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan, disease response is determined by the International Workshop Criteria (IWC) (",
"    <a class=\"graphic graphic_table graphicRef64921 \" href=\"mobipreview.htm?29/27/30140\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/76\">",
"     76",
"    </a>",
"    ]. A complete remission has been achieved if all of the following criteria are met:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no evidence of disease or disease-related symptoms on history and physical examination.",
"     </li>",
"     <li>",
"      All post-treatment residual masses are negative on PET scan.",
"     </li>",
"     <li>",
"      The spleen and liver are non-palpable and no nodules are detected by imaging.",
"     </li>",
"     <li>",
"      If a pretreatment bone marrow biopsy was positive, a repeat bone marrow biopsy must be negative. If morphologically indeterminate, immunohistochemistry should be negative.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A discussion of the accuracy of",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    in the follow-up of patients with lymphoma is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15658?source=see_link&amp;anchor=H17#H17\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Evaluating response to treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who fail to obtain a complete response are treated as refractory disease. (See",
"    <a class=\"local\" href=\"#H4261492\">",
"     'Treatment of relapsed disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1227511\">",
"    <span class=\"h2\">",
"     Surveillance for relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the completion of therapy, restaging, and documentation of complete remission, patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse. The frequency and extent of these visits depends upon the comfort of both the patient and physician. There have been no prospective, randomized trials comparing various schedules of follow-up.",
"   </p>",
"   <p>",
"    Our approach to patient surveillance is to schedule patient visits every one to two months during the first year, every two to three months during the second year, and every four to six months starting two years after complete response. At these visits we perform a history and physical examination, complete blood count, chemistries, and LDH.",
"   </p>",
"   <p>",
"    There is no role for routine PET or",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    imaging in the longitudinal follow-up of asymptomatic patients after response assessment. For those patients who achieve complete remission, follow-up CT scanning should be considered at six and 12 months post-treatment. Beyond one-year risk of recurrence is low, and scanning should be performed only as clinically indicated. Clinical follow-up is recommended every three to six months for five years. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15658?source=see_link&amp;anchor=H18#H18\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Consensus opinion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Relapsed disease can be suggested by changes on imaging studies but can only be confirmed by biopsy. As such, a biopsy should always be obtained to document relapsed disease before proceeding to salvage therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4261492\">",
"    <span class=\"h1\">",
"     TREATMENT OF RELAPSED DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Second-line chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although prospective trials have not evaluated clinical outcomes in patients treated with second-line chemotherapy, it is usual practice to administer platinum-based salvage regimens commonly employed in the non-immunocompromised population such as ICE, ESHAP, or DHAP for patients with relapsed or refractory DLBCL. Many of these regimens have been utilized in for salvage therapy in the autologous transplant studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. As is the case in those with",
"    <span class=\"nowrap\">",
"     relapsed/refractory",
"    </span>",
"    non-immunodeficiency-related lymphomas, outcome is poor in the absence of subsequent treatment with high-dose chemotherapy and autologous stem cell support in those with chemotherapy-responsive disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33178?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of relapsed or refractory diffuse large B cell lymphoma\", section on 'Achieving a second response'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H4261241\">",
"     'Hematopoietic cell transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A retrospective study from the AIDS Malignancy Consortium reported the outcomes of 88 patients with primary refractory (61 percent) or relapsed AIDS-related lymphoma diagnosed from 1999 to 2008 and treated with curative intent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/80\">",
"     80",
"    </a>",
"    ]. The most common histologic variants were DLBCL (60 percent), Burkitt lymphoma and variants (14 percent), Hodgkin lymphoma (11 percent), plasmablastic lymphoma (6 percent), and T cell lymphoma (6 percent). The overall response rate to second line therapy was 37 percent (24 percent complete) and median survival was 38 weeks. At a median follow-up of 88 weeks, estimated one- and two-year overall survival rates were 42 and 35 percent, respectively. The best outcomes were seen in patients with Hodgkin lymphoma, those with relapsed rather than refractory disease, those with a complete or partial response to second-line therapy, and those who underwent high-dose chemotherapy and autologous stem cell support.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Platinum-based regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective study evaluated the use of ESHAP (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , cytosine arabinoside, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ) in 13 patients with relapsed or refractory AIDS-related NHL after at least one prior chemotherapy regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/81\">",
"     81",
"    </a>",
"    ]. Complete and partial responses were seen in four (31 percent) and three (23 percent) patients, respectively. Median survival was 7.1 months. Hematologic toxicity was substantial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12457685\">",
"    <span class=\"h3\">",
"     Novel treatment approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Novel treatment approaches that are under investigation include the use of the protease inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    , histone deacetylase inhibitors, and the use of risk stratification to determine therapy. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       Bortezomib",
"      </a>",
"      has established antitumor activity in a variety of lymphoid malignancies, and has been shown both in vivo and in vitro to dramatically reduce transcription from the HIV-1 LTR-promoter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/82\">",
"       82",
"      </a>",
"      ]. In addition, proteasome inhibitors, including bortezomib, markedly inhibit HIV-1 replication in human peripheral blood mononuclear cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/83\">",
"       83",
"      </a>",
"      ] and have been shown in vitro to reverse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      resistance and sensitize rituximab-resistant HIV-associated B cell NHL cell lines to chemotherapy-induced apoptosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/84\">",
"       84",
"      </a>",
"      ]. A phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      trial of bortezomib in combination with rituximab and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      <span class=\"nowrap\">",
"       /",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      <span class=\"nowrap\">",
"       /",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      (ICE) is currently being conducted through the AIDS Malignancy Consortium.",
"     </li>",
"     <li>",
"      Histone deacetylase inhibitors (HDAC) may also have a potential role in management of HIV-lymphomas. Activity has been observed in some lymphomas, but there is evidence that HDAC inhibitors may activate latent HIV gene expression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/85,86\">",
"       85,86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As in aggressive B cell lymphomas in non-immunocompromised patients, current initial treatment strategies are focusing on risk stratification using immunophenotyping or gene expression profiling as well as HIV risk factors to identify patients who may have better outcomes with different therapies. One study is currently evaluating use of R-CHOP for higher risk HIV patients with large cell lymphoma while using R-EPOCH for patients with better control of HIV disease and those with non-germinal center B cell lymphomas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4261241\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autologous hematopoietic cell transplantation (HCT) is a treatment option for select patients with relapsed AIDS-related lymphoma demonstrating sensitivity to second-line chemotherapy. In contrast, the role of allogeneic HCT in AIDS-related lymphoma is unknown given the paucity of published data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4261248\">",
"    <span class=\"h3\">",
"     Autologous transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-dose chemotherapy with autologous stem cell support is effective therapy in patients with HIV-associated lymphomas. Patients with relapsed or refractory disease (Hodgkin or non-Hodgkin lymphoma) should be considered potential candidates for this treatment approach, ideally in the setting of a clinical trial. To be eligible, these patients should have a demonstrated response to highly active antiretroviral therapy (HAART), adequate organ function, chemosensitive disease, and no active CMV infection or other opportunistic infections.",
"   </p>",
"   <p>",
"    Autologous hematopoietic cell transplantation (HCT) has been successfully used for the treatment of patients with relapsed or refractory HIV-associated lymphoma receiving HAART in both prospective and retrospective studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/77,78,80,87-91\">",
"     77,78,80,87-91",
"    </a>",
"    ]. In general, the incidence of bacteremia and neutropenic fever has been similar to that seen in the HIV-negative transplant setting. Regimen-related toxicity is not significantly increased when antiretroviral therapy is combined with the high-dose chemotherapy and radiation therapy required for HCT.",
"   </p>",
"   <p>",
"    In the largest prospective, single arm trial, 50 patients with relapsed or refractory non-primary central nervous system lymphomas demonstrating HIV response to HAART therapy received high-dose chemotherapy followed by autologous HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/79\">",
"     79",
"    </a>",
"    ]. Inclusion criteria included age &lt;60 years; adequate organ function and overall functional status; no history of cytomegalovirus (CMV) pneumonia; and no active major opportunistic infections. Twenty-seven (54 percent) patients had chemosensitive disease, underwent successful stem cell mobilization, and proceeded to HCT using BEAM as the preparative regimen. Time to neutrophil engraftment",
"    <span class=\"nowrap\">",
"     (&gt;500/microL)",
"    </span>",
"    was 10 days and to platelet engraftment",
"    <span class=\"nowrap\">",
"     (&gt;20,000/microL)",
"    </span>",
"    12 days. Of these, 21 patients achieved a continuous complete response (CR) at a median follow-up of 44 months and 6 patients had disease progression or relapse after CR. No patient died from transplant-related complications. There were four cases of CMV reactivation and six cases of herpes zoster infection.",
"   </p>",
"   <p>",
"    Other prospective trials include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AIDS-Malignancy Consortium trial 020 in which 20 of 27 patients enrolled underwent autologous HCT with median times to neutrophil and platelet engraftment of 11 and 13 days, respectively. There was only one treatment-related death and no unusual infectious complications. Fifty-three percent were in CR at 100 days post-transplantation.",
"     </li>",
"     <li>",
"      A single-institution case series of 20 patients with chemotherapy-sensitive relapsed AIDS-related NHL reported on the efficacy of high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"       carmustine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      (CBV, 17 patients) or the combination of total body irradiation, cyclophosphamide, etoposide (3 patients) followed by autologous HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/87\">",
"       87",
"      </a>",
"      ]. After a median followup of 31.8 months post-transplant, 17 patients are alive and disease-free. Engraftment times were rapid and infectious complications were not unusual. Two cases of Pneumocystis jiroveci pneumonia (PCP, previously Pneumocystis carinii pneumonia) occurred in individuals who were non-compliant with prophylaxis. CMV reactivation occurred in two and CMV retinitis in one. Although patients were continued on HAART, many discontinued due to gastrointestinal toxicities. Most patients were able to restart HAART within two months of transplant. CD4 counts recovered to baseline within one year and were significantly higher at two years.",
"     </li>",
"     <li>",
"      Another series reported on the outcomes of 16 patients with chemosensitive relapsed or refractory AIDS-related lymphoma, 10 of whom underwent autologous HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/77\">",
"       77",
"      </a>",
"      ]. There were no treatment-related deaths and six patients were alive and disease-free a median of eight months post-transplant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A multi-institution retrospective study reported on 68 HIV-positive patients with lymphoma who underwent autologous HCT in the following settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/78\">",
"     78",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      First CR (16 patients)",
"     </li>",
"     <li>",
"      Second or greater CR, partial remission, or with chemotherapy sensitive disease (44 patients)",
"     </li>",
"     <li>",
"      With chemotherapy refractory disease (8 patients)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The nonrelapse mortality rate was 7.5 percent at one year, mostly due to bacterial infections. Times to",
"    <span class=\"nowrap\">",
"     neutrophil/platelet",
"    </span>",
"    engraftment were 10 and 14 days, respectively. With a median follow-up of 32 months, the rates of three-year progression-free and overall survival were 56.5 percent and 61 percent, respectively.",
"   </p>",
"   <p>",
"    In total, these studies support the use of autologous HCT for patients with control of their HIV who would otherwise be candidates for HCT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4261285\">",
"    <span class=\"h3\">",
"     Allogeneic transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial interest in the investigational use of allogeneic hematopoietic cell transplantation (HCT) in HIV-associated lymphoma came after there were reports of successful solid organ transplantation in the HIV population. There is a paucity of published data on the use of allogeneic HCT in HIV-infected patients; only case reports and retrospective series are available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/92-95\">",
"     92-95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest retrospective analysis evaluated 23 HIV positive patients undergoing myeloablative (87 percent) or nonmyeloablative (13 percent) allogeneic HCT between 1987 and 2003 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/93\">",
"     93",
"    </a>",
"    ]. The median time to neutrophil recovery was 18 days. The cumulative incidence rates of acute and chronic graft-versus-host disease were 30 and 28 percent, respectively. At a median follow-up of 59 months, overall survival rates at one and two years were 30 percent, each. Overall survival rates were higher for those transplanted after 1996. There were nine treatment-related deaths, most often due to pulmonary toxicity.",
"   </p>",
"   <p>",
"    Prospective trials are needed and a multicenter study is currently in development through the BMT Clinical Trials Network and the AIDS Malignancy Consortium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1225476\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although few patients diagnosed early in the HIV epidemic were cured of their lymphoma, the introduction of highly active antiretroviral therapy (HAART) in the late 1990s resulted in a marked improvement in the ability of these patients to tolerate standard chemotherapy regimens and clinical outcomes that now approach those in the general population. As described above, outcomes with full-dose chemotherapy for aggressive B cell lymphomas appear to be similar in HIV-positive and HIV-negative populations treated with similar regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. Survival in patients with AIDS-related lymphoma is related to factors associated with both HIV infection and the lymphoma. More than 50 percent of patients with AIDS-related NHL will have long-term survival with conventional dose chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/14,25,26,44,60-62,67\">",
"     14,25,26,44,60-62,67",
"    </a>",
"    ]. Of the patients who do not do well, almost one-half die from progression or recurrence of the lymphoma, and the remainder from opportunistic infections or other AIDS-related complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/5,8,9,35,45,46,67,72\">",
"     5,8,9,35,45,46,67,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1225483\">",
"    <span class=\"h2\">",
"     Risk factors prior to therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1225490\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response rate and survival of the AIDS-related lymphomas appear to correlate with the number of adverse prognostic features. The largest pre-HAART study, from the AIDS Clinical Trials Group, that addressed pretherapy prognostic features consisted of 192 patients treated with low or standard dose M-BACOD (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/45\">",
"     45",
"    </a>",
"    ]. The following were identified as adverse factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &gt;35 years",
"     </li>",
"     <li>",
"      Intravenous drug use",
"     </li>",
"     <li>",
"      Stage III or IV disease",
"     </li>",
"     <li>",
"      CD4 cell count",
"      <span class=\"nowrap\">",
"       &lt;100/microL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with no or one adverse factor, compared with those with three or four adverse factors, had a higher median survival (46 versus 18 weeks) and 2.8-year survival rate (30 versus zero percent).",
"   </p>",
"   <p>",
"    Somewhat similar findings were noted in a series of 68 patients treated with CHOP (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients at high risk of relapse were identified by at least two of the following three features: CD4 cell count",
"    <span class=\"nowrap\">",
"     &lt;50/microL,",
"    </span>",
"    ECOG performance status of 3 or 4, and pre-existing AIDS-defining opportunistic infection. The median survival was 21 months in the good risk group compared with four months in the high risk group.",
"   </p>",
"   <p>",
"    A prognostic index has been proposed based on the experience in 111 patients with HIV-lymphoma identified from a large cohort of HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/17\">",
"     17",
"    </a>",
"    ]. Regression modeling identified CD4 count and IPI score as significant prognostic factors and four internally validated risk strata were identified with one-year overall survival rates of 82 percent, 47 percent, 20 percent, and 15 percent.",
"   </p>",
"   <p>",
"    Other studies have confirmed that a greater degree of immunosuppression, whether assessed by the CD4 cell count or a prior history of an AIDS-defining illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/3,6,46,98\">",
"     3,6,46,98",
"    </a>",
"    ], advanced stage of the lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/3,99\">",
"     3,99",
"    </a>",
"    ], age &gt;35 to 40 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/46,98\">",
"     46,98",
"    </a>",
"    ], and high-risk disease as defined by the International Prognostic Index (IPI) (",
"    <a class=\"graphic graphic_table graphicRef70850 \" href=\"mobipreview.htm?17/21/17757\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/9,17,67,100-102\">",
"     9,17,67,100-102",
"    </a>",
"    ] are important adverse risk factors. There are conflicting data on the importance of performance status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/3,45,99\">",
"     3,45,99",
"    </a>",
"    ], serum lactate dehydrogenase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/46,103\">",
"     46,103",
"    </a>",
"    ], and intravenous drug use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/3,45\">",
"     3,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1225497\">",
"    <span class=\"h3\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;In HIV-negative patients with diffuse large B cell lymphoma (DLBCL), the immunophenotype has been shown to be of prognostic importance. As is the case for non-immunocompromised patients with DLBCL, immunophenotypic analysis reveals a post-germinal center phenotype (non-GC) to be associated with significantly worse outcome when compared with a GC phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/67,98,102\">",
"     67,98,102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29127?source=see_link&amp;anchor=H17219010#H17219010\">",
"     \"Prognosis of diffuse large B cell lymphoma\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Features associated with the plasmablastic and primary effusion subtypes of DLBCL, including negativity for CD20, negativity for CD10, and positivity for",
"    <span class=\"nowrap\">",
"     CD138/Syn-1,",
"    </span>",
"    are associated with a worse prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/53,55\">",
"     53,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1225504\">",
"    <span class=\"h2\">",
"     Effect of HAART",
"    </span>",
"    &nbsp;&mdash;&nbsp;Finally, as noted above, there is retrospective evidence to support a survival benefit from the addition of HAART to chemotherapy. Treatment outcomes in prospective trials conducted since the introduction of HAART show markedly improved survival times when compared with studies from the pre-HAART era. (See",
"    <a class=\"local\" href=\"#H62463420\">",
"     'Incorporating HAART'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As an example, in a large French study in 485 patients treated with a risk-adapted approach to chemotherapy, HAART use, immune status, and IPI score were independently associated with prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/9\">",
"     9",
"    </a>",
"    ]. In another study the two-year overall survival of HIV-positive patients with low, low-intermediate, or high-intermediate-risk disease as defined by the IPI (",
"    <a class=\"graphic graphic_table graphicRef70850 \" href=\"mobipreview.htm?17/21/17757\">",
"     table 2",
"    </a>",
"    ) who were treated with chemotherapy plus HAART was not significantly different from that of HIV-negative patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/28/38346/abstract/17\">",
"     17",
"    </a>",
"    ]. These authors suggested that a weighted prognostic score combining the IPI with the CD4 cell count (&lt;100 versus &gt;100",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    provided further independent prognostic information for HIV-infected patients with systemic lymphoma treated in the HAART era.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HIV infection are at increased risk for systemic non Hodgkin lymphoma (NHL). The treatment of systemic NHL in the setting of HIV is complicated by the patient&rsquo;s immunocompromised state and also requires specific treatment for the HIV. The following represents our general approach to the management of systemic non-central nervous system (CNS), non effusion lymphomas in HIV-positive patients. Treatment of CNS and primary effusion lymphoma is addressed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7321?source=see_link\">",
"     \"AIDS-related lymphomas: Primary central nervous system lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30969?source=see_link\">",
"     \"AIDS-related lymphomas: Primary effusion lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal initial therapy for lymphomas in the setting of HIV has yet to be defined. Highly active antiretroviral therapy (HAART) is started or modified (if already begun) to control the HIV infection and allow for the administration of chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy. As in the HIV-seronegative population, the choice of therapy is principally determined by the subtype of NHL and the stage of disease. Modifications are made based upon the degree of immunosuppression from HIV as measured by the CD4 count.",
"   </p>",
"   <p>",
"    The following represents our approach for patients with diffuse large B cell lymphoma (DLBCL). A similar approach may be taken for other types of clinically aggressive NHL, although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    is",
"    <strong>",
"     not",
"    </strong>",
"    used for NHL that lacks expression of CD20.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most patients with DLBCL that have a CD4 count &gt;50",
"      <span class=\"nowrap\">",
"       cells/microL,",
"      </span>",
"      we suggest the combination of CHOP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (R-CHOP) rather than CHOP alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Rituximab plus CHOP or CDE'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The decision to use",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in the setting of a CD4 count &lt;50",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      must be individualized. For most patients with DLBCL who have a CD4 count &lt;50",
"      <span class=\"nowrap\">",
"       cells/microL,",
"      </span>",
"      we suggest CHOP chemotherapy without rituximab rather than the combination (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Caution is advised if rituximab is incorporated into CHOP chemotherapy in the setting of CD4 count",
"      <span class=\"nowrap\">",
"       &lt;50/microL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H4\">",
"       'CHOP chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Rituximab plus CHOP or CDE'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For DLBCL patients with &gt;80 percent growth fraction, or plasmablastic histology in the setting of CD4 count",
"      <span class=\"nowrap\">",
"       &gt;50/microL,",
"      </span>",
"      we suggest the standard dose-adjusted EPOCH (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      plus oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      and IV bolus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ) regimen plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef88411 \" href=\"mobipreview.htm?30/9/30878\">",
"       table 3",
"      </a>",
"      ) rather than R-CHOP (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In such cases, we suggest concurrent rather than sequential rituximab (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Dose-adjusted EPOCH plus rituximab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If treatment with R-EPOCH is chosen, supportive care should include prophylaxis for Pneumocystis jiroveci pneumonia (PCP, previously Pneumocystis carinii pneumonia), and antibiotic prophylaxis for enteric organisms. Given the high incidence of recurrent Herpes simplex, Herpes zoster, and Candida infections in this population, many clinicians also advise instituting antiviral and antifungal prophylaxis. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Dose-adjusted EPOCH plus rituximab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lumbar puncture should be performed at diagnosis in the setting of &gt;2 extranodal sites of disease accompanied by elevated LDH, or specific high-risk sites such as paranasal sinuses, testes, epidural space, and bone marrow. CNS prophylaxis is not routinely administered. (See",
"      <a class=\"local\" href=\"#H1701337\">",
"       'CNS directed therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/45/26330?source=see_link&amp;anchor=H15#H15\">",
"       \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'AIDS-related lymphoma'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We take the following approach for patients with Burkitt",
"    <span class=\"nowrap\">",
"     lymphoma/leukemia",
"    </span>",
"    (BL). A similar approach may be used for patients with immunoblastic lymphoma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most patients with AIDS-related BL, we suggest the",
"      <span class=\"nowrap\">",
"       CODOX-M/IVAC",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef72511 \" href=\"mobipreview.htm?35/40/36493\">",
"       table 4",
"      </a>",
"      ) regimen rather than CHOP (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Alternatively, infusional chemotherapy with dose-adjusted EPOCH plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      may be considered. (See",
"      <a class=\"local\" href=\"#H1224044\">",
"       'Burkitt lymphoma/leukemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Dose-adjusted EPOCH plus rituximab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During treatment, HAART should be continued, if tolerated, along with Pneumocystis jiroveci pneumonia (PCP, previously Pneumocystis carinii pneumonia) prophylaxis, and antibiotic prophylaxis for enteric organisms. If significant gastrointestinal toxicity is observed and resulting in the inconsistent use of antivirals, HAART therapy may be discontinued for the duration of chemotherapy and restarted once chemotherapy is completed. Given the high incidence of recurrent Herpes simplex, Herpes zoster, and Candida infections in this population, many clinicians also advise instituting antiviral and antifungal prophylaxis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33450?source=see_link\">",
"       \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3001?source=see_link\">",
"       \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/4/19530?source=see_link\">",
"       \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      All patients should undergo lumbar puncture at diagnosis. Patients with Burkitt lymphoma and no evidence of leptomeningeal involvement should have CNS prophylaxis, with intrathecal chemotherapy and systemic administration of high doses of antineoplastic agents that cross the blood-brain barrier. (See",
"      <a class=\"local\" href=\"#H1701337\">",
"       'CNS directed therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although few patients diagnosed early in the HIV epidemic were cured of their lymphoma, the introduction of highly active antiretroviral therapy (HAART) in the late 1990s resulted in a marked improvement in the ability of these patients to tolerate standard chemotherapy regimens and clinical outcomes that now approach those in the general population. (See",
"    <a class=\"local\" href=\"#H1225476\">",
"     'Prognosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Autologous hematopoietic cell transplantation (HCT) is a treatment option for select patients with relapsed AIDS-related lymphoma demonstrating sensitivity to second-line chemotherapy. In contrast, the role of allogeneic HCT in AIDS-related lymphoma is unknown given the paucity of published data. Otherwise, chemotherapy protocols that contain agents that are not cross-resistant with those previously administered can be considered. Ideally, if available, the patient should be referred for an investigational treatment protocol. (See",
"    <a class=\"local\" href=\"#H4261492\">",
"     'Treatment of relapsed disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1108978\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate would like to acknowledge Caroline M Behler, MD, MS, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/1\">",
"      Knowles DM. Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 2003; 17:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/2\">",
"      Sandler AS, Kaplan LD. Diagnosis and management of systemic non-Hodgkin's lymphoma in HIV disease. Hematol Oncol Clin North Am 1996; 10:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/3\">",
"      Straus DJ. Human immunodeficiency virus-associated lymphomas. Med Clin North Am 1997; 81:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/4\">",
"      Kasamon YL, Swinnen LJ. Treatment advances in adult Burkitt lymphoma and leukemia. Curr Opin Oncol 2004; 16:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/5\">",
"      Weiss R, Huhn D, Mitrou P, et al. HIV-related non-Hodgkin's lymphoma: CHOP induction therapy and interferon-alpha-2b/zidovudine maintenance therapy. Leuk Lymphoma 1998; 29:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/6\">",
"      Sparano JA, Hu X, Wiernik PH, et al. Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy. J Natl Cancer Inst 1997; 89:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/7\">",
"      Mounier N, Spina M, Gisselbrecht C. Modern management of non-Hodgkin lymphoma in HIV-infected patients. Br J Haematol 2007; 136:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/8\">",
"      Kaplan LD, Straus DJ, Testa MA, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997; 336:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/9\">",
"      Mounier N, Spina M, Gabarre J, et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood 2006; 107:3832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/10\">",
"      Kwee TC, Kwee RM, Nievelstein RA. Imaging in staging of malignant lymphoma: a systematic review. Blood 2008; 111:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/11\">",
"      Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood 2007; 110:3507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/12\">",
"      Kim S, Chatelut E, Kim JC, et al. Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol 1993; 11:2186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/13\">",
"      Tan B, Ratner L. The use of new antiretroviral therapy in combination with chemotherapy. Curr Opin Oncol 1997; 9:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/14\">",
"      Weiss R, Mitrou P, Arasteh K, et al. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial. Cancer 2006; 106:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/15\">",
"      Mwanda WO, Orem J, Fu P, et al. Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa. J Clin Oncol 2009; 27:3480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/16\">",
"      Lim ST, Karim R, Tulpule A, et al. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. J Clin Oncol 2005; 23:8477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/17\">",
"      Bower M, Gazzard B, Mandalia S, et al. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med 2005; 143:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/18\">",
"      Clayton A, Mughal T. The changing face of HIV-associated lymphoma: what can we learn about optimal therapy inl the post highly active antiretroviral therapy era? Hematol Oncol 2004; 22:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/19\">",
"      Matthews GV, Bower M, Mandalia S, et al. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000; 96:2730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/20\">",
"      Hoffmann C, Wolf E, F&auml;tkenheuer G, et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS 2003; 17:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/21\">",
"      Thirlwell C, Sarker D, Stebbing J, Bower M. Acquired immunodeficiency syndrome-related lymphoma in the era of highly active antiretroviral therapy. Clin Lymphoma 2003; 4:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/22\">",
"      Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001; 91:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/23\">",
"      Navarro JT, Ribera JM, Oriol A, et al. Advanced stage is the most important prognostic factor for survival in patients with systemic acquired immunodeficiency syndrome-related non-Hodgkin's Lymphoma treated with CHOP and highly active antiretroviral therapy. Int J Hematol 2007; 86:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/24\">",
"      Lim ST, Karim R, Nathwani BN, et al. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol 2005; 23:4430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/25\">",
"      Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003; 101:4653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/26\">",
"      Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005; 106:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/27\">",
"      Navarro JT, Ribera JM, Oriol A, et al. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br J Haematol 2001; 112:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/28\">",
"      Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001; 15:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/29\">",
"      Ratner L, Redden D, Hamzeh F, et al. Chemotherapy for HIV associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy (HAART) is not associated with excessive toxicity. Third AIDS Malignancy Conference, Bethesda, MD 1999. Abstract 92. J AIDS 1999; 21:A34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/30\">",
"      Wong JK, Hezareh M, G&uuml;nthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/31\">",
"      Bower M, McCall-Peat N, Ryan N, et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 2004; 104:2943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/32\">",
"      Hicks C, Gulick RM. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis 2009; 48:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/33\">",
"      Powles T, Imami N, Nelson M, et al. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS 2002; 16:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/34\">",
"      Simonelli C, Zanussi S, Cinelli R, et al. Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma. Clin Infect Dis 2003; 37:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/35\">",
"      DeMario MD, Liebowitz DN. Lymphomas in the immunocompromised patient. Semin Oncol 1998; 25:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/36\">",
"      Tulpule A, Sherrod A, Dharmapala D, et al. Multidrug resistance (MDR-1) expression in AIDS-related lymphomas. Leuk Res 2002; 26:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/37\">",
"      Lucia MB, Rutella S, Leone G, et al. In vitro and in vivo modulation of MDR1/P-glycoprotein in HIV-infected patients administered highly active antiretroviral therapy and liposomal doxorubicin. J Acquir Immune Defic Syndr 2002; 30:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/38\">",
"      Navarro WH, Kaplan LD. AIDS-related lymphoproliferative disease. Blood 2006; 107:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/39\">",
"      Levine AM, Noy A, Lee JY, et al. Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047. J Clin Oncol 2013; 31:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/40\">",
"      Levine AM, Tulpule A, Espina B, et al. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. J Clin Oncol 2004; 22:2662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/41\">",
"      Zaja F, Tomadini V, Zaccaria A, et al. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2006; 47:2174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/42\">",
"      Martino R, Perea G, Caballero MD, et al. Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study. Haematologica 2002; 87:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/43\">",
"      Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990; 8:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/44\">",
"      Sparano JA, Lee JY, Kaplan LD, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood 2010; 115:3008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/45\">",
"      Straus DJ, Huang J, Testa MA, et al. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142--low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases. J Clin Oncol 1998; 16:3601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/46\">",
"      Vaccher E, Tirelli U, Spina M, et al. Age and serum lactate dehydrogenase level are independent prognostic factors in human immunodeficiency virus-related non-Hodgkin's lymphomas: a single-institute study of 96 patients. J Clin Oncol 1996; 14:2217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/47\">",
"      Levine AM. Challenges in the management of Burkitt's lymphoma. Clin Lymphoma 2002; 3 Suppl 1:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/48\">",
"      Bishop PC, Rao VK, Wilson WH. Burkitt's lymphoma: molecular pathogenesis and treatment. Cancer Invest 2000; 18:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/49\">",
"      Wang ES, Straus DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 2003; 98:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/50\">",
"      Rizzieri DA, Johnson JL, Niedzwiecki D, et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer 2004; 100:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/51\">",
"      Mead GM, Barrans SL, Qian W, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 2008; 112:2248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/52\">",
"      Noy A, Kaplan L, Lee J. Feasibility and toxicity of a modified dose intensive R-CODOX-M/IVAC for HIV-associated Burkitt and atypical Burkitt lymphoma (BL): preliminary results of a prospective multicenter phase II trial of the AIDS Malignancy Consortium (AMC). Blood (ASH Annual Meeting Abstracts) 2009; 114:Abstract 3673.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/54\">",
"      Castillo JJ, Winer ES, Stachurski D, et al. Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. Oncologist 2010; 15:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/55\">",
"      Castillo JJ, Furman M, Beltr&aacute;n BE, et al. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer 2012; 118:5270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/56\">",
"      Teruya-Feldstein J, Chiao E, Filippa DA, et al. CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients. Ann Oncol 2004; 15:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/57\">",
"      Klepfish A, Schattner A, Shvidel L, et al. Successful treatment of aggressive HIV-associated non-Hodgkin's lymphoma with combination chemotherapy, biotherapy with rituximab and HAART: presentation of a therapeutic option. Leuk Lymphoma 2003; 44:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/58\">",
"      Bower M, Stebbing J, Tuthill M, et al. Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma. Blood 2008; 111:3986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/59\">",
"      Miles SA, McGratten M. Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma. J Clin Oncol 2005; 23:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/60\">",
"      Spina M, Jaeger U, Sparano JA, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood 2005; 105:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/61\">",
"      Bou&eacute; F, Gabarre J, Gisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol 2006; 24:4123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/62\">",
"      Ribera JM, Oriol A, Morgades M, et al. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol 2008; 140:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/63\">",
"      Ribera JM, Morgades M, Gonz&aacute;lez-Barca E, et al. Long-term follow-up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP. Br J Haematol 2012; 157:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/64\">",
"      Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/65\">",
"      Straus DJ. HIV-associated lymphoma: promising new results, but with toxicity. Blood 2005; 105:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/66\">",
"      Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 2002; 99:2685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/67\">",
"      Dunleavy K, Little RF, Pittaluga S, et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood 2010; 115:3017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/68\">",
"      Barta SK, Lee JY, Kaplan LD, et al. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer 2012; 118:3977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/69\">",
"      Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 2008; 26:2717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/70\">",
"      Hegde U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005; 105:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/71\">",
"      Sarker D, Thirlwell C, Nelson M, et al. Leptomeningeal disease in AIDS-related non-Hodgkin's lymphoma. AIDS 2003; 17:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/72\">",
"      Levine AM, Wernz JC, Kaplan L, et al. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial. JAMA 1991; 266:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/73\">",
"      Spina M, Chimienti E, Martellotta F, et al. Phase 2 study of intrathecal, long-acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer 2010; 116:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/74\">",
"      Jabbour E, O'Brien S, Kantarjian H, et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 2007; 109:3214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/75\">",
"      Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/76\">",
"      Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/77\">",
"      Re A, Cattaneo C, Michieli M, et al. High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol 2003; 21:4423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/78\">",
"      Balsalobre P, D&iacute;ez-Mart&iacute;n JL, Re A, et al. Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol 2009; 27:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/79\">",
"      Re A, Michieli M, Casari S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood 2009; 114:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/80\">",
"      Bayraktar UD, Ramos JC, Petrich A, et al. Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium. Leuk Lymphoma 2012; 53:2383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/81\">",
"      Bi J, Espina BM, Tulpule A, et al. High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma. J Acquir Immune Defic Syndr 2001; 28:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/82\">",
"      Einsele H. Bortezomib. Recent Results Cancer Res 2010; 184:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/83\">",
"      Yu L, Mohanram V, Simonson OE, et al. Proteasome inhibitors block HIV-1 replication by affecting both cellular and viral targets. Biochem Biophys Res Commun 2009; 385:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/84\">",
"      Vega MI, Martinez-Paniagua M, Jazirehi AR, et al. The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. Leuk Lymphoma 2008; 49:1982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/85\">",
"      Edelstein LC, Micheva-Viteva S, Phelan BD, Dougherty JP. Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. AIDS Res Hum Retroviruses 2009; 25:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/86\">",
"      Copeland A, Buglio D, Younes A. Histone deacetylase inhibitors in lymphoma. Curr Opin Oncol 2010; 22:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/87\">",
"      Krishnan A, Molina A, Zaia J, et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood 2005; 105:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/88\">",
"      Gabarre J, Azar N, Autran B, et al. High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma. Lancet 2000; 355:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/89\">",
"      D&iacute;ez-Mart&iacute;n JL, Balsalobre P, Re A, et al. Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood 2009; 113:6011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/90\">",
"      Krishnan A, Molina A, Zaia J, et al. Autologous stem cell transplantation for HIV-associated lymphoma. Blood 2001; 98:3857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/91\">",
"      Spitzer TR, Ambinder RF, Lee JY, et al. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant 2008; 14:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/92\">",
"      Holland HK, Saral R, Rossi JJ, et al. Allogeneic bone marrow transplantation, zidovudine, and human immunodeficiency virus type 1 (HIV-1) infection. Studies in a patient with non-Hodgkin lymphoma. Ann Intern Med 1989; 111:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/93\">",
"      Gupta V, Tomblyn M, Pedersen TL, et al. Allogeneic hematopoietic cell transplantation in human immunodeficiency virus-positive patients with hematologic disorders: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/94\">",
"      Kang EM, de Witte M, Malech H, et al. Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome. Blood 2002; 99:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/95\">",
"      Tomonari A, Takahashi S, Shimohakamada Y, et al. Unrelated cord blood transplantation for a human immunodeficiency virus-1-seropositive patient with acute lymphoblastic leukemia. Bone Marrow Transplant 2005; 36:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/96\">",
"      Spagnuolo V, Galli L, Salpietro S, et al. Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies. Int J Cancer 2012; 130:2990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/97\">",
"      Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group, Bohlius J, Schmidlin K, et al. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS 2009; 23:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/98\">",
"      Carbone A, Gloghini A, Larocca LM, et al. Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood 2001; 97:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/99\">",
"      Levine AM, Sullivan-Halley J, Pike MC, et al. Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival. Cancer 1991; 68:2466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/100\">",
"      Navarro JT, Ribera JM, Oriol A, et al. International prognostic index is the best prognostic factor for survival in patients with AIDS-related non-Hodgkin's lymphoma treated with CHOP. A multivariate study of 46 patients. Haematologica 1998; 83:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/101\">",
"      Rossi G, Donisi A, Casari S, et al. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma. Cancer 1999; 86:2391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/102\">",
"      Hoffmann C, Tiemann M, Schrader C, et al. AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping. Blood 2005; 106:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/28/38346/abstract/103\">",
"      Davis AJ, Goldstein D, Milliken S. Long term follow-up of CEOP in the treatment of HIV related non-Hodgkin's lymphoma (NHL). Aust N Z J Med 1998; 28:28.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4753 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C264CC6E5B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_28_38346=[""].join("\n");
var outline_f37_28_38346=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6051206\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6237308\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1226113\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H62463420\">",
"      Incorporating HAART",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H62464350\">",
"      Prophylaxis for opportunistic infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1700389\">",
"      Standard chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CHOP chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6236970\">",
"      Dose-adjusted EPOCH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1224044\">",
"      - Burkitt lymphoma/leukemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1224066\">",
"      - Plasmablastic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Role of Rituximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Rituximab plus CHOP or CDE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Dose-adjusted EPOCH plus rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1701337\">",
"      CNS directed therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1227497\">",
"      PATIENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1227504\">",
"      Response evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1227511\">",
"      Surveillance for relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4261492\">",
"      TREATMENT OF RELAPSED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Second-line chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Platinum-based regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12457685\">",
"      - Novel treatment approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4261241\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4261248\">",
"      - Autologous transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4261285\">",
"      - Allogeneic transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1225476\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1225483\">",
"      Risk factors prior to therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1225490\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1225497\">",
"      - Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1225504\">",
"      Effect of HAART",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1108978\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4753\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4753|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/59/37819\" title=\"table 1\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/21/17757\" title=\"table 2\">",
"      Int prognostic index NHL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/9/30878\" title=\"table 3\">",
"      daEPOCH-R for non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/40/36493\" title=\"table 4\">",
"      R-CODOX-M IVAC regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/2/22574\" title=\"table 5\">",
"      R-CHOP21 regimen for non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/27/30140\" title=\"table 6\">",
"      NHL treatment response criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/4/7242?source=related_link\">",
"      AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/36/20042?source=related_link\">",
"      AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7321?source=related_link\">",
"      AIDS-related lymphomas: Primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30969?source=related_link\">",
"      AIDS-related lymphomas: Primary effusion lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3370?source=related_link\">",
"      Considerations prior to initiating antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/36/27206?source=related_link\">",
"      HIV infection and malignancy: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/45/26330?source=related_link\">",
"      Initial treatment of advanced stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33450?source=related_link\">",
"      Primary prevention of opportunistic infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29127?source=related_link\">",
"      Prognosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3001?source=related_link\">",
"      Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/4/19530?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adults with hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/17/39194?source=related_link\">",
"      Secondary involvement of the central nervous system by non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36217?source=related_link\">",
"      Treatment of Burkitt leukemia/lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33178?source=related_link\">",
"      Treatment of relapsed or refractory diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_28_38347="Ca P Mg needs PN infant";
var content_f37_28_38347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Calcium, phosphorus, and magnesium requirements (mmol [mg/dL]) in infants who receive parenteral nutrition (PN)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Term infants, usual short-term",
"       </td>",
"       <td class=\"subtitle1\">",
"        Premature infants, usual short-term",
"       </td>",
"       <td class=\"subtitle1\">",
"        All infants, long-term use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium",
"       </td>",
"       <td>",
"        1.2 (48)",
"       </td>",
"       <td>",
"        1.5 (60)",
"       </td>",
"       <td>",
"        1.75 (70)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phosphorus",
"       </td>",
"       <td>",
"        1.2 (37)",
"       </td>",
"       <td>",
"        1.5 (47)",
"       </td>",
"       <td>",
"        1.75 (54)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Magnesium",
"       </td>",
"       <td>",
"        0.21 (5)",
"       </td>",
"       <td>",
"        0.25 (6)",
"       </td>",
"       <td>",
"        0.25 (6)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Short-term: assumes PN with &ge;2.4 percent amino acids + cysteine.",
"    <br>",
"     Long-term: assumes PN with &gt;2.5 percent amino acids + cysteine.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Adapted from:",
"      <br>",
"       1. Schanler RJ, Rifka M. Calcium, phosphorus, and magnesium needs for low birth weight infants. Acta Paediatr 1994; 83:111.",
"       <br>",
"        2. Greene HL, Hambidge KM, Schanler RJ, Tsang RC. Guidelines for the use of vitamins, trace elements, calcium, magnesium, and phosphorus in infants and children receiving total parenteral nutrition: report of the Subcommittee on Pediatric Parenteral Nutrient Requirements from the Committee on Clinical Practice Issues of The American Society for Clinical Nutrition. Am J Clin Nutr 1988; 48:1324.",
"        <br>",
"         3. Laine L, Shulman RJ, Pitre D, et al. Cysteine usage increases the need for acetate in neonates who receive total parenteral nutrition. Am J Clin Nutr 1991; 54:565.",
"        </br>",
"       </br>",
"      </br>",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_28_38347=[""].join("\n");
var outline_f37_28_38347=null;
var title_f37_28_38348="Suspected UTI without pyuria algorithm";
var content_f37_28_38348=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Evaluation of the child with suspected urinary tract infection and initial urine with bacteriuria but no pyuria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 321px; height: 217px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_28_38348=[""].join("\n");
var outline_f37_28_38348=null;
var title_f37_28_38349="Osmotic v C difficile diarrhea";
var content_f37_28_38349=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Antibiotic-associated osmotic versus Clostridium difficile diarrhea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 221px; background-image: url(data:image/gif;base64,R0lGODlhsAHdANUAAP///0BAQMDAwICAgAAAAPDw8ODg4NDQ0DAwMFBQUGBgYKCgoLCwsCAgIHBwcJCQkEBm/8DN/4CZ/xAQEPDz/9DZ/+Dm/zBZ/wAz/2CA/6Cz/7DA/3CN/1Bz/yBN/5Cm/xBA/wAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACwAd0AAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw38bEh8UWxYWTRwVABXJThoaxErGEs9LEEIRQhsQHBQZEBHaRBTP1ErpSOAcT8vWRhQXEhEaHudTEhJC60zKAXD2pN+8IxAyRADnTQkGIdwseKAw7gOACPCKVIBnMMnGIxIpLukI8KCQDxmGaOgArQMEfxY0SICgoUKHDswozJSQDMJL/wsRvI0LJ63bTQ/eNDDj4HODEAkWoNb8EEECB3INwXV4ZoHc1l4o0SHRkPAhAH8SPEjIl0Hq04QVYp71N9QfEbkLsZ5VG6GukKHifEINCqArzX8bbjLzBcHp34cgolmMgJSCWgph255NmUGhTn8Xqm04Z+GChXreBDq1zAzDTwh8Z1qo4AFAYgohZ0Orzasxk9sWzD7UcMHcBaoRuF2FtiH5XADFB9rtxk02bQDEI5T2xgG06Aqd+xqs3KEa0bCMGwp56IFD34vcAAh0DmJI/Y79Klw48iGjwPlMgeCNWfI11NFDHbSVVlLkEKiLQEt04Jhw8EHkDX1FOZefWhKQQ/+EhnY95Bxt/ZCjHxH4ZRNfBCzNF18vGVQjxHWYdQACBc4VWCGBD6WYYxEd/bfQBc8IRCCEB8qHXF9XtQajRds0RGGOLgLgIIgRFBfUPiCuV2GWQZnz43Nz5ehclb5QJk0H/jSkZXxVSngRS1Y9xRMIOS1mW3zRlVMnalYOgWSIZ7EEAG6+BdcLZYuZc5ae0h06JZwXcnMYNCBSENmMH1ZHqHOaahMNnodGlZFBN55lEZq+gAOBPUJ0cMEF8FBZKTQ+QcDVBboatAGvEEDKwQUZ9NkXr7IOKKiBhA7Eq2m0heOgLr/6hJOV6h0q2KQWVlhBrs15Cs2z01WYZI76ver/T7XBltbrurNm0NOtJtVr77345qvvvvz26++/AAcs8MAEF2zwwQgnrPDCDDfs8MMQRyzxxBRXbPHFGGes8cYcd+zxxyCHLPLIJFtxgAFNFHAAAAssQITKSxiAMhUOrMzFAQ44IQAVBxQQxQABLBBAIAL4zETPAAxNBNJK7Mxzzl203ITMU8AMxQEJBO0yIBMofYQASuMMwAADLA11EWQLITUVAexMwBZgO+F1FDVDsUACABTw9h8HEFA2Em0LUffeQ9RtBOFzRxF32lowvsTaUYgNRQM9O97HAgo0MLMADCgQ+AANDCCAAS4PoIDnK5OeN9AD+BxAAAMYIMDOBXju/4DKWf89hNCwC9G2AH67zEAACaS+gAC6CwG0AisLrQDKcRfAus+kA/2A8kIMnwADRHCO+vAKqI0y1gFcv8ABDxQ9fdKwG7C38yiTjjwADrzO/RsKgD7EAOADYEAD+WMZygggNKgtAHoJSMDOgDeA0mWPeNwDWvGIYADPTTBur4vd2AKgAJ+dL30vs10BKhg05ZWNhFtbAAMSCD3aiZAI/AvA7Ty3M9VtkHnyK5sAErjA4KUNhWpD3+yy1kE4bM8B19ugAQ7QAJYhYHSLS4DKJgCAuAXQdAA4nfrKhgDhHWACPUviEIoGgAS4rG3uE8ABVjjCBhRAABNIQPIcEL413v/tjU20YtmwKIAGFE1zAHgbAxAwwq0pLwBLnIDLzJi00VGuANcLQOgEcMXwaVFvLJNiH6sYx7JxrwCAdMMECoAAmxGwjAsgJQgDR4CdJSCSjpSZ5tK4MkESknQPwNsaKbgyJlZxaJd0gCeHJknREaGLAGAAE4vGyLT5sQCMlCEkw5c2ZCqTCKdkoS/jRkcArBGOcvyfLGXWygM4k5lnnOTJAPCA8LmhAFQ8AAJMKIS3xe2XY/vb74ZGRSFQkXFkkycRGuAAMlIQaKFrZCCFkID8gW52iQPAKIegQN8dIG79lCg+Ffq27R2BcXtLW9secDaFatSf+axnGZ0WgIt6TQD/9ZuA09iwQnZCLaRlCxxHhYBBATzgbwO4HuE6ej8nns8ImAuAPYfGuAmQbQBv0+kQBCqEAyhth/m0Kk/xFrjFDYCqh6PnQjFqtI3+VHlCNaFWq8hVp0EyAQiIaBoW0DWlogykG/Wq7yC6UJUCVHRze+tEhfC/CObUbb5L3+zeGFHCmXSffR2r0lhpUrT9DaeNtJxOh5rSheoUssksZWXXkLkAIKCJfRUpSxGLz7b9NbJRnWkVHZDQwj1Psp1t5ex2JlWevvSqTAWsbxXq1XuGNbf4dOw9X4vTe/ZUCAh4AGPf4FH6XQ+vApgnPtMGT3x6FKsDgBrZ4ImyETrtiWPU/24AWemzAeAtb7KLaAm9SdK85XFo38XbPSmLRW/C8LL0/B1qV6bT/CK3vqDcaHjzht42DFa0mA3A/Shr3UZStaWBNNrb+nsApA2PCBL231LHBrXyVXW0eZtAeQ0w0aCmtMWw3G7rVAxfbIp1xPN1aVW1i2HMwtikBPCgXM/Q3R0jl33HY2oDTMu9uFn1damLqzk9GVdEwhUBJc1iXOWo0AFgmX5xRUB8jfBkCdcOAQho8tDKvLL9IvbMvdsfgFP6uS2blM3IPXOaN0pK4jV4DTUVQn0xO0hius20RawzAoD65bfBmX9htllVl+yAERtAytBEc1uNUGhEDhIBRUzbp/8TvcDghvZ1M1Mpcp38Ogkb18uLVrWo0UxqtS3ZcyXLta53zete+/rXwA62sIdN7GKrobfGbtqQk30EZDP7a8t+NohlK20jGLfagKM2tscYbWw7e9sbBfcQ3EeAchPgveCutLkJUFRwN2DdYtw2A9YdZHELQQHrlvS29Wbubid7AebOqLiVWu7kgZvfBHCnvaFabm1vGwHlNqS4gUcAgdtb3am29wTObe/uEQC1HS8jAeLdcQJkWdwPIEDGOx7ikPsP5C6XrsuxN/Oa2/zmOM+5znfO8577/OdAD7rQh070omNBdqO7AtOYALkoNJ3MJ0eC4a4ANImrYemGYEBAmXD/1QfOsG36FgLMnh4Ff1e1rJGLuhSmjgewfRsKbFeC5aAw9yJcWwlvH0Le1YY3tHPh7TqN+yA4yLm993Vo/ytA7a4HU6h3lgqOVYLgdWZ2rju8DoxTYQKlZ+KxDc+AGRTf2AwQu9rFmYRxnmrWzBd6lgnRdKhTGwehBzsTM8BpnGNrAvw4+tjx7oQALJvpDZ5BAwxfeaQn3QqlaL2qZu1+MQzf/wL4+5dTH4EV9TwH+dDOlyHBeSEdW+gWEHwbLu9kpRO+5wyeTAjq3mnvm73/FtB8ASKPbC4jH/SJp+/sVn2rFTU7/sM9qnN8KHYHjCNND/BEoDRA3PNKVeQz0XRo/7GDXsIEAOgVQOP2SIwngekkOu41RZmER1X0TJrzYUnDAJdmfOhFAO1DRmakSjtjgclzSTQYSO2jgAw4S2JWAKy0SKkUXQvkgTLYSOIkToEEhHvQckrARu6jUgvwRPKkWEPTTd9kajc4BINUSEcISG9zR5vUR3+EMmgEUQ6wgj7oU7rUbn1kfJTThWPmAPNUTTtzgYYXBwlYanvVV3FDesW0U94UOqbTUtplOfU1bgh1WGLVNtnXUm4GALPURIdIYf6TiArFRGSDa3IWiJk4NIijh430ALDDOqmliJX4h5/lU0CVVo+HB3dYXXszYsTFT2XlVZg4iERQXey0igvViP86plA6JTTsNIqwE4VH1T1KQzZnNTZpxUFYo0aCiGt3CAd5uFEUBjaFRWeslV279YuW4zjZqFqLCDar9YjthESdRWHhqIjcODv6ljbtqEaR1VWThTwKsFsDFGA11ACG9Vj3R0+YpQcKQHLNBn8q9Yhxo1zBFY/6JlXM5Y+PGDhM1F73ODvQQ1vJs1xPFWAL4AAM8AB59ETueIB2UI2PuDdIlF33poh7A0820zMTdYFjNGAqmUWmyF1UhGD3tYeg5EbtB13bqF459UlgdGKb6JIn9onWODs+6V8R1mRCmYJ7dWG1JFZ50IY8tTIaVDjCF4tL2Vpbo2PjVZT+tT/u1GH/PFaVOvmVbUNKNtNHRtNhPoOCw4WBaGlR7CRar5NiL0mSdEB+DXBGoMhKiOYzCrBlLDlVYVY2UZhABudlxKNlxHOTS7ZneqZme5hFZyOHh8laksllheZNi/lfO2ZaZaOUjxiFTFaKp/aZVGZoY4Nmc1Z3dtBpCTBAsuWDsOOVCLlmrXZ7piZPphlCcbVHsqlSl8mWyFNXOaOaaVZoojVGXRNrsUmdvmSTpRlr09gHkQcIoWR0v9CdfoA54Fme5nme6Jme6rme7Nme7vme8Bmf8jmf9Fmf9nmf+Jmf+gkG22lsd8dyl4dt/2lv/VlsAzpwAVptBwpuBUpsCypt5GZu/+i2bepmbu22be9mbgQpbfO2bn6HbfhmbmFXbQjngiEHcOVmcdtGcH4TcgincOLGcK3kchB3Sh1HcSqabuW2cuC2cRNqb8ADc/aWACNXcyY3cynHowN3oeL2PzYnczPHfvs5pVRapVZ6pViapVq6pVzapV76pWAapu55UQaVBpVnBVTjBwl6BFazBgbwU2vqBG0qCGcqOW+AdW1AfrelBuKZBfdEdmdwh5+VdmwQhbfXUFhgp4LQp9AWBrR5BJO3BoFTPZ1nerczO1KjPaljQStjekWkqbKHb0XAea3jTbkzf1WHNbe5OrDTXpMkgJaKduRzPUDEMss3M9rDPaBKqf+0Gny9RzqhN317FKozE31FoDre06BVQGNCQDm/SkLGtEMc5DPJWkP5d6qUej4sZHeOiTIfpD6tOjZq40HG5zlFNEZERK2dE4wcFHmYKjz8p2DTylbzSj5/A6qeinbFB0ToU1Xmc1f9035MSAZdZYIoY03mNAEOoHltNEK91EQQqExO6EZOGHmVJFFhVIJ/1Drdd7FRODrV5EUbmLHPFE23031bqHxSlHhi2IBF6IKxA4NBCEJfqEmolU0StziIdJ1jUJOCc5rtk4Fls07dBzRLtJNgBEkaC0ocC6NoiF7FREl7FD5tqUi9eD3XNFUoU7Q720QVizYKy7AsW4XD5E3/Wxs+SYu1K+tGEatvl1SyizRjBOY2QDiRNlQG9DiV2iVWDUU2vJdUb6MA24MyfftQsFgEGUVFBEVGvXlSGqWRYEUEh+hNV7VpcaOLhetHEWmQhGWJm7VSeBmQw4VXZHBtabM3VMVduRRXqzY0i0ut9RhuNrWHOpW4+UR/xQNMgzuqq2tqvXg/kcc4mctXTkU2jta7kFhQEuhQfiS4KmhZlLtVDIZMgEg2LAZCgTqYfLWJSaNYRUNH+cgyCiBT5bNbaahqQ8BZgjVdswhbCiZcRuA4zgWbz5VY5ru5qraOQOaPrMltRzYGTkpRLrM3GomB0qVXuLW+jcu9gfO5B7l5/0HzN5gjU8d0wL4bW+i7iN47XbolgNE1XetbvoslvhS8ifMrOINFYT8Emdm7lOQFXwD1XiMUYk/oNMLkXmJnABeISbnYZPoFlI1rYDU5lis2kyf2Y3nLYTgMXxEJvDwVlS33NmvZv6M7ZwSbRF/kMy0Zk6cpZK1bRUAcu9eGglDrNAaGgeGzgAv0s9jkxXi1w8ELVDI8Zp1XS158XsgzxzacPAsmUe2FtWnGY6xlveXFqF3gABNQSo/YaaSnO3JoWkcrQxtWZT7zyD2YQZGHZ1eWM42LZ0g2a6gGQ3Y2aq6jh48GZpC8yKxLOIc5ma3paIe5Z1QsYxksBqYHZejbmP+9Q34cdMHehWacLMaJw5m8p1OezEhPGJuvg3a8jGt4pZtQBb2CE2ZjlmkIgDfNjF/APM2QDJkBgHaX1lKkzEQoczrVW4GmZXVVajQKoM5dYDTfKaaxEMtqxwWV6c7ynM/63KWAagRzagSRus+48KhFoKhGoKwCLQqxSqrtdUKek0K3On+HxDzTZkMHZKubV3/6pzwBm9CWgLAXe07QdEYnGz7cVEftBloNfLI7KDOXTLeo5NGVELm2G1CV275kVZD462aiSDa9I7oyHQnXxllkc8J5m5DZttP1aDr4OMtB/QgvPEIGljZIrIcYFJbTJlCkxFvaC5dJaZUd86AYw8j/eDZroFbK+MRq9jNtZXTNZfyVzsk9QM0xYv3U9lLXdm0SeJ3X87DXfE0Mfv3XwhDYgg0MhF3YvnDYiM0Lir3YutDYwobQwQbZwSbZwEbZwGbZv4bZv6bZvsbZvubZvQbauhah5faj20baupah5bahz1ah5cak1Rai5TaiHEpvH1ptKFpxHVeiZzpsLxpyLCql2Faj+CxtMhqnyYZxIYejMxekM+ejRlrP1Uakrr2isr1tSVpzUBpyAezY90Lc4D3e5F3e5n3e6J3e6r3e7N3e7v3e8B3f+6J13X10SgrQvZTb33fcm0Cm5rsEeJqoOfPPT2DQu+MyadoEBu4FAd1s/3kTdgFeCaQkOuRn20+Qefytd3Vo4R8l3ptAf5ljvUvQ4FPgZFFH0HUZv4yZ4chIsMqdvt6UM4xD4pDQfXxnqr2TrapaXutTfLD6Qui6eztz0fXTcrHje69HRzq1q5x6CffE0NLjM1F+0caKNp9nek6DrxKEeC4jrYnWPjck5Vt+rJ7TOwJYfa7nvS0DNhr9fIKz1t2TrlW0rriXQLxHBLnKMvK3UKpTfFQer5XAhJiUtksbOtOEnVh0SSGbTJL2tFydTPY1QDk4SUbrSxPrsIHo5EpzsaLYvRylhNi0SLdp6WtbABcojE52tll0j6ZetqeeOEKbUjKbNJQeti3Lg//GFzifFM9ES01d6z89+GehVUhgeLP4dEkjtYaW0Ftv87pfiVFD8E9A9VV7K7kl9ugwFQAUrJTINbziq1SajlLifpjupMIGF5AdxbxwBLv49Fas21RP9TYTdW2pu0cn5LlOwzg8TYw6FFO5ibx4NYmyhbksVZUI3DbGyOGO0M5T1UQKLMzu+1cDWo1tM0hzO4/5DmAi/L23ZciNcE+clUwzes5FgO7da74EPDRx88EI3MHbODcFbL38qI1i5WZMbZEWP1os78vVqOE+v1MHv0AYaQleXUY6FMZ7eLk+TGImFNWpRsZcvWBbjfE3NjZzTMMezwj3ZGD/g5XmXvJVv8TII4ReH5aQblxiWIyBO0OXKVbJ9l6T65XxdSlgcSn1wl5vwohXUA9DZznFI9bHYDeXv30IwzOcbf1lndxqUdZSoIxIRMCZZdxncOWZOkW6lhzJlRbulAtlpMQ9UXi+c23yqCxm8tRQKj802QzsLWXNunTNmrg718xladPKXFb5f5OaYcYAki/sqW/5oCbsj5acuBXOVsU5kSbfyJ/8yr/8zN/8zv/80B/90j/91F/91n/92J/92r/93N/93v/94B/+4j/+5K/8QQAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_28_38349=[""].join("\n");
var outline_f37_28_38349=null;
var title_f37_28_38350="Fluoroscopic view of self-expanding stent CPC";
var content_f37_28_38350=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Self-expanding metal stent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fluoroscopic view of the metal stent (arrow) in the distal esophagus extending into the stomach. The gastric bubble (arrowhead) can be easily visualized.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andres Gelrud, MD and Douglas Pleskow, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_28_38350=[""].join("\n");
var outline_f37_28_38350=null;
var title_f37_28_38351="Hyphema associated with endophthalmitis";
var content_f37_28_38351=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F51972&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F51972&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hyphema associated with endophthalmitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 322px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hazy cornea and hypopyon and markedly inflamed conjunctiva.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Trobe JD, Hackel RE. Field Guide to the Eyes. Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_28_38351=[""].join("\n");
var outline_f37_28_38351=null;
